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1. Current status glucocorticoids in the treatment of inflammatory disorders 
It was more than half a century ago when glucocorticoids were discovered as miraculously 
active compounds against inflammatory disorders, such as rheumatoid arthritis, asthma, 
allergic reactions, systemic lupus erythematosus and vasculitis. Their dramatic anti-
inflammatory activity and broad applicability have made the introduction of glucocorticoids 
into the clinic one of the major breakthroughs of drug discovery research in the last century 
(1). 
The enthusiasm about this new group of drugs gradually tempered when the toxicity 
profile became more apparent (2). A range of endocrinal, cardiovascular, musculoskeletal, 
dermatological and gastrointestinal effects was discovered strongly limiting the use of 
glucocorticoids in the clinic (3). Among the most pronounced side effects are osteoporosis 
(leading to fractures), skin atrophy, Cushing’s syndrome, susceptibility for infections, 
hyperglycemia, ulceration of the stomach, psychiatric disorders, and hypertension (4-11). 
Due to the poor safety profile, systemic (i.e. oral, intravenous and intramuscular) treatment 
with glucocorticoids became only reserved for severe, refractive forms of inflammatory 
diseases in which other drugs were not sufficiently active. 
The finding that the detrimental musculoskeletal and dermatological side effects of 
glucocorticoids were more related to long-term use of glucocorticoids offered some 
perspective (12). The disease course of inflammatory disorders is often characterized by 
exacerbations (relapses) of inflammation besides the long-term progression of tissue 
damage (13,14). Short-term treatment with repeated injections of high doses of 
glucocorticoids is one of the few strategies that can rapidly suppress exacerbations. This so-
called ‘pulse therapy’ involves three to five (alternate) daily i.v. injections of up to 1 gram of 
(methyl)prednisolone or 0.1-0.2 g dexamethasone. Although cardiovascular, endocrinal and 
gastrointestinal side effects still do occur, pulse therapy is generally fairly well tolerated (15). 
Topical administration proves to be the primary strategy to avoid (systemic) adverse 
effects. Application on the skin proved to be successful in treatment of inflammatory skin 
disorders while inhalation of glucocorticoids became the first choice treatment of asthma 
and allergic rhinitis (16). However, local treatment is only attractive when the target organ is 
easily accessible, which is often not the case. In rheumatoid arthritis local treatment can be 
realized by means of intra-articular injection (5-10 mg methylprednisolone acetate or 5 mg 
triamcinolone acetonide are most commonly used). However, intra-articular treatment 
requires a special technique and to prevent local reactions such as osteonecrosis, a 
particular joint should not be given more than 4-5 injections a year. Furthermore, this 
treatment approach is only attractive when single large joints are affected. In most cases 
rheumatoid arthritis involves a range of (smaller) affected joints and systemic therapy 
remains the only option (17). 
Besides the poor safety profile, also the poor pharmacokinetic behavior limits the 
usefulness of glucocorticoids in systemic therapy (18). Glucocorticoids are drugs with a 
relatively high clearance rate and a large volume of distribution. This implies that to reach 
pharmacologically active drug levels at the site of inflammation, high and frequent doses 
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must be administered. The majority of these systemically administered doses localizes in 
healthy non-target tissues if not rapidly excreted from the body. To increase the amount of 
drug at the target site after systemic administration and to decrease localization at non-
target tissues the so-called ‘drug targeting’ approach may offer perspective. Drug targeting 
makes use of colloidal carrier systems in which the drug is incorporated or to which the drug 
is attached. Distribution of the carrier-associated drug to organs/tissues is reduced, as the 
carrier cannot diffuse into extravascular tissues. 
 
2. Drug targeting to inflamed sites 
Drug targeting can be defined as a treatment approach leading to increased localization of a 
therapeutic agent at the target site in the body. Drug targeting can be realized by employing 
a drug carrier, which shows preferential affinity for the (pathological) target tissues. The 
increased target concentration of the carrier-associated drug as compared to the free drug 
may lead to a higher activity of the drug at the target site and/or reduced side effects at 
healthy non-target tissues. 
 Drug targeting may be considered as a means of local administration that makes use 
of the systemic route, since ideally drug targeting leads to 100% delivery of the systemically 
administered drug at the target site. Approaching this ideal situation depends on the type of 
drug carrier and target site. For instance, drug targeting to organs in which the mononuclear 
phagocyte system (MPS) is present (such as liver, spleen and bone marrow) can be highly 
efficient, as phagocytes in these organs are exposed to the blood circulation and rapidly take 
up the majority of the injected drug carrier (19). Meanwhile this phenomenon has 
compromised the use of drug carriers for targeting to non-MPS sites and additional 
modifications were necessary to enable significant drug delivery to these sites. 
  Over the last decades, a range of carriers has been investigated for the purpose of 
drug targeting. These include: plasma proteins, soluble antibodies, lipoproteins, 
nanoparticles, viruses, erythrocytes and erythrocyte-based structures, blood platelets, 
polymers, polymeric micelles and liposomes (20-31). To impose target selectivity to these 
carriers targeting ligands can be attached, such as antibodies or natural ligands for target 
site-specific receptors. This approach is often referred to as ‘active drug targeting’. Some of 
these carriers may show target selectivity without the use of targeting ligands. The above-
mentioned affinity of several unmodified drug carriers for the mononuclear phagocyte 
system is just an example. This phenomenon is usually referred to ‘passive drug targeting’. 
 Interestingly, the approach of passive drug targeting can effectively be employed in 
inflammatory diseases. Inflammation generally results in locally increased vascular 
permeability, enabling cellular, (macro)molecular and colloidal blood components to 
extravasate and enter the inflamed site. I.v. injected colloidal drug carriers that stay long 
enough in the circulation spontaneously extravasate into sites of inflammation as well. This 
phenomenon of preferential localization at inflamed areas has been shown to occur with 
several colloidal drug carriers (32-34). Of these colloidal drug carriers, so-called ‘long-
circulating liposomes’ may be among the most attractive ones. 
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3. Long-circulating liposomes 
Liposomes are small lipid bilayer vesicles enclosing an aqueous core in which water-soluble 
drugs can be entrapped. The attractiveness of liposomes as drug carrier relates to their 
relatively high drug loading capacity, good biocompatibility, low toxicity, versatility and ease 
of preparation. Creating a lipid film by evaporation of a solution of membrane-forming lipids 
and subsequently hydrating this film with the aqueous drug solution spontaneously results in 
the formation of drug-encapsulating liposomes. Repeated extrusion, sonication or high-shear 
homogenization can be employed to produce liposomes of the desired size. The 
unencapsulated drug can easily be removed by dialysis, gel-filtration or centrifugation (35). 
Size and lipid composition are crucial parameters determining the in vivo behavior of 
liposomes after systemic administration. First, to prevent leakage of the drug from 
liposomes both upon storage and after injection in the circulation, stability of the drug-
containing liposome formulation must be investigated and optimized. Second, the liposomes 
must be sufficiently small and have a sufficiently long circulation half-life so that they are 
allowed to extravasate at sites of pathology to a significant extent. Liposome formulations 
that meet these requirements/specifications are generally referred to as ‘long-circulating 
liposomes’’ (31). 
 The most extensively studied long-circulating liposome systems are PEG-liposomes. 
This liposome type is created by grafting low-molecular poly(ethylene glycol) (PEG) to the 
lipid bilayer surface (Figure 1). It is generally thought that surface-grafted water-soluble 
polymers can oppose adhesion of plasma proteins to the liposomes that would otherwise 
‘tag’ liposome for recognition and subsequent premature uptake by phagocytes of the 
mononuclear phagocyte system. PEG-liposomes can circulate with a half-life as long as 24 
hrs in rats and up to 50 hours in humans. PEG-liposomes have been developed for the 
targeted delivery of cytotoxic agents to tumors, as the tumor vasculature is often loosely 
organized, providing increased access for blood components (36). Several liposomally 
encapsulated cytotoxic agents are on the market or in late phase clinical trials (37,38). 
 Preclinical and clinical studies have revealed that i.v. administered PEG-liposomes 
can indeed preferentially localize in inflamed tissues. For instance, Brouwers et al. showed 
that PEG-liposomes can be employed for the scintigraphic detection of inflamed sites in 
patients with Crohn’s disease (39). Despite these results, PEG-liposomes have hardly been 
used for the purpose of drug targeting in inflammatory disorders. Corvo et al. reported 
increased therapeutic activity of superoxide dismutase (SOD) upon encapsulation in PEG-
liposomes and i.v. administration in an experimental rat model of arthritis (40). 
Disappointing results were obtained with the disease-modifying anti-arthritic drug 
methotrexate in PEG-liposomes (41). Although encapsulation of glucocorticoids in long-
circulating liposomes for targeted delivery in inflammatory disorders seems logic and 
straightforward, the approach has never been proposed and investigated. Only a few studies 
on liposomal formulations of glucocorticoids for local, intra-articular treatment of inflamed 
joints in experimental arthritis exist (42,43). 
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Figure 1. Schematic representation of a drug-containing long-circulating PEG-liposome 
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4. Aims and outline of this thesis 
The primary aim of this thesis was to investigate application of PEG-liposomes as passive 
targeting system for the delivery of glucocorticoids to sites of inflammation. Chapter 2 
provides a background to the field of advanced drug delivery with liposomes. The present 
status of both passive and active drug targeting with liposomes is reviewed. 
Chapter 3 describes the pharmacokinetics, tissue distribution, degree of inflamed 
joint targeting and therapeutic activity of prednisolone phosphate-PEG-liposomes in rat 
adjuvant arthritis, a widely accepted animal model for rheumatoid arthritis. Chapter 4 also 
addresses the anti-arthritic effect of prednisolone phosphate-PEG-liposomes, but in a 
different model: murine collagen induced arthritis. This model allows a mechanistic study of 
the localization and anti-arthritic effect of liposomal glucocorticoid at a microscopic level. 
Besides application for arthritis treatment, we also studied the therapeutic activity of 
liposomal glucocorticoid in experimental models of multiple sclerosis. Chapter 5 describes 
pharmacokinetics, the degree of targeting to the inflamed nervous system and the beneficial 
effects of prednisolone phosphate-PEG-liposomes, both at a microscopic as well as a 
macroscopic level, in comparison to standard treatment with (free) methylprednisolone. To 
our surprise, liposomal prednisolone phosphate not only proved to be highly effective in 
models of inflammatory disorders, but also in murine tumor models, as reported in Chapter 
6. The effect on tumor growth is evaluated both macroscopically as well as under the 
microscope. Some possible mechanisms are discussed that could explain this unexpected 
antitumor effect. 
Chapter 7 describes the evaluation of glucocorticoids other than prednisolone in 
PEG-liposomes in experimental arthritis. Dexamethasone and budesonide are studied 
regarding both therapeutic activity and systemic adverse effects. An approach is proposed 
and evaluated to optimize the therapeutic index of liposomal glucocorticoid by encapsulating 
inhaled high-clearance glucocorticoids. Chapter 8 addresses the phenomenon of 
complement-related hypersensitivity reactions, which has been observed with PEG-liposomes 
in the clinic. The study in this chapter aims at finding the responsible key factor(s) and 
proposes a long-circulating liposome type that does not induce complement activation. Since 
the biological fate of liposomes-attached PEG after cellular uptake is not known, it was the 
objective of the work presented in Chapter 9 to design a biodegradable polymer-lipid 
conjugate for the preparation of long-circulating liposomes. Targeted delivery of 
glucocorticoids and therapeutic activity in experimental arthritis of this new type of liposome 
is also evaluated. Finally, Chapter 10 provides a summary and a general discussion of the 
results presented in this thesis. 
introduction and organization of the thesis 
15 
REFERENCES 
 
1. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? 
Arthritis Rheum 2002;46:2553-63. 
2. Bollet AJ, Black R, Bunim JJ. Major undesirable side effects resulting from prednisolone 
and prednisone. JAMA 1955;158:459-63. 
3. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis 
receiving prednisone compared to matched controls. J Rheumatol 1994;21:1207-13. 
4. Lukert BP, Raisz Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 
1994;20:629-50. 
5. Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal 
atrophy. Clin Exp Dermatol 1991;16:416-9. 
6. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin 
CW, Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid 
antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40. 
7. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking 
glucocorticosteroids. Rev Infect Dis 1989;11:954-63. 
8. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related 
diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505. 
9. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of 
adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-4. 
10. Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 
1989;30:135-9. 
11. Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause 
hypertension? Clin Sci (Lond) 1981;61 Suppl 7:381s-383s. 
12. Dunlap NE, Fulmer JD. Corticosteroid therapy in asthma. Clin Chest Med 1984;5:669-83. 
13. Bodman KB, Roitt IM. The pathophysiology of rheumatoid arthritis. Fund Am Clin 
Immunl 1994;2:73-81. 
14. Miller A. Current and investigational therapies used to alter the course of disease in 
multiple sclerosis. South Med J 1997;90:367-75. 
15. Weusten BL, Jacobs JW, Bijlsma JW. Corticosteroid pulse therapy in active rheumatoid 
arthritis. Semin Arthritis Rheum 1993;23:183-92. 
16. Bielory L, Wolff AH. Inhaled steroids in the treatment of asthma. N J Med 1996;93:180-2. 
17. Moeser PJ. Corticosteroid therapy for rheumatoid arthritis. Benefits and limitations. 
Postgrad Med 1991;90:175-6, 178-82. 
18. Snell ES. The pharmacological properties of corticosteroids in relation to clinical efficacy. 
Br J Dermatol 1976;94 suppl 12:15-23. 
19. Liliemark E, Sjostrom B, Liliemark J, Peterson C, Kallberg N, Larsson BS. Targeting of 
teniposide to the mononuclear phagocytic system (MPS) by incorporation in liposomes 
and submicron lipid particles; an autoradiographic study in mice. Leuk Lymphoma. 
1995;18(1-2):113-8. 
chapter 1 
16 
20. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 
2002;2:750-63. 
21. Meijer DK, Beljaars L, Molema G, Poelstra K. Disease-induced drug targeting using novel 
peptide-ligand albumins.J Control Release 2001;72:157-64. 
22. Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A. Immunotoxins: is there a clinical 
value? Ann Oncol 1994;5 Suppl 1:97-103. 
23. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. 
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug 
Deliv Rev 2001;47(2-3):251-76. 
24. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, Georgin D, Fattal E, 
Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as 
new drug carrier for brain delivery. Pharm Res 2001;18:1157-66. 
25. Curiel DT. Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 
1999;886:158-71. 
26. Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, Gaudreault R. Nanoerythrosome, 
a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug 
carrier for daunorubicin. Anticancer Res 1994;14:915-9 
27. Tuohy VK, Mathisen PM. T cell design for therapy in autoimmune demyelinating disease. 
J Neuroimmunol 2000;107:226-32. 
28. Crawford N, Chronos N. Electro-encapsulating drugs within blood platelets: local delivery 
to injured arteries during angioplasty. Semin Interv Cardiol 1996;1:91-102. 
29. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 
2002;2:209-26. 
30. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, 
characterization and biological significance. Adv Drug Deliv Rev 2001;47:113-31. 
31. Storm G, Crommelin DJA. Liposomes. Quo Vadis? PSTT, 1998, 1, 19. 
32. Wu NZ, Klitzman B, Rosner G, Needham D, Dewhirst MW. Measurement of material 
extravasation in microvascular networks using fluorescence video-microscopy. Microvasc 
Res 1993;46:231-53. 
33. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. 
Microvasc Res 1986;31:288-305. 
34. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased 
microvascular permeability contributes to preferential accumulation of Stealth liposomes 
in tumor tissue. Cancer Res 1993;53:3765-70. 
35. Amselem S, Gabizon A, Barenholz Y. A large-scale method for the preparation of sterile 
and non-pyrogenic liposomal formulations of defined size distributions for clinical use. In: 
Gregoriadis G, editor. Liposome Technology. CRC Press, Boca Raton, Fl; 1993. p. 501-
25. 
36. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. 
Trends Pharmacol Sci 1994;15:215-20. 
introduction and organization of the thesis 
17 
37. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr 
Oncol Rep 2001;3:156-62. 
38. Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, Boehm K, Williams T. 
Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with 
intravenous liposomal all-trans retinoic acid. Blood 2001;97:73-80. 
39. Brouwers AH, De Jong DJ, Dams ET, Oyen WJ, Boerman OC, Laverman P, Naber TH, 
Storm G, Corstens FH. Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's 
disease. J Drug Target 2000;8:225-33. 
40. Corvo M, Jorge JC, van't Hof R, Cruz ME, Crommelin DJ, Storm G. Superoxide dismutase 
entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat 
adjuvant arthritis. Biochim Biophys Acta 2002;1564:227-36. 
41. Williams A, Goodfellow R, Topley N, Amos N, Williams B. The suppression of rat collagen-
induced arthritis and inhibition of macrophage derived mediator release by liposomal 
methotrexate formulations. Inflamm Res 2000;49:155-61. 
42. Shaw IH, Knight CG, Thomas DP, Phillips NC, Dingle JT. Liposome-incorporated 
corticosteroids: I. The interaction of liposomal cortisol palmitate with inflammatory 
synovial membrane. Br J Exp Pathol 1979;60:142-50. 
43. Phillips NC, Thomas DP, Knight CG, Dingle JT. Liposome-incorporated corticosteroids. II. 
Therapeutic activity in experimental arthritis. Ann Rheum Dis 1979;38:553-7. 

  2 
Josbert M. Metselaar, Enrico Mastrobattista, and Gert Storm 
 
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical 
Sciences, Utrecht University, The Netherlands 
LIPOSOMES FOR INTRAVENOUS DRUG TARGETING: 
DESIGN AND APPLICATIONS 
 
CHAPTER 
chapter 2 
20 
ABSTRACT 
 
Drug targeting with liposomes has been studied for over 25 years and has demonstrated its 
value in clinical practice. This minireview offers an overview of the design and application of 
liposomes for i.v. drug targeting. Two approaches are outlined: passive and active targeting. 
The former approach is based on liposomes with prolonged circulation and selective target 
localization properties, while in the latter approach specific targeting ligands are coupled to 
the liposome surface in order to achieve enhanced interaction with target cell membranes. 
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I. INTRODUCTION 
 
Successful treatment of life-threatening and chronic diseases by intravenous (i.v.) 
administration of therapeutic agents often involves relatively high and frequent dosing. Due 
to rapid elimination or a large volume of distribution, many drugs poorly accumulate at 
target sites while large amounts are wasted or unintendedly localize at healthy tissue sites. 
As a consequence, a systemic treatment approach is frequently limited by toxicity and 
therefore characterized by a low benefit/risk ratio. For decades research has been focusing 
on the possibility of encapsulating drugs in carrier vehicles that take their drug load 
specifically to target sites in the body, meanwhile protecting it against rapid degradation 
and/or elimination and preventing undesired localization in non-diseased organs (‘drug 
targeting’). 
Among a variety of drug carrier systems, liposomes (small, biocompatible lipid-
bilayer vesicles, see Figure 1) have been investigated extensively and the preclinical and 
clinical findings have demonstrated their versatility to accommodate a large variety of drugs 
for a wide range of therapies (1,2). The attraction of liposomes as drug carrier system was 
initially based on expectations of good biocompatibility, low toxicity and a lack of immune 
system activation or suppression. These assumptions were based on the fact that liposomes 
are typically composed of natural lipids that form bilayers with structural resemblance to cell 
membranes. Although reality turned out to be more complex, the approval of several 
liposome-based pharmaceutical products in the last decade illustrates a growing acceptance 
of the liposomal delivery system as an important parenteral drug formulation. 
A breakthrough in the liposome research field has been the finding that i.v. injected 
liposomes have the ability to spontaneously localize into sites of pathology (‘passive 
targeting’) (3,4). It was this finding that facilitated clinical development of liposomes for 
therapeutic purposes. In certain cases however, it remains desirable to couple a specific 
targeting ligand to the surface of the liposomes to achieve receptor-mediated target cell 
binding (‘active targeting’) (3). This minireview aims at providing the reader with a 
condensed overview of the design and application of liposomes for i.v. drug targeting. Both 
the passive and active strategy will be discussed. 
  
chapter 2 
22 
II. PASSIVE TARGETING 
 
One of the important barriers limiting the application of liposomes for intravenous drug 
targeting has been a short blood circulation time resulting from rapid and efficient 
recognition and removal from blood by cells of the mononuclear phagocyte system (MPS), 
particularly those in the liver and spleen. This immune system’s first line of defense consists 
of macrophages specialized in nonspecific elimination (phagocytosis) of all exogenous 
material in the circulation, including liposome particles. Plasma proteins like antibodies and 
other so-called opsonins recognize and adhere to liposomal bilayers, provoking the uptake of 
liposomes by MPS-macrophages (5,6). This MPS-directed behavior of liposomes has been 
successfully exploited to achieve selective delivery of antimicrobials in models of intracellular 
infections caused by pathogens localized in MPS cells (7). However, in the majority of 
diseases, the rapid sequestration by the MPS often eliminates the intended beneficial effects 
and moreover can pose considerable risk of toxicity to these cells (8,9). 
Therefore, the introduction of liposomes exhibiting prolonged circulation by virtue of 
their capability to oppose rapid MPS uptake represents a milestone in liposomal drug 
delivery research. These newer forms of liposomes (referred to as long-circulating liposomes 
(LCL)) are actively being investigated worldwide and the results have substantially expanded 
the role of liposomes in developing new therapeutics (see Table 2). The key factor 
responsible for the increased interest in liposome drug delivery is the observation that LCL 
spontaneously and selectively accumulate at sites of enhanced vascular permeability that are 
fortunately present in diseased tissues like tumors and areas of infection and inflammation 
(3,4). This phenomenon is usually referred to as ‘passive targeting’. The explanation for the 
fascinating passive targeting effect is straightforward: since LCL are generally smaller than 
the ‘pores’ that appear in the endothelial linings at pathological sites, their prolonged 
circulation property increases the chance that they extravasate into the extravascular space. 
Retention of LCL at these sites will lead to accumulation and the creation of a relatively high 
local drug concentration (10).  
The ability to passively target drugs to extravascular sites of pathology via LCL is 
dependent on a combination of: 
1.  Prolonged blood circulation, providing ample opportunities to encounter the region of 
disease. 
2.  Adequate access to the pathological tissue and target cells therein. 
3.  Ability of the LCL to interact with target cells and to deliver the encapsulated drug in an 
active form. 
Each aspect is briefly addressed below. 
 
II.1 Prolonged circulation 
Qualitatively, the mechanism behind the approaches taken to enhance the residence time of 
liposomes in the blood compartment is generally explained by reduction of the adsorption of 
various blood components onto the liposomal surfaces (e.g., adsorption of proteins 
long-circulating liposomes: design and applications 
  23 
interacting with one or more receptors on the MPS-macrophage cell surface, a process 
termed opsonization). Thus liposomes types able to resist rapid opsonization are likely to 
show prolonged blood circulation times (11,12). 
One of the first major advances in prolonging blood residence was made possible 
through careful studies of the dependence of MPS-uptake on liposomal lipid composition 
(13). These studies led to findings that small (i.e., less than about 100 nm in diameter), 
neutral and rigid (i.e., composed of fully saturated lipids and a high cholesterol content) 
liposomes can exhibit prolonged circulation, but only at relatively high lipid doses (13,14). 
This success in generating LCL has been exploited for development of the marketed 
liposomal formulations of the anticancer drug daunorubicin and the antifungal drug 
amphotericin B (15,16). (Table 2). It is believed that the use of highly cohesive bilayers 
inhibits interaction of plasma proteins with the liposome particles. Consequently, the opsonic 
proteins are not able to induce the surface modifications which otherwise would ‘mark’ the 
liposomes for MPS uptake. Another approach to create LCL utilized the inclusion of specific 
glycolipids such as monosialoganglioside Gm1 or phosphatidylinositol. It was hypothesized 
that these glycolipids act through creating a carbohydrate ‘shield’ over negatively charged 
groups located underneath (17). Overall, these methods achieved some success, but are all 
dependent on rigid liposome bilayers, which can impose a limitation when fluid bilayers are 
needed to achieve appropriate drug release rate profiles in vivo. 
A more recent development to prepare LCL with less restriction to lipid bilayer 
composition is based on modification of the liposome surface with hydrophilic polymers to 
protect the lipid surface of the liposome against protein adsorption and consequent uptake 
by mononuclear phagocytes. A list of polymer coatings investigated over the years is 
presented in Table 1. Stable coating with hydrophilic polymers is generally achieved by 
coupling the polymers to lipid anchor molecules that can insert into the liposome bilayer. 
The hydrophilic part of the conjugate is believed to form a repulsive steric barrier that can 
‘hide’ the liposome bilayer from plasma proteins (18-20). 
At present, by far the most extensively explored coating polymer is polyethylene 
glycol (PEG). The PEGylation strategy is often referred to as ‘steric stabilization’ or ‘Stealth 
technology’. Typically an incorporated molar amount of 5% proves to be sufficient to achieve 
prolonged circulation (25). In rats the plasma half-life of a 100 nm PEG-coated liposome is 
around 20 – 24 hrs while in humans a half-life of 45 hrs can be realized (26). PEG surface 
modification has been shown to have important advantages over the other methods to obtain 
prolonged circulation behavior (27). One important claimed advantage is that PEG-liposomes 
possess, within certain limits, dose-independent log-linear blood concentration-time profiles 
(28). This permits dose escalation without complications arising from changes in 
pharmacokinetic behavior. Another advantage is the possibility of varying the lipid 
composition without affecting circulation time and tissue distribution, which provides an 
ability to optimize the liposome physicochemical properties for drug loading and release 
(29). 
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Table 1. Polymers with capacity to extend the circulation time of liposomes 
Polymer Reference 
Poly(ethylene glycol) (4) 
Poly(acrylamide) (21) 
Poly(vinyl pyrrolidon) (21) 
Poly(acryloyl morpholine) (22) 
Poly(2-methyl-2-oxazoline) and Poly((2-ethyl-2-oxazoline) (23) 
Poly(vinyl alcohol) (24) 
Hydroxypropylmethylcellulose (24) 
 
 
II.2 Localization at pathological sites 
Besides rapid uptake by MPS-macrophages, another significant barrier for i.v.-injected 
particulate systems is the endothelial lining between the vascular space and extravascular 
target tissue. In most tissues the vascular system is lined with a continuous layer of 
endothelial cells often supported by a basement membrane. This barrier virtually excludes 
extrasavasation of particles such as LCL except for a few selected sites where the endothelial 
lining is discontinuous. Fortunately, it has been found that regions of increased capillary 
permeability include pathological sites such as tumors and sites of infection and 
inflammation. LCL have been shown to extravasate into these pathological areas (3,4). The 
mechanism(s) of extravasation (often referred to as ‘enhanced permeability and retention 
(EPR) effect’) is not well understood but can be thought of simply as ‘leakage in the 
plumbing’ (10). Inflammatory processes are accompanied by locally increased vascular 
permeability. In case of tumors, the angiogenesis process results in tumor blood vessels with 
increased permeability. Up to 10% of the injected LCL dose has been shown to localize in 
such sites of pathology, suggesting potential for substantial improvements in efficacy of 
encapsulated therapeutic agents that are active towards these pathologies. 
 
II.3 Therapeutic availability 
Conceptually, many agents could benefit from enhanced delivery to the pathological target 
and/or reduced distribution to healthy tissues. At present abundant literature is available 
showing that many therapeutic agents indeed profit from encapsulation in LCL by passive 
targeting resulting in enhanced localization in diseased tissues (Table 1). These results 
suggest broad applicability of LCL for drug delivery. For most LCL-entrapped drugs improved 
efficacy requires a liposomal composition capable of retaining the drug in the LCL during 
prolonged circulation but releasing it once the LCL have accumulated in the site of 
pathology, the latter aspect being referred to as therapeutic availability. These requirements 
have apparently been met by several formulations, as they show striking therapeutic 
activities in animal disease models and in some cases in humans. 
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As LCL are designed to be stable in the circulation, release of the active ingredients at 
the target site cannot be taken for granted (see also Figure 2, option 1). If the LCL remain 
intact at the target site, the release of drug will be a time-consuming process and local 
therapeutic levels of active drug are only slowly achieved. Fortunately, at sites of 
inflammation and tumors enzymes are active that can cause degradation of the liposome 
phospholipid bilayer (30). Especially LCL without polymer coating are expected to be 
affected by enzymatic degradation. A hydrophilic polymer coating may hamper the 
degradation process, although recently, it has been shown that inclusion of PEG in the lipid 
bilayers appears to enhance enzymatic degradation (31). 
When enzymatic degradation at the target site is insufficient, drug release may be 
achieved with triggering by external means. For over two decades researchers have been 
investigating the possibility of using thermosensitive liposomes. This approach is based on 
release of drug from the liposome as a result of enhanced fluidity of normally rigid liposome 
bilayers, when target tissue is heated above the transition temperature of the lipid 
composition. Several studies show that this concept can indeed result in increased 
therapeutic efficacy of a liposomally encapsulated drug (32,33). Another potential 
mechanism for drug release within the target site is uptake and intracellular processing of 
drug-LCL by local phagocytes. Intracellular degradation of the LCL bilayers may liberate the 
drug, which may subsequently diffuse out of the endosomal compartment and become 
active in the cytoplasm of he phagocyte. Successful targeting and modulation of macrophage 
populations at inflamed tissue has been achieved with long-circulating liposomes containing 
clodronate that can cause cell death when it becomes intracellularly available (34,35). 
Additionally, when a drug is able to pass membranes, it may eventually diffuse out of the 
phagocyte into the extracellular environment and thereby become available for interaction 
with the intended target cells. This concept of ‘macrophage-mediated drug release’ has been 
exemplified with the antitumor drug doxorubicin (36). 
It should be mentioned that drug release within the target site is not always required. 
This is the case when the LCL are used for diagnostic purposes. LCL-based formulations 
containing isotopes for scintigraphic imaging of infection and inflammation have been shown 
to represent promising radiopharmaceuticals in nuclear medicine (37,38). Table 2 shows the 
developmental status of the various liposomal pharmaceuticals that are currently in clinical 
and preclinical studies. 
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Table 2. Current developmental status of intravenous liposomal therapeutic agents 
 
Status 
 
Active ingredient (product name) 
 
Therapeutic field 
 
Reference 
 
Commercially 
available 
 
 
Doxorubicin (Doxil/CaelyxTM) 
Daunorubicin (DaunoxomeTM) 
Amphotericin (AmbisomeTM) 
 
Oncology 
 
(39,15) 
(39,15) 
(40,41) 
 
Clinical study 
Phase III 
 
 
 
Phase II 
 
 
 
Phase I 
 
Tretinoin (AtragenTM) 
Nystatin (NyotranTM) 
Amikacin (MikasomeTM) 
Prostaglandin E1 (VentusTM) 
 
Cisplatin (SPI-77) 
NDDP, a cisplatin analogue 
Vincristine (ONCO-TCS) 
 
Annamycin 
Paclitaxel 
 
Oncology 
Fungal infections 
Fungal infections 
Acute Respiratory Distress 
Syndrome 
Oncology 
 
 
 
Oncology 
 
 
(42) 
(43) 
(44) 
(45) 
 
(46) 
(47) 
(48) 
 
(49) 
(50) 
 
Preclinical, 
animal study 
 
 
Gentamicin 
Ceftazidime 
Streptomycin 
Kanamycin 
Cefoxitin 
Clofazimine 
Rifampicin 
Isoniazid 
 
Irinotecan (CPT-11) 
Boron derivatives for Boron Neutron 
   Capture Therapy 
GL147211C, camptothecin analogue 
TNF-alpha 
Adriamycin 
Interleukin-2 
Epirubicin 
MTP-PE, muramyl tripeptide derivative 
CNDAC, beta-D-arabino-
furanosylcytosine derivative 
 
20(S)-Camptothecin 
Amarogentin 
Atovaquone 
N-methylglucamine antimoniate 
 
Superoxide Dismutase 
Metotrexate 
Indomethacin 
Clodronate 
 
Cyclosporin 
Busulphan 
 
Hemoglobin 
 
Albuterol 
 
Bacterial infections 
 
 
 
 
 
 
 
 
Oncology 
 
 
 
 
 
 
 
 
 
 
 
Leishmaniasis 
 
 
 
 
Arthritis 
 
 
 
 
Transplantation 
 
 
Blood substitute 
 
Inflamed airways 
 
(51) 
(52) 
(53) 
(54) 
(55) 
(56) 
(57) 
(57) 
 
(58) 
(59,60) 
 
(61) 
(62) 
(63) 
(64) 
(65) 
(66) 
(67) 
 
 
(68) 
(69) 
(70) 
(71) 
 
(72) 
(73) 
(74) 
(75) 
 
(76) 
(77) 
 
(78) 
 
(79) 
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Taking together, passive targeting and improved therapeutic behavior of LCL-
encapsulated drugs is based on selective but non-specific extravasation into pathological 
tissues accessible from the circulation due to a locally increased vascular permeability. In 
most cases mentioned in Table 2, drug release takes place extracellularly. Subsequently, the 
released drug is able by itself to reach the therapeutic intervention site (often intracellular), 
which often will require passive diffusion over membrane barriers. However, when target cells 
are not localized in the extravascular space but for example in the blood circulation, the 
localization process requires more sophisticated strategies such as specific carrier-target cell 
recognition. In addition, an increasing number of new drug molecules, especially the new 
biotechnology derived agents such as proteins and nucleic acids, can not readily pass cell 
membranes due to their hydrophilicity and relatively high molecular weight. These molecules 
require liposomal carriers that are able to deliver the entrapped drug to the subcellular 
target compartment (often the cytoplasm or nucleus). In these situations surface-conjugated 
targeting ligands and/or membrane-translocating functionalities for intracellular delivery 
have to be included in the LCL system. Both ligand-mediated active targeting of liposomes 
and new approaches to obtain cytosolic drug delivery are discussed in more detail below. 
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III. ACTIVE TARGETING 
 
Active targeting of liposomes refers to the conjugation of site-directing ligands to the surface 
of liposomes to obtain specific binding to cell receptors on the surface of the target cells. 
Active targeting aims at improving the therapeutic availability of liposomal drugs to target 
cells within the pathological site and to minimize undesired side effects to non-target cells 
within the pathological tissue. Although ‘active targeting’ may suggest that liposomes are 
actively seeking their targets, resulting in increased amounts of drugs delivered at the 
diseased sites, this is far from reality. Ligand-mediated binding of liposomes to target cells 
only occurs when the intravenously administered liposomes ‘passively’ encounter a target 
cell. Target cells located in the circulation can be expected to be readily accessible. Target 
cells outside the vasculature are more difficult to reach and liposomes need to extravasate 
before being able to bind (80-82). As extravasation of liposome particles is the rate-limiting 
step in the targeting process, the presence of targeting ligands on the surface of liposomes is 
not likely to further enhance the amount of drug delivered at the target site. Nevertheless, 
the presence of targeting ligands on the surface of liposomes can be beneficial by binding to 
specific target cell receptors leading to improved cellular internalization of the liposomal 
drug contents. There are different methods available for attaching targeting ligands to PEG-
LCL. The most popular methods are based on ligand attachment to the terminal end of PEG 
(Figure 1) (83-85). For successful ligand-directed targeting of liposomes both the choice of 
the targeting ligand as well as the cell surface epitope to which the ligand will be directed are 
critically important.  
 
III.1 Choice of targeting ligand  
For active targeting of liposomes any ligand with specificity for cell-surface receptors that are 
selectively expressed on the surface of the target cell population can be used, as long as 
chemical conjugation of the ligand to the liposomal surface is feasible without loss of 
receptor specificity and/or affinity. Frequently used ligands for this purpose are antibodies 
(86-88), as they can easily be raised against a variety of antigens and often show high 
selectivity and affinity for their antigen. Besides antibodies other ligands have been studied, 
such as vitamins (89), peptides (90) and aptamers (91,92).  
An important aspect to consider when choosing the appropriate targeting ligand is its 
immunogenicity. Some ligands, especially those produced in other species, can be 
recognized as ‘foreign’ by the immune system of the patient especially when the ligands are 
conjugated to the distal ends of the PEG chains of LCL (Figure 1) (93). This ligand-mediated 
immune recognition may oppose the MPS-avoiding characteristics of LCL, resulting in 
increased clearance rates of i.v.-administered targeted liposomes. For instance, the presence 
of whole antibodies exposing the constant parts (Fc) of the antibody on the surface of 
liposomes makes these liposomes highly susceptible to Fc-receptor-mediated phagocytosis 
by cells of the MPS (94). To prevent this Fc-mediated immune-recognition, antibody 
fragments such as Fab’ and scFv molecules, lacking the constant part of antibody molecules 
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are frequently used. Important to note is that ligands with low intrinsic immunogenicity may 
become strongly immunogenic when conjugated to the surface of liposomes. In most cases 
chemical modification of the targeting ligand is required for covalent conjugation to the 
liposomal surface. Such modifications may also lead to increased immunogenicity (95).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obviously, the affinity of the liposome-conjugated ligand for the target receptor is also 
an important aspect. Binding to the target receptors should be strong enough to retain the 
liposomal carrier to the surface of target cells. As multiple targeting ligands are often 
conjugated to the surface of liposomes, affinity is in most cases not a problem. Even 
targeting ligands with low affinity for their receptor can be used to obtain strong binding to 
target cells due to the multivalent character of the targeted liposomes. However, very high 
affinity interactions between liposomes and target cells should be prevented as this may 
hamper the distribution of targeted liposomes within the pathological site. This so-called 
‘binding site barrier’ phenomenon has been described for antibodies (96) and scFv 
molecules (97). Similarly, this phenomenon was offered as an explanation for the 
observation that immunoliposomes targeted to solid tumors in a nude mice xenograft model 
were primarily located in the perivascular zones after systemic administration (98,99).  
 
 
 
Liposome membrane
Hydrophilic
drug
Targeting ligand
Lipophilic drug
Close-up of
phospholipid
bilayer
Poly(ethylene glycol)
PEG
Figure 1. Schematic drawing of a PEGylated liposome with targeting ligands and incorporated drug 
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III.2 Choice of target receptor 
In choosing the most suitable target receptor, several requirements have to be met. First, the 
target receptor should be expressed in sufficient amounts to allow accumulation of 
pharmacologically active drug levels in the pathological tissue. Second, the target receptors 
should be qualitatively or at least quantitatively different from receptors found in healthy 
tissue. Although cell surface receptors that are exclusively expressed under pathological 
conditions are scarce, disease-related overexpression of receptors is often found. For 
example, overexpression of adhesion molecules is common in inflamed tissue (100,101) and 
overexpression of growth factor receptors is often found in tumor tissue (102,103). Third, 
the target receptor should not be shed from the surface of target cells and should be readily 
accessible to the ligand-directed liposomes. Fourth, if cytosolic delivery of liposomal drug is 
required, receptor-mediated internalization of liposomes is highly desired (see Figure 2, 
option 3) It should be realized that targeting of liposomes to receptors with known 
internalizing capacities does not necessarily guarantee internalization of the liposomes. 
Binding of the targeting ligand may occur to specific epitopes on the internalizing receptor 
which do not trigger internalization (104). 
 
III.3 Cytosolic drug delivery 
Cytosolic access is problematic with many new biotherapeutic molecules (e.g. proteins, 
(poly)peptides and nucleic acids). Although ligand-mediated binding of liposomes to cell 
surface receptors can increase the cellular uptake of liposome-encapsulated drugs, the 
internalization process itself is not sufficient to yield an enhanced therapeutic effect as long 
as the entrapped drug is not delivered to the (sub)cellular intervention site. In most cases, 
the drug needs to be delivered into the cytosol in order to become effective. Some of the 
delivery strategies leading to cytosolic drug delivery are depicted in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Potential ways of cytosolic drug delivery with passively and actively targeted liposomes 
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III.3.1 Cell membrane fusion 
In case of targeting to receptors that do not internalize the liposomal drug carrier, cytosolic 
drug delivery can be obtained by fusion of the membranes of the cell-bound liposomes with 
the plasma membrane of the target cells (Figure 2, option 4). Such fusogenic liposomes have 
been constructed simply by fusing liposomes with Sendai virus particles. The virus-liposome 
fusion products retain fusogenic activity and can be used for the cytosolic delivery of 
liposome entrapped hydrophilic compounds into cells (105,106). Although these fusogenic 
virosomes have been used for many applications, among which gene delivery and vaccination 
purposes, specific targeting of these fusogenic vesicles to predefined cell populations 
remains problematic as the viral receptors present on the virosomes determine which type of 
cells can be targeted (107,108). Target-sensitive liposomes have been constructed whose 
bilayers destabilize upon target cell binding (109,110). This binding-induced destabilization 
results in extracellular release of liposome-entrapped compounds. Therefore, this strategy is 
not suitable for the delivery of biotherapeutics that require cytosolic delivery but may be 
useful to improve the therapeutic availability of small, membrane-permeant drugs at target 
sites. 
 
III.3.2 Endosomal escape 
When target cell binding results in internalization of the targeted liposome particles, the 
majority of the liposomes will face degradation in the endocytic/lysosomal pathway. This 
delivery route may be useful to obtain cytosolic delivery of drug molecules that can resist 
lysosomal degradation and diffuse out of the endosomal and/or lysosomal compartments 
once the liposomes have been degraded as has been reported for doxorubicin (36). However, 
in many cases delivery into the endosomal pathway results in degradation of the liposome-
entrapped drug. To prevent lysosomal degradation and to allow endosomal escape of the 
liposome-entrapped drug into the cytosol of target cells, endosomolytic functionalities should 
be incorporated (Figure 2, option 5). These functionalities should induce membrane-
perturbing activity preferentially in the low pH environment of endosomal compartments. 
Several proteins with pH-dependent membrane-perturbing activity have been identified in 
biological systems and some of them used to obtain enhanced cytosolic delivery are listed 
below. 
 
Hemolysins. Bacterial hemolysins are proteins with membrane pore-forming capacities that 
are produced by a variety of bacteria (111). In most cases, the pore-forming activity 
compromises the integrity of cells resulting in cell death. However, one of these hemolysins, 
listeriolysin O (LLO) secreted by the intracellular pathogen Listeria monocytogenes 
exclusively attacks membranes at low pH. Its function is to allow the escape of Listeria 
monocytogenes from the host’s phagocytic vacuoles into the cytosol. Incorporation of LLO 
into liposomes has resulted in efficient cytosolic delivery of co-entrapped compounds from 
internalized liposomes without measurably harming the cells (112). As the pores formed by 
such hemolysins are rather big, ranging in size from 15-35 nm dependent on the type of 
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hemolysin, this approach will be essentially suitable for the cytosolic delivery of bulky 
macromolecules such as DNA. 
 
Viral fusion proteins. Several enveloped viruses, among which the human influenza virus A, 
enter cells by the process of receptor-mediated endocytosis, routing the viral particles into 
the endosome. The low pH within the endosomes triggers the fusion of viral envelopes with 
the endosomal membrane, thereby releasing the viral nucleocapsids into the cytoplasm of 
host cells. In case of the human influenza virus both the adhesion of virus particles to the 
host cell membrane, which triggers internalization, and the low pH-induced membrane 
fusion reaction are mediated by the viral spike glycoprotein hemagglutinin (HA) (113,114). 
The envelopes of influenza viruses have been solubilized, purified and reconstituted into 
vesicles (115,116). These so-called ‘influenza virosomes’ bearing both the HA and the 
neuraminidase (NA) spike proteins retain fusogenic activity exclusively at low pH and have 
been used as carriers for the delivery of normally membrane-impermeable substances into 
the cytosol of cells via the endocytic pathway (114-119). However, as these virosomes have a 
tropism for sialic acid-bearing cells similar to the native virus, targeting of influenza 
virosomes to specific cell types is hampered. Recently, we have targeted influenza virosomes 
towards ovarian carcinoma cells by virtue of virosome-conjugated antibodies (Figure 3, 
unpublished results). This was accomplished by incorporating poly(ethylene glycol) (PEG) 
conjugated to phospholipids into the virosome membrane. We demonstrated that this PEG-
layer on the surface of influenza virosomes shields the interaction of HA with ubiquitous 
sialic acid residues and at the same time served as spatial anchor for antibody attachment. 
In this way, virosome binding to cells was exclusively antibody mediated without loss of 
fusogenic activity. Such antibody-redirected influenza virosomes may be useful carriers for 
the cytosolic delivery of otherwise membrane-impermeant therapeutic compounds via the 
route of receptor-mediated endocytosis. Antibody-directed virosomes are expected to be 
immunogenic due to the presence of viral proteins bearing highly antigenic determinants. 
This immunogenicity can provide adjuvant-activity when these carriers are used for the 
delivery of antigens for the purpose of vaccination (120).  
 
pH-dependent viral fusion peptides. The use of pH-dependent fusion peptides represents 
another approach to obtain cytosolic delivery of biotherapeutic molecules with targeted LCL 
via the route of receptor-mediated endocytosis (121). Synthetic peptides derived from viral 
fusion proteins are expected to be less immunogenic than the original fusion proteins as they 
lack the major antigenic determinants. This is even more true when these peptides are 
entrapped inside liposomes (122). In addition to reduced immunogenicity, peptides have the 
advantage that they can be readily synthesized at a large scale without the need for laborious 
purification procedures. Studies with synthetic peptides resembling the native sequence of 
the influenza virus N-terminal domain of the HA2 subunit have clearly demonstrated that 
such peptides are able to destabilize both model membranes (such as liposomes) and 
natural membranes in a pH-dependent manner (123-125). Fusion peptide-induced lipid 
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mixing between liposomes has been demonstrated, indicating that these peptides have 
fusogenic capacities. Influenza virus-derived fusion peptides have been successfully used to 
enhance the liposomal and endosomal escape of both DNA (122) and bacterial toxin 
fragments (personal observation) after cellular uptake of targeted liposomal formulations 
with co-encapsulated fusogenic peptides. This approach of cytosolic drug delivery is 
particularly effective as it combines targeting with efficient cytosolic delivery. The targeting 
step provides specificity and ensures delivery of the entire liposomal drug package into the 
target cells. In addition, the encapsulated fusogenic peptide triggers endosomolytic activity 
resulting in cytosolic drug delivery. 
  
III.3.3 Membrane translocating peptides 
Recently, protein transduction domains (PTD) within proteins have been identified that 
possess the ability to traverse biological membranes (126). Although the exact mechanism is 
unknown, transduction occurs in a receptor- and transporter-independent fashion and 
appears to target the cell membrane directly. Several studies have demonstrated that 
proteins and even large colloidal particles can be shuttled into cells when conjugated to such 
PTDs (127). In addition, it was recently demonstrated that conjugation of the protein 
transduction domain of HIV-TAT to the distal ends of PEG-chains, which were anchored into 
liposomal bilayers results in translocation of entire liposome particles into target cells 
(Figure 2, option 6) (128). This transduction process occurred even at low temperatures and 
in the presence of metabolic inhibitors. Although preliminary, this study shows that PTDs 
can be used to enhance the intracellular delivery of liposomes into cells. Unfortunately, as 
the transduction process is independent of specific receptors the PTD-mediated transduction 
is non-specific and cannot discriminate between cell types. It remains to be investigated 
whether PTD-mediated transduction of proteins and/or particulate carriers can be limited to 
specific cell types. 
Virosome ShieldedVirosome
  Shielded 
Immuno- 
Virosome
A B C
Figure 3. Antibody-redirected targeting of influenza virosomes. Unmodified influenza virosomes expose on 
their surface many copies of the hemagglutinin membrane protein, which contain the binding pocket for sialic 
acid residues (A). Poly(ethylene glycol) grafted at high densities on the surface of influenza virosomes can 
effectively shield the viral spike proteins, thereby preventing HA from interacting with sialic acid residues (B). 
Conjugation of antibody-Fab’ fragments at the distal ends of the surface-exposed PEG chains results in 
specific binding of virosomes to target cells that is predominantly mediated by the exposed Fab’ fragments and 
not by the HA proteins (C). 
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IV. FINAL REMARKS 
 
So far, long circulating liposomes appear to offer a range of opportunities for i.v. targeting to 
pathological sites. The multifaceted capabilities of liposomal formulations seem to 
continuously provide researchers with new opportunities for drug targeting. The flexibility of 
the system allows the design and development of liposome systems for the delivery of a wide 
range of drug molecules: from small stable drugs to larger, fragile biotherapeutics. However, 
liposomal preparations that are clinically investigated or commercially available mainly 
exploit the passive targeting effect for reaching tumors or sites of infection/inflammation. 
Obviously, the more sophisticated targeted liposome designs face a more complicated 
development route to reach clinical practice. Several complicating factors may play a role: 
for instance, any additional modification to a given drug carrier system requires thorough 
investigation of its influence on the safety profile of the delivery system as a whole. Another 
issue concerns the observation that modification of the surface of long circulating liposomes 
with targeting ligands or other functionalities often enhances immunogenicity and/or 
jeopardizes in vivo behavior. The latter aspect means that disappointing in vivo behavior may 
obscure each in vitro success yielding improved active targeting or cytosolic delivery. 
We hope that this review provides the reader with some insight in the design and 
development of liposomal delivery systems, and envisage that the versatility of the liposomal 
drug carrier will continue to offer ample opportunities for the development of new and 
improved liposome systems, applicable in the treatment of life-threatening and chronic 
diseases. 
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ABSTRACT 
 
Objective. To increase the therapeutic activity of glucocorticoids in experimental arthritis by 
encapsulation in long-circulating PEG-liposomes, which show the ability to preferentially 
accumulate in inflamed joints after i.v. administration. 
Methods. Rats with adjuvant arthritis (AA) were i.v. treated with liposomal and free 
prednisolone phosphate (PLP) a few days after the first signs of the disease. The effect on 
paw inflammation scores during the weeks after treatment was evaluated. Liposome 
biodistribution and joint localization was investigated by labeling the preparation with 
radioactive 111In. By studying PLP encapsulated in other types of liposomes, which show a 
distinctive tissue distribution pattern and reduced accumulation in inflamed joints, the 
importance of targeted delivery to inflamed joints for the increased therapeutic effect was 
illustrated. 
Results. Liposomal PLP proved to be highly effective in a rat adjuvant arthritis model. A 
single injection of 10 mg/kg resulted in complete remission of the inflammatory response for 
almost a week. In contrast, the same dose unencapsulated prednisolone did not reduce 
inflammation, while only a slight effect was observed after repeated daily injections. Evidence 
was found that preferential glucocorticoid delivery to the inflamed joint is the key factor 
explaining the observed strong therapeutic benefit obtained with the liposomal preparation, 
excluding other possible mechanisms like splenic accumulation or prolonged release of 
prednisolone in the circulation.  
Conclusion. Targeted delivery using long-circulating liposomes is a promising, novel means to 
successfully intervene in arthritis with glucocorticoids. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder, involving joint inflammation 
and progressive cartilage destruction (1). RA is primarily an inflammatory disease of the 
connective tissue characterized by spontaneous remissions and exacerbations (flare-ups). 
Glucocorticoids can be highly effective in treating joint inflammation, but their 
systemic application is limited due to a high incidence of serious adverse effects, especially 
related to long-term treatment (2,3). In addition it is generally assumed that, contrary to the 
so-called ‘disease modifying anti-arthritic drugs’, glucocorticoids only suppress the 
inflammatory process, leaving the progression of disease-related joint destruction unaffected 
(4,5).  
Two aspects are important for the efficacy-safety issues related to systemic 
glucocorticoid treatment. First is the unfavorable pharmacokinetic behavior of 
glucocorticoids upon i.v. administration, which is characterized by rapid clearance in 
combination with a large volume of distribution. Therefore high and frequent dosing is often 
necessary to achieve an effective concentration of glucocorticoid at inflamed target sites. 
Combined with the second aspect, namely the profound physiological activity of 
glucocorticoids in many different tissues, this explains the high risk of occurrence of side 
effects (6). 
We hypothesized that a drug-targeting approach could increase the therapeutic index 
(7). Glucocorticoids can be incorporated in particulate carriers that show enhanced 
localization in the target site relative to the drug in unbound form. One of the most 
interesting carriers for drug-targeting in inflammatory disorders is the long-circulating 
liposome (LCL) system. Liposomes are small lipid bilayer vesicles (LCL are approximately 
100 nm in diameter) with an aqueous core that can be used to entrap water-soluble agents. 
Often water-soluble polymers like poly(ethylene glycol) (PEG) are attached to the surface of 
LCL to reduce adhesion of opsonic plasma proteins that would otherwise induce recognition 
and rapid removal from the circulation by macrophages in liver and spleen (8-10). Using this 
approach PEG-coated LCL can remain in the circulation with a half-life as long as 50 hours 
(11,12). Studies with radiolabels entrapped in PEG-liposomes have indicated that PEG-
liposomes can selectively extravasate in inflammatory tissues, by virtue of increased 
permeability of the local vascular endothelium (13,14).  
To evaluate whether drug targeting can improve delivery and therefore the efficacy of 
glucocorticoids, we studied pharmacokinetics, tissue distribution, target localization and 
therapeutic activity of PLP-PEG-liposomes in a rat model of experimental arthritis. The 
results indicate that liposomal encapsulation can strongly increase the therapeutic efficacy of 
PLP. To investigate the critical role of the drug-targeting effect on the improved therapeutic 
activity, liposome types with short circulation times and reduced localization in the arthritic 
sites were investigated. The present study shows that enhanced joint accumulation of PLP 
realized with the long-circulating liposomal formulation explains the increased activity. 
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METHODS 
 
Preparations 
Liposomes were prepared by the film-extrusion method (15). Briefly a lipid solution was 
prepared in ethanol, containing dipalmitoyl phosphatidylcholine (DPPC) (Lipoid GmbH, 
Ludwigshafen, Germany) and cholesterol (Sigma Chemical Co., Poole, UK) in a molar ratio of 
2.0:1.0. For PEG-liposomes 7.5% of DPPC is replaced by PEG 2000-distearoyl 
phosphatidylethanolamine (DSPE) conjugate (Avanti Polar Lipids Inc, Alabaster, AL), 
resulting in a composition containing DPPC, PEG-DSPE and cholesterol in a molar ratio of 
1.85:0.15:1.0. A lipid film was created by rotary evaporation. The film was hydrated with a 
solution of 100 mg/ml PLP in sterile water. The resulting lipid dispersion was sized by 
repeated extrusion through a series of polycarbonate filter membranes. Unencapsulated 
prednisolone was removed by dialysis against 0.9% phosphate buffered saline using Slide-A-
Lyzer dialysis cassettes with a molecular weight cut-off of 10,000 (Pierce, Rockford, IL). 
Mean particle size was determined by dynamic light scattering with a Malvern 4700 system 
(Malvern Ltd., Malvern, UK). Small PEG and non-PEG liposomes were sized to a diameter 
between 90 and 100 nm while the diameter of large PEG liposomes was set between 450 
and 500 nm. Phospholipid content was determined with a phosphate assay (16) in the 
organic phase after extraction liposomal preparations with chloroform. The aqueous phase 
after extraction was used for determining the PLP content. With high performance liquid 
chromatography using a mobile phase of acetonitril-water with pH of 2 and monitoring the 
eluens with a UV-detector, which was set at 254 nm, both prednisolone and its phosphate 
ester could be measured in one single run. The liposomal preparation contained around 5 
mg PLP/ml and an average of 60 µmol/ml phospholipid. 
 
Adjuvant Arthritis 
The institutional Committee of Animal Experiments approved all animal studies. Male inbred 
Lewis rats between 7 and 9 weeks of age (200-250 g) were obtained from Maastricht 
University (Maastricht, the Netherlands). To induce arthritis, 100 ml of incomplete Freund’s 
adjuvant containing 1 mg of heat-inactivated Mycobacterium tuberculosis H37RA (both 
purchased from DIFCO laboratories, Detroit, MI) was injected intracutaneously at the base of 
the tail. 10 days after the immunization, the first signs of joint inflammation became 
apparent, together with a loss of body weight due to the upcoming of the disease. 20 days 
post-immunization the disease reached maximal severity, after which the inflammation 
process gradually resolved (18). 
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Clinical scoring 
Starting at day 10, rats were daily weighed and examined for visual signs of inflammation. 
The severity of the joint inflammation was graded by assigning a score to each paw from 0 to 
4, based on erythema, oedema and deformation of the joints. The sum of these four grades 
for each animal is the clinical score. 
 
Therapeutic efficacy 
Rats were treated on day 14 or 15 post-immunization, when the average score of all rats in 
the experiment reached 7, which is about half the maximal scores reached in these 
experiments. On the day of treatment, groups of five rats were formed with equal average 
clinical scores. All preparations were given intravenously via the tail vein. When multiple 
injections of free glucocorticoid were required, each following day treatment was given at the 
same time of the day. Clinical score and body weights were monitored daily for up to 2 
weeks post-treatment. During the last week of the experiment scoring, was performed less 
frequently. 
 
Labeling procedure 
Liposomes containing diethylene-triamine penta-acetic acid (DTPA) co encapsulated with 
PLP in the aqueous core were incubated with radioactive 111In-oxine at 60 ºC for 1 hr. 
Efficient transportation of the label through the lipid bilayer at this temperature followed by 
chelation by DTPA in the liposomal interior resulted in a labeling efficiency exceeding 90% of 
the total radioactivity added. Non-encapsulated 111In-oxine was removed by gel filtration on a 
Sephadex PD-10 column. The final preparation contained 120 mCi 111In-label, 40 µmol 
phospholipid and 3 mg PLP per ml. Since biodistribution studies require less activity than 
scintigraphic imaging studies, liposomes used for biodistribution were mixed with an equal 
amount of unlabeled PLP liposomes, in order to keep the total PLP content of each dose 
constant. 
 
Imaging studies 
Whole body scintigraphy was performed with three rats at six time points after injection of 
100 mCi 111In-labeled liposomes containing 2.5 mg PLP in the tail vein. Rats were 
anesthetized and placed prone on a single-head gamma camera equipped with a parallel-
hole low energy collimator (Siemens Orbiter, Hofmann Estates, IL). Per image 300,000 
counts were acquired and stored in a 256 * 256 matrix. 
 
Biodistribution studies 
At four time points (1, 4, 24 and 48 hours) after injection of a dose of liposomes containing 
50 mCi 111In-label and 2.5 mg PLP, five rats were euthanized with an overdose 
pentobarbital. After death, samples of blood, liver, spleen, lungs, kidneys, small intestine, 
muscles, front and hind paws were collected and counted in a shielded well-type gamma 
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counter. Injection standards were counted with the tissue samples to correct for physical 
decay and the percentage of liposome uptake per organ as well as uptake per gram tissue 
were calculated. 
 
Prednisolone plasma concentration 
Blood samples for determination of prednisolone plasma concentrations were centrifuged to 
obtain plasma and stored at –80 ºC. After the radioactivity in the samples had decayed 
(approximately 30 days), plasma was extracted according to the method reported by 
Derendorf et al. (17). An HPLC-method similar to that described above was used for the 
determination of both PLP and prednisolone in the extracts. The detection limit of the 
method was approximately 20 ng/ml. 
 
Statistical analysis 
For comparing clinical scores between groups, the nonparametric Wilcoxon/Kruskal-Wallis 
test (rank sums) was used. For evaluating differences between groups with respect to other 
parameters, one-way analysis of variance was used. P values of less than 0.05 were 
considered significant. 
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RESULTS 
 
Pharmacokinetics 
Figure 1 A shows that encapsulation of PLP in PEG-liposomes resulted in a change of the 
pharmacokinetics of the drug. First, the plasma concentration immediately after injection of 
5 mg/kg increased from approximately 1 µg/ml to over 100 µg/ml by encapsulating the 
drug in PEG-liposomes. Calculation of the volume of distribution revealed that PEG-
liposomes reduced the distribution volume of PLP from approximately 5 l/kg to less than 50 
ml/kg, indicating that PEG-liposomes limit the distribution of the drug to a volume only 
slightly larger than the plasma volume itself. 
Furthermore, liposomal encapsulation strongly reduced the elimination rate of the 
drug. As unencapsulated (‘free’) drug in plasma, PLP is rapidly converted into prednisolone. 
Indeed, neither PLP nor prednisolone were detectable anymore in the plasma samples within 
1 hour after injection of the free drug whereas i.v. injection of the liposomal drug yielded an 
exponential decline of PLP with a half-life of approximately 18 hours. Clearly, the liposomes 
protected PLP against rapid clearance, and therefore the plasma-concentration time profile 
of PLP was largely determined by the clearance of the liposome particles. This was 
confirmed by comparing the radioactivity the plasma samples with the PLP-concentration in 
the same plasma samples (Figure 1 B). The fact that both PLP and the liposome-associated 
radiolabel showed the same elimination profile indicated that the majority of PLP measured 
in plasma remained liposome-associated. Interestingly, despite the stability of the 
formulation in the circulation, low quantities of free prednisolone could be detected (Figure 1 
A). 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pharmacokinetics. (A) Plasma concentration of PLP (closed circles) and prednisolone (open circles) 
after 5 mg/kg liposomal PLP, and PLP (closed squares) and prednisolone (open squares) after 5 mg/kg 
unencapsulated PLP. (B) % of the injected dose in plasma of liposome label (squares) and encapsulated PLP 
(circles). Each data point represents the mean of 5 rats ± SD. 
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Tissue distribution 
The scintigraphic images of three rats acquired at different time points after injection of 
111In-labeled PLP-PEG-liposomes are shown in Figure 2 A. High blood levels were observed, 
as reflected by a clearly visible region in the thorax (heart and large vessels), which is in 
accordance with the results presented in Figure 1. Liver and spleen were also clearly 
visualized, showing that they represent important organs of liposome uptake. The inflamed 
joints of front and hind paws became clearly and increasingly visualized at 4, 20, 24 and 48 
hrs after injection. This observation points at gradual accumulation and retention of the 
liposomes at inflamed sites and excludes other possible explanations like increased blood 
flow in inflamed tissues. 
In Figure 2 B quantitative biodistribution data at 48 hrs post-treatment are shown for 
arthritic and healthy rats. Similar percentages of the injected dose per gram were found in 
tissues isolated from arthritic rats and healthy rats, with the exception of the paws. Hind 
paws of arthritic rats had a 7-fold higher liposome uptake than hind paws of healthy rats, 
indicating localization of liposomes to the inflamed areas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. In vivo fate of labeled liposomes. (A) Whole body scintigraphic images recorded at 0 to 48 hours post 
injection of 111In-labeld PLP-PEG-liposomes (B) Organ distribution of 111In-PEG-liposomes in healthy rats (open 
bars) and arthritic rats (black bars) 48 hours post injection. 
 
Therapeutic activity 
 Figure 3 A shows the anti-inflammatory activity of free and liposomal PLP at different doses 
in the rat model of AA. A single dose of 10 mg/kg free PLP did not result in a significant 
effect on paw inflammation scores. In contrast, the same dose encapsulated in PEG-
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liposomes resulted in the complete disappearance of the clinical signs of AA within two days. 
Resolution of the disease symptoms lasted until day 20 (6 days post-treatment) after which 
joint inflammation gradually reappeared, reaching the same score as the saline control 
group around day 28 (two weeks post-treatment). Liposomal PLP was also effective at a 10-
fold lower dose (1 mg/kg), and, even at a dose of 0.1 mg/kg, significant suppression of paw 
inflammation was observed two days after treatment (p < 0.05). Only liposomal PLP 
significantly reversed disease-induced weight loss. Within 8 days these rats completely 
regained the body weight they lost due to the disease. During the same period, the groups 
that received saline and free PLP kept loosing weight (Figure 3 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Therapeutic activity in adjuvant arthritis of a single treatment with PLP. (A) Effect on macroscopic 
inflammation scores of 10 mg/kg (black circles), 1 mg/kg (gray circles), 0.1 mg/kg (open circles) PLP-PEG-
liposomes, 10 mg/kg free PLP (black squares), and saline control treatment (open squares) (B) Effect on 
disease-induced body weight loss of 10 mg/kg PLP-PEG-liposomes (black circles), 10 mg/kg free PLP (black 
squares), and saline control treatment (open squares). Each point represents the mean of 5 rats ± SEM. Arrow 
indicates treatment. 
 
 
Repeated dosing with daily injections of 10 mg/kg free PLP only induced slight 
reduction of paw inflammation (Figure 4). This dosing regimen was based on clinical 
experience in RA patients with glucocorticoid ‘pulse’ therapy (4,5,19) which generally 
involves 3 to 5 daily injections of 1 gram (methyl)prednisolone. Even though daily treatment 
of AA rats was continued up to 7 days, no further remission of paw inflammation was 
accomplished. One day after finishing the last free PLP-injection (day 21), inflammation 
scores already returned to the average score of the control groups. In contrast, a single 
injection of liposomal PLP again resulted in almost complete disappearance of joint 
inflammation until day 20. Figure 4 also shows that control treatment with a single injection 
of empty liposomes did not have a significant effect. 
 
0
2
4
6
8
10
12
14
0 5 10 15 20 25 30 35 40
day after immunization
pa
w
 in
fla
m
m
at
io
n 
sc
or
e
A 
80
85
90
95
100
105
0 5 10 15 20 25 30 35 40
day after immunization
w
ei
gh
t l
os
s 
(d
ay
 o
f i
m
m
un
iz
at
io
n 
= 
10
0%
)
B 
chapter 3 
50 
0
2
4
6
8
10
12
0 10 20 30 40
day number
ar
th
rit
is
 s
co
re
day after immunization 
 
 
 
Figure 4. Therapeutic activity of liposomal PLP vs 
multiple treatment free PLP. Therapeutic activity of a 
single injection of 10 mg/kg PLP-PEG-liposomes (black 
circles), and 7 daily injections of 10 mg/kg free PLP 
(black squares). Control treatments are: empty PEG-
liposomes (open circles) and saline (open squares). 
Each point represents the mean of 5 rats ± SEM. Arrow 
indicates treatment. 
 
 
 
Importance of targeting effect 
To study the importance of targeting, two different liposome types with shorter circulation 
times and reduced joint localization were prepared. (1.) PEG-liposomes with a relatively large 
mean diameter, referred to as ‘large PEG-liposomes’, which are known to mainly target to 
the spleen and (2.) liposomes without the PEG-coating, referred to as ‘non-PEG-liposomes’, 
which show enhanced uptake by liver and spleen. 
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Figure 5. Importance of targeting effect. (A) Plasma
concentration-time curves of small PEG-liposomes (black
squares), non-PEG-liposomes (gray circles), and large
PEG-liposomes (black triangles) Error bars indicate SD.
(B) Targeting of the different types of liposomes in spleen
(left) and inflamed paws (right). Error bars indicate SD.
(C) Therapeutic activity in AA of 10 mg/kg PLP in small
PEG-liposomes (black circles), non-PEG-liposomes
(black diamonds) and large PEG-liposomes (black
triangles) compared to saline as control treatment (open
squares). Error bars indicate ± SEM. Arrow indicates
treatment. All data in (A), (B) and (C) represent the mean
of 5 rats.  
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In Figure 5 A and B the in vivo behavior of both liposome types compared to the small PEG-
liposome type is shown. As compared to the small PEG-liposomes, both preparations indeed 
showed a reduced circulatory half-life with clearly diminished accumulation in the inflamed 
joints. A much larger fraction of both liposomal formulations was taken up by the spleen. 
The therapeutic activity of the three different PLP-liposomal formulations was 
compared in the AA model. The small PEG-liposomes were clearly the most effective 
preparation, followed by the non-PEG-liposomes whereas the large PEG-liposomes were only 
marginally effective (Figure 5 C). Although therapeutically much less active, large PLP-PEG-
liposomes completely abolished disease-induced splenomegaly within two days. This 
indicates that PLP in large PEG-liposomes is potentially equally active as PLP in small PEG-
liposomes but that the reduced activity in the joints is caused by reduced localization of PLP 
in the joints (spleen weight at 48 hrs: 0.38 ± 0.07 g after treatment with large PLP-PEG-
liposomes; 0.42 ± 0.04 g after treatment with small PLP-PEG-liposomes versus 1.41 ± 0.19 
g in diseased non-treated rats and 0.36 g ± 0.03 g in healthy rats).  
 
Systemic availability 
To address the question whether the low quantities of free prednisolone levels observed after 
injection of liposomal PLP (see Fig 1 A) contribute to the anti-inflammatory effect, 
prednisolone levels were determined after injection of the three liposome types described 
above. As shown in Figure 6, the plasma concentration profiles of free prednisolone were not 
significantly different, despite the clear differences in circulation half-lives and therapeutic 
activity (see Figure 5). The absence of a clear correlation between the plasma concentration 
profiles of free prednisolone in the circulation and the anti-inflammatory activity of the three 
different liposomal preparations does not indicate an essential role of these low systemic 
glucocorticoid levels in the therapeutic activity of PLP-PEG-liposomes. 
 
 
 
 
 
Figure 6. Systemic availability. Plasma concentration-
time profiles of free prednisolone after injection 10 
mg/kg PLP in small PEG-liposomes (circles), non-PEG-
liposomes (diamonds) and large PEG-liposomes 
(triangles), Each point represents the mean of 5 rats ± 
SD. 
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DISCUSSION 
 
The first part of this paper indicates that an i.v. targeted drug delivery approach using long-
circulating PEG-liposomes could be a highly attractive alternative to current glucocorticoid 
treatment strategies, such as i.v. pulse therapy or local intra-articular injections (19-22). 
Long-circulating liposomes provide the opportunity to achieve high concentrations of 
glucocorticoid selectively at all arthritic joints by simple i.v. injection. The results indicate 
that in rat experimental arthritis a single i.v. injection of glucocorticoid-PEG-liposomes can 
already induce a strong, rapid and long-lasting therapeutic benefit. Complete remission of 
joint inflammation can be accomplished within two days of treatment, and the therapeutic 
benefit of the injection lasts for up to two weeks. Furthermore, the results show that an 
equivalent dose of free PLP is not effective. Limited efficacy, which is certainly not lasting, 
can be realized only with a treatment regimen involving daily injections of free PLP. 
The second part of this paper is devoted to the question of whether the increased 
therapeutic activity of liposomal PLP can be attributed to drug targeting. The results in this 
paper indeed point to a crucial role of drug targeting. Encapsulation of PLP in PEG-
liposomes strongly influenced the pharmacokinetics of i.v. injected glucocorticoid as shown 
in Figure 1. I.v. dosing of free PLP in rats resulted in only low and short-lasting plasma 
concentrations, presumably due to the rapid conversion of PLP into prednisolone. In its turn, 
free prednisolone was also quickly eliminated, which explains the lack of therapeutic activity 
of the free drug. Liposomal encapsulation markedly enhanced the concentration of PLP in 
the circulation. Apparently, liposomal encapsulation protects PLP against conversion and 
degradation. It also prevents it from the rapid and extensive tissue distribution, which occurs 
with free PLP. The plasma concentration-time profile of PLP largely resembled the plasma 
concentration-time curve of a liposome-associated radioactive marker, indicating that 
leakage of PLP from circulating liposomes does not play a significant role. Since the volume 
of distribution of PEG-liposomes is much smaller than the free drug, liposomal encapsulation 
may not just enhance the concentration of drug at the target site, but also lower drug 
concentrations at non-target tissues. The possibility of reduced toxicity may further improve 
the therapeutic index of glucocorticoid upon encapsulation in long-circulating PEG-
liposomes. 
A second confirmation of the crucial role of drug targeting in the enhanced 
therapeutic activity of liposomal PLP relates to the observation of selective accumulation of 
the liposomes at arthritic sites (Figure 2). Co-encapsulation of a radioactive marker indicated 
that the amount of liposomes that is taken up by the inflamed paws increased during the 
first 24 hrs post-injection, despite decreasing concentrations of liposomes in the circulation. 
This accumulation process appears to be inflammation-driven, as the degree of joint 
localization is much lower in healthy rats. Besides the inflamed paws, liver and spleen also 
appeared to be important organs of liposome uptake in rats with AA. Hepatosplenic uptake is 
largely responsible for the elimination of liposomes from the circulation and appears to be 
mediated by resident macrophages in these organs (23,24).  
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Interestingly, macrophages in lymphoid organs such as lymph nodes and spleen have 
been shown to be involved in the development of AA (25). The presumed uptake of 
glucocorticoid-PEG-liposomes by macrophages in the spleen may therefore (partly) explain 
the therapeutic activity of the preparation. Although it was found that PLP-PEG-liposomes 
completely reversed disease-induced splenomegaly within two days, the effect on joint 
inflammation did not relate to spleen targeting, as became evident from the effect obtained 
with the large PLP-PEG-liposomes. This liposome type, which homed to the spleen to an 
even higher extent without the capacity to localize in the inflamed joints, completely reversed 
splenomegaly as well, but only induced a partial remission of joint inflammation. 
Comparison of the activities of large PLP-PEG-liposomes and small PLP-non-PEG-liposomes 
to the activity of small PLP-PEG-liposomes, reveals that the therapeutic activity of liposomal 
glucocorticoid is related to joint accumulation. From our studies it appears that the better 
liposomes can accumulate in the inflamed joint, the stronger the therapeutic benefit. The 
process of spleen homing inversely correlated with the process of joint accumulation. 
Increased spleen uptake may have contributed to the shorter circulation half-life of large 
PEG-liposomes and liposomes without PEG, resulting in less joint accumulation and 
consequently in less anti-inflammatory activity. These relationships stress the importance of 
a prolonged residence time in the circulation for the realization of sufficient joint localization 
to guarantee strong anti-inflammatory activity of liposomal glucocorticoids. 
Besides a strong alteration of pharmacokinetics induced by liposomal encapsulation 
of PLP, Figure 1 also shows that sustained low levels of free prednisolone in the circulation 
were generated. Since little to no leakage of PLP from circulating liposomes occurred, it is 
hypothesized that a certain quantity of encapsulated PLP is released back into the 
circulation. Possibly, after hepatic and splenic uptake of liposomal PLP, phagocytes in these 
organs generate and release active prednisolone. The phenomenon of drug release from 
liposomes mediated by phagocytes in liver and spleen has previously been shown to occur 
with several liposomal preparations of cytotoxic drugs (26,27). The fact that large PEG-
liposomes and non-PEG-liposomes also generated such low levels of free prednisolone 
supports the hypothesis regarding the drug release by liver and spleen phagocytes. As the 
therapeutic activity of the latter two liposome types is limited, it is indicated that the 
phenomenon of sustained levels of active prednisolone in the circulation is not responsible 
for the increased therapeutic activity achieved by liposomal encapsulation of PLP. 
In conclusion, the results in this study indicate that a single i.v. dose of 
glucocorticoids encapsulated in long-circulating PEG-liposomes can lead to rapid, complete 
and durable resolution of joint inflammation as a result of enhanced and preferential 
localization of the liposomal drug in the inflamed joints. This novel approach could offer 
important advantages over existing therapies in arthritis, such as pulse therapy and intra-
articular injections.  
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LIPOSOMAL TARGETING OF GLUCOCORTICOIDS TO 
SYNOVIAL LINING CELLS STRONGLY INCREASES 
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ABSTRACT 
 
Objective. To investigate the effect of a single intravenous treatment with glucocorticoids 
encapsulated in long-circulating PEG-liposomes on both joint inflammation as well as 
cartilage destruction and to investigate the phenomenon of selective homing of these 
liposomes in the inflamed synovium. 
Methods. Mice with collagen type II – induced arthritis (CIA) were i.v. treated with liposomal 
and free prednisolone phosphate (PLP) a few days after the first signs of the disease. Paw 
inflammation was scored during one week post-treatment, after which sections of the knee 
joints were prepared for assessment of cartilage damage. In addition, arthritic mice were 
treated with colloidal gold-containing liposomes. At 24 hours post-injection knee joint 
sections were prepared in which the location of liposomes was visualized using silver 
enhancement. 
Results. Treatment of CIA with 10 mg/kg liposomal PLP resulted in a complete resolution of 
paw inflammation. The effect was visible until 1 week post-treatment. 10 mg/kg free PLP 
could only become slightly effective after repeated daily injections. Although the paw-
inflammation recurred at 1 week after treatment with liposomal PLP, knee joint sections 
prepared at this time point indicated that the cartilage damage was still reduced. 
Localization of gold-labeled liposomes in the inflamed joints was seen in the proximity of 
blood vessels, in the cellular infiltrate, but mainly in the synovial lining, which is crucial in the 
arthritic process. Unaffected joints did not take up liposomes. 
Conclusions. This study shows that by using the property of LCL to target the synovial lining 
selectively in inflamed joints, the anti-inflammatory activity glucocorticoids can be greatly 
increased, showing also a beneficial effect at the level of cartilage destruction. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder, characterized by joint 
inflammation and cartilage destruction (1,2). An important role in the pathogenesis of joint 
inflammation is ascribed to the synovial lining layer that surrounds the connective tissue in 
the joints. Normally, the synovial lining consists of a few cell layers of mainly fibroblast-like 
and macrophage-like synoviocytes. In RA however, the synovial lining layer expands as a 
result of newly arrived macrophages from the periphery (3,4). Macrophages in the synovial 
lining of arthritic joints have been shown to produce many pro-inflammatory cytokines, 
attract new inflammatory cells and produce enzymes that can damage the cartilage (3,5,6).  
Liposomes were shown to be valuable for targeting macrophages as these cells 
efficiently phagocytose them upon exposure (7-9). Intra-articular administration of a 
liposomal form of pro-apoptotic clodronate resulted in selective depletion of the phagocytic 
lining cells, which resulted in a marked decrease of joint inflammation (10,11). To realize 
macrophage depletion at inflamed synovia via the systemic route, Camilleri et al. and 
Richards et al. successfully employed small-sized liposomes that localized in inflamed joints 
after i.v. injection (12,13,14). However, as the majority of i.v. injected liposomes are 
generally taken up by the mononuclear phagocyte system (MPS) in liver and spleen, 
systemic treatment with liposomal clodronate may result in unintended elimination of 
hepatosplenic phagocytes, which play an important role in the immune defense of the body 
(15,14). 
Effective suppression without elimination of synovial macrophages can be 
accomplished with glucocorticoids (GC). GC can strongly reduce the generation and release 
of pro-inflammatory cytokines and cartilage-degrading enzymes by macrophages in arthritic 
joints (16,17,18). Besides activated macrophages, also the pro-inflammatory activity of 
fibroblasts, lymphocytes and endothelial cells is suppressed, and this may explain the 
striking anti-arthritic activity of GC. However, serious adverse effects limit systemic use of 
glucocorticoids in arthritis patients (19,20). Moreover, high and frequent dosing is necessary 
to achieve sufficient activity in the joints, since target localization is usually poor as a result 
of efficient clearance (21).  
For efficient delivery of GC into inflamed joints via systemic treatment, the use of 
small-sized liposomes coated with poly(ethylene glycol) (PEG) may be advantageous. PEG 
has been shown to be very effective in reducing recognition and rapid removal of liposomes 
from the circulation by the MPS, enabling liposomes to stay in the circulation for a prolonged 
period of time (22-24). The long-circulation property provides the liposomes the opportunity 
to substantially extravasate and accumulate in inflamed tissue (25). A study in arthritis 
patients treated with 99mTc-labeled PEG-liposomes indicated that PEG-liposomes can remain 
in the circulation with a half-life as long as 50 hours and that they selectively extravasate in 
inflamed joints (26). 
The objective of this study was to evaluate the capacity of long-circulating PEG-
liposomes to target the inflamed synovium and to expose phagocytic cells in the lining to 
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encapsulated GC. In the murine model of type II collagen-induced arthritis (CIA) the effect of 
liposomal GC on paw inflammation was investigated and compared with the effect of 
unencapsulated (‘free’) GC. Knee sections were prepared to evaluate the effect of liposomal 
GC on cartilage damage. Gold-labeled liposomes were used to determine the exact location 
of uptake in the inflamed tissue and to evaluate whether liposome localization is indeed 
inflammation-driven. 
Our results indicate that selective targeting of the inflamed synovial lining can be 
realized with long-circulating PEG-liposomes. Encapsulation of GC in these liposomes results 
in a dramatic increase of the anti-inflammatory activity of GC in the inflamed synovium. 
Besides a complete resolution of paw inflammation, a significant reduction of cartilage 
damage still visible at 1 week post-treatment was achieved. The approach of targeted 
delivery to the inflamed synovium mediated by PEG-liposomes may strongly improve the 
value of GC in the treatment of arthritis 
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METHODS 
 
GC-containing PEG-liposomes 
Liposomes were prepared by the film-extrusion method (27). Briefly a lipid solution was 
prepared in ethanol, containing dipalmitoyl phosphatidylcholine (DPPC) (Lipoid GmbH, 
Ludwigshafen, Germany), PEG 2000–distearoyl phosphatidylethanolamine (DSPE) and 
cholesterol (Sigma Chemical Co., Poole, UK) in a molar ratio of 1.85:0.15:1.0. The lipid 
solution was transferred to a round-bottom flask and a lipid film was created by rotary 
evaporation. The film was hydrated with a solution of 100 mg/ml prednisolone phosphate 
(PLP) in sterile water. The resulting lipid dispersion was sized by multiple extrusion through 
polycarbonate filter membranes. Unencapsulated prednisolone was removed by dialysis 
against 0.9% phosphate buffered saline using Slide-A-Lyzer dialysis cassettes with a 
molecular weight cut-off of 10,000 (Pierce, Rockford, IL, USA). Mean particle size was 
determined by dynamic light scattering with a Malvern 4700 system (Malvern Ltd., Malvern, 
UK). The liposomes were sized to a diameter between 90 and 100 nm. Phospholipid content 
was determined with a phosphate assay (28) in the organic phase after extraction liposomal 
preparations with chloroform. The aqueous phase after extraction was used for determining 
the PLP content. With high performance liquid chromatography using a mobile phase of 
acetonitril-water with pH of 2, connected to an UV-detector, which was set at 254 nm, both 
prednisolone and its phosphate ester could be measured in one single run. Each ml 
liposomal preparation contained around 4.5 mg PLP and an average of 60 µmol 
phospholipid. 
 
Gold-labeled PEG-liposomes 
Colloidal gold containing PEG-liposomes were prepared as described by Huang et al. with 
some modifications (29). The method of preparation is similar to the method described 
above for the preparation of PLP-PEG-liposomes except for the hydration step, which was 
performed with a freshly prepared tetrachloroaurate solution in citrate buffer. Sizing was 
performed at 4 ºC as described above. Immediately after extrusion, colloidal gold was 
formed by incubation of the dispersion at 37 ºC. To remove non-encapsulated gold, the 
preparation was eluted on a Sephacryl S1000-SF column (Pharmacia, Uppsala, Sweden). 
 
Collagen-induced arthritis 
The Dutch Committee of Animal Experiments approved all animal studies. Male DBA/1lacJ 
mice between 10 and 12 weeks of age (20-25 g) were obtained from Jackson Laboratories 
(Bar Harbor, ME, USA). To induce arthritis, 100 mg of bovine type II collagen dispersed in 
complete Freund’s adjuvant containing 2 mg/ml of heat-inactivated Mycobacterium 
Tuberculosis (both purchased from DIFCO laboratories, Detroit, MI, USA) was injected 
subcutaneously at the base of the tail. At day 21 a booster injection of 100 mg of bovine type 
II collagen was given intraperitoneally. At day 24 post-induction, the first signs of joint 
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inflammation became visible. From that day on, the mice were regularly examined for the 
visual signs of inflammation. The severity of the joint inflammation was blindly graded by 
assigning a score to each paw from 0 to 2, based on erythema, swelling and deformation of 
the joints. The sum of the grades for each animal is the clinical score and varies from 0-8 (30). 
 
Therapeutic efficacy 
All mice were treated on day 28 post-induction, when the average score of all mice in the 
experiment is about half the maximal scores. At day of treatment, groups of 6-7mice were 
formed with equal average clinical scores. 10 mg/kg PLP both encapsulated in PEG-
liposomes and in unencapsulated form was given as a standard dose. This dose was based 
on clinical experience with so-called ‘pulse’ treatment of arthritis patients involving single or 
repeated injections of 1 gram methylprednisolone (31,32). All preparations were given 
intravenously in the tail vein. Regarding multiple injections of free glucocorticoid, each 
following day treatment was repeated at the same time during 5 days. The effect of 
treatment on clinical scores and body weight was monitored 1 week post-treatment. 
 
Histology 
At 1 week post-treatment knee joints were dissected and fixed in 4% formaldehyde in 
phosphate-buffered saline (PBS). In addition the joints were decalcified with 5% formic acid 
in PBS during 7 days. After dehydration and embedment in paraffin, sections of the knee 
joint were cut that included patella, femur, menisci and tibia. These sections were mounted 
on gelatin-coated microscopic slides, stained with hematoxylin and eosin and examined 
using a light microscope (Leica, DMR, Germany). As a measure of inflammation, infiltrate 
and exudates were scored by two blind observers. Infiltrate is defined as the influx of 
leukocytes in the synovium. Exudate is defined as the influx of leukocytes in the joint cavity. 
The scores varied between 0 and 3, 0 being no cellular influx or exudate whereas 3 indicates 
maximal cellular influx or exudate. Besides inflammation also cartilage matrix erosion was 
scored using the same scale, 0 being no cartilage erosion whereas 3 indicates maximal 
cartilage erosion found at that time-point. Both the tibia and the femur were evaluated.  
 
Visualization of gold-liposomes 
A separate group of mice was treated with colloidal gold-containing PEG-liposomes to 
visualize the exact location of the liposomes in the synovium. 24 hours after treatment knee 
joints were dissected and decalcified in EDTA/PVP (polyvinylpyrrilodine) in TRIS buffer 
during 2 weeks. After freezing in liquid nitrogen, sections were cut in a cryostat (Microm, 
HM500M, Walldorf, Germany). These sections were mounted on Superfrost microscopic 
slides (Menzel Gläser, Germany). Silver enhancement of colloidal gold was performed with 
Sigma silver enhancer kit (Sigma, St. Louis, MO, USA) and terminated by incubating with a 
0.5% sodium thiosulphate solution in distilled water. The sections were then stained with 
hematoxylin and eosin and examined using light microscopy. 
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Statistical analysis 
For statistically assessing and comparing therapeutic efficacy in different groups the 
nonparametric Wilcoxon/Kruskal-Wallis test (rank sums) was used. For evaluating 
differences between groups regarding infiltrate and exudate, one-way analysis of variance 
was used. For statistical evaluation of the effect on cartilage damage Fisher’s test was used. 
P values of less than 0.05 were considered significant. 
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RESULTS 
 
Therapeutic activity 
Figure 1 A shows the anti-inflammatory activity of free and liposomal PLP at a dose of 10 
mg/kg in the murine CIA model. A single dose of free PLP did not result in a significant 
effect on paw inflammation scores. However, the same dose encapsulated in PEG-liposomes 
resulted in a complete disappearance of paw inflammation at 5 days post-treatment. In 
Figure 1 B the effect of repeated daily injections of 10 mg/kg free PLP is shown in 
comparison to 10 mg/kg and 1 mg/kg liposomal PLP. Surprisingly, also repeated 
administration with 10 mg/kg PLP had only limited effect. The effect is significant compared 
to the control mice but not significantly different from the effect of a single injection of a ten-
fold lower dose of liposomal PLP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Paw inflammation scores after single treatment with 10 mg/kg PLP-PEG-liposomes (♦),1 mg/kg 
PLP-PEG-liposomes (◊), 10 mg/kg unencapsulated PLP (∆), compared to both empty PEG-liposomes (■) and 
saline (●) as controls. In contrast to liposomal PLP, a single treatment with 10 mg/kg unencapsulated PLP had 
no significant effect (A). Multiple treatment with 5 daily injections of 10 mg/kg unencapsulated PLP (▲) had 
significant effect at day 32 and 35 but the effect was not better than 1 mg/kg PLP-PEG-liposomes (B). Each 
point represents the mean of 7 mice ± SEM. Arrows indicate treatment. 
 
Histological evaluation of inflammation and cartilage damage 
Figure 1 shows that 1 week post-treatment paw inflammation scores are recurring. However, 
the knee sections prepared at this time point still show a profound therapeutic effect of 
liposomal PLP on the integrity of the cartilage layers (Figure 2). In most of the tissue 
sections taken from control mice the cartilage appeared highly damaged whereas in the 
majority of the treated mice loss of cartilage was hardly visible. Figure 3 reveals only little 
difference regarding infiltrate and exudate as parameters for inflammation. These results 
correspond with the recurrence of the inflammation score as shown in Figure 1. Scoring of 
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the cartilage loss, however, revealed a significant beneficial effect in the treated group 
(Fishers’s test, p < 0.05). In 4 of the 7 mice treated with liposomal PLP no cartilage 
degradation was detected whereas in the control group all mice showed profound loss of 
cartilage.  
 
 
 
 
 
 
 
 
 
Figure 2. Effect of liposomal PLP on cartilage loss 1 week post-treatment. (A) Knee joint section after 
treatment with saline and (B) The same knee joint after treatment with 10 mg/kg PLP-PEG-liposomes. Original 
magnification x 200. T, tibia; F, femur, JS, joint space; C, cartilage layer.  
 
 
 
 
 
 
Figure 3. Histological evaluation of the effect 
on exudate and infiltrate as measures for 
inflammation and on cartilage erosion of 10 
mg/kg liposomal PLP at 1 week post-
treatment. Data indicate the mean of 7 mice + 
SEM.  
 
 
Localization of PEG-liposomes in the inflamed synovium 
The localization of colloidal gold containing PEG-liposomes in the knee sections of CIA-mice 
was visualized by silver enhancement and shown in Figure 4. Microscopic evaluation revealed 
that most of the liposomes accumulated in the region of the synovial lining. The majority of 
visualized gold appeared to be cell-associated. In areas around certain blood vessels the 
density of liposomes appeared to be relatively high. Despite the severity of the arthritis 
model, some mice had knee joints without inflammation. Interestingly, hardly any liposomes 
were visible in joints that did not show signs of inflammation (Figure 5). Clearly, the presence 
of an inflammatory process is a key factor for the liposomes in order to be able to localize in 
the synovium. 
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Figure 4. Visualization of gold-labeled PEG-liposomes in the inflamed knee joint. (A) Original magnification X 
50. (B) A magnification of X 100 of an area surrounding the synovial lining. Insert: magnification of X 200 of an 
area surrounding blood vessels. Gold particles are visible as black dots. Note that the liposomal gold is mainly 
localized in the synovial lining and some around blood vessels. Relatively few gold is visible in the cellular 
infiltrate. P, patella; F, femur, JS, joint space; CI, cellular infiltrate; SL, synovial lining; V, vessels. 
 
 
 
 
 
 
 
Figure 5. Visualization of gold-labeled PEG-
liposomes in an unaffected knee joint. Original 
magnification X 50. Note the absence of cellular 
infiltrate and gold-liposomes the synovial lining. P, 
patella; F, femur, JS, joint space; SL, synovial lining. 
 
 
 
 
 
 
 
 
Figure 6. Spleen localization of gold-labeled PEG 
liposomes. (A) Original magnification X 100. (B) A 
section of the white pulp surrounded by gold-labeled 
macrophages that reside in the red pulp. WP, white 
pulp; RP, red pulp. 
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Localization of PEG-liposomes in the spleen 
Silver enhancement of tissue sections from the spleen shows that almost all liposomes that 
were taken up by the spleen localized in the marginal zone and the red pulp. Visualized gold 
appeared to be largely cell-associated. Hardly any gold was detected in the white pulp 
(Figure 6). 
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DISCUSSION 
 
In the previous chapter we reported that encapsulation of PLP in long-circulating PEG-
liposomes resulted in a strong increase of the anti-inflammatory activity of PLP as compared 
to the free drug. A single i.v. injection of liposomal PLP could induce a complete resolution of 
rat adjuvant arthritis. Mechanistic studies with PLP encapsulated in different types of 
liposomes revealed that the observed increased therapeutic efficacy was a result of the 
specific property of small long-circulating PEG-liposomes to selectively home to inflamed 
paws. The present study focuses on the anti-arthritic effect of PLP-PEG-liposomes in murine 
CIA, which is an experimental arthritis model with a different etiology. This model also 
allowed a more in-depth investigation of the anti-arthritic effect by histological evaluation of 
inflamed joints. Furthermore, it became possible to visualize the exact location of the PEG-
liposomes inside the inflamed synovium after extravasation from the vasculature. 
The data in this study confirm the profound anti-inflammatory activity of PLP-PEG-
liposomes. The reduction of paw inflammation scores after a single injection of 10 mg/kg 
was rapid and complete resolution of arthritis was achieved at day 5 post-treatment. The 
therapeutic effect lasted for more than a week. 10 mg/kg unencapsulated PLP was only 
effective after repeated injection but this strategy, which was based on the clinical ‘pulse’ 
treatment regimen employed in RA patients, was not more beneficial than a single injection 
of 1 mg/kg liposomal PLP. Although after 1 week post-treatment joint inflammation clearly 
recurred, cartilage erosion was still reduced in mice treated with PLP-PEG-liposomes. 
Apparently, treatment with liposomal PLP results in a profound delay of the cartilage erosion 
process. This finding may be of importance as treatment of RA with i.v. ‘pulse’ GC is often 
criticized for the lack of ability to induce a delay in the progression of joint erosion (33,34).  
Knee joint histology performed after injection of gold-labeled PEG-liposomes revealed 
that the liposomes mainly localized in the synovial lining. Higher magnifications showed that 
almost all gold particles were cell-associated. The fact that a clear distinction was observed 
between cells that are positive for gold staining and cells without intracellular gold, strongly 
suggests that PEG-liposomes selectively localized in cells with phagocytic capacity after 
extravasation in the inflamed synovium. As it was shown before that gold-labeled PEG-
liposomes are stable in vivo, it is assumed that all intracellular gold originated from 
phagocytosed liposomes (29). The affinity of liposomes for phagocytes was also clearly 
visible in the spleen, in which the phagocyte-rich red pulp showed strong liposome uptake 
whereas the T cell-rich white pulp showed no sign of liposome uptake at all. As the PEG-
coating was used for its capacity to shield liposomes from recognition by MPS phagocytes, 
the extensive uptake by tissue phagocytes was somewhat unexpected. However, other 
researchers also report on similar observations with PEG-liposomes targeted to sites of 
bacterial infection (35,36).  
Besides the synovial lining also some gold staining was visible in the infiltrate and 
around the blood vessels, which brings up two possible explanations for the observed 
localization of liposomes in the inflamed synovium. First, the gold found in the inflamed 
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synovium is associated with infiltrating monocytes/macrophages that phagocytosed 
liposomes in the periphery or second, gold around some blood vessels are liposomes 
extravasating from the circulation without the help of leukocytes. Schiffelers et al. addressed 
this issue and found support for the second explanation (35). Also, the fact that Camilleri et 
al. and Richards et al. report their small clodronate containing liposomes to eliminate 
synoviocytes despite the depletion of peripheral phagocytes, points in the direction of a 
phagocyte-independent localization mechanism (12,13,14). 
 As the onset of CIA varies, some knees of the CIA mice did not yet show signs of 
inflammation at the day of treatment. Tissue sections from these knee joints did not reveal 
any sign of liposome localization. Clearly, PEG-liposomes show selectivity for inflamed 
synovia, which further supports the suggested role of inflammation-enhanced vascular 
permeability as an essential phenomenon for liposome localization. 
 The affinity of PEG-liposomes for macrophages in inflamed synovia makes them 
highly attractive carriers for GC. Macrophages play an important role in the onset and 
progression of arthritis, as they produce the pro-inflammatory cytokines TNF-α, IL-1, IL-6, 
generate chemokines, tissue-degrading enzymes and play a role in the presentation of auto-
antigens to T cells (5,6). Selective depletion of activated macrophages from the inflamed 
joint via intra-articular injection of liposomal clodronate was indeed shown to be a promising 
treatment approach (10,11). Depletion of macrophages via the systemic route appeared to 
be less attractive, since elimination of macrophages from liver and spleen was shown to 
strongly affect MPS-functioning (15). GC may be more interesting to encapsulate in 
liposomes for a systemic treatment approach as GC can effectively downregulate the pro-
inflammatory effector production without eliminating the macrophages. 
The small PEG-liposomes used in this study offer the advantage of reduced uptake by 
the MPS, along with a prolonged circulation property resulting in enhanced accumulation at 
inflamed sites (22-26). The extensive phagocytosis of PEG-liposomes we observed within the 
inflamed tissue will inevitably result in exposure of the macrophages to high intracellular 
concentrations of GC, which may be one plausible explanation for the strong anti-
inflammatory effect. However, as GC can easily pass cellular membranes, the drug may 
escape from the intracellular compartment, suppressing other inflammatory cells in the 
synovium as well. Besides their role as target cell in arthritis, macrophages may therefore 
also play a crucial role in the release of GC from liposomes and the generation of relatively 
high and prolonged concentrations of active drug in the synovium. Previously we showed that 
the liposomal formulation used in our studies was highly stable in vivo and that leakage of GC 
from the liposomes without the involvement of an external trigger is not likely. The suggested 
need for activated macrophages to release GC from liposomes may add an additional form 
of target selectivity to the liposomes besides selective accumulation at inflames sites. 
Further studies are however necessary to address the uptake and intracellular processing of 
liposomal GC by macrophages. 
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Our study indicates that the observed property of PEG-liposomes to selectively target 
the inflamed synovial lining can strongly enhance the beneficial effects of GC in arthritis. The 
observed affinity of PEG-liposomes for macrophages may lead to high concentrations in 
inflammatory cells at arthritic joints combined with less exposure of healthy non-target 
tissues to GC. 
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ABSTRACT 
 
High-dose glucocorticoid hormones are a mainstay in the treatment of relapses in multiple 
sclerosis (MS). We present a way to deliver ultra high doses of glucocorticoids to inflamed 
sites in the central nervous system (CNS) in experimental autoimmune encephalomyelitis 
(EAE) using a novel formulation of PEG-coated long-circulating liposomes encapsulating 
prednisolone (PL). 3H-labeled PL showed selective targeting to the inflamed CNS, where up 
to 4.5-fold higher radioactivity was achieved than in healthy control animals. HPLC revealed 
much higher and more persistent levels of prednisolone in spinal cord after PL compared to 
an equal dose of free prednisolone. Gold-labeled liposomes could be detected in the target 
tissue, mostly taken up by macrophages (Mϕ), microglial cells and astrocytes. Blood-brain-
barrier disruption was strongly reduced by 10 mg/kg PL, which was superior to a 5-fold 
higher dose of free methylprednisolone (MP). PL was also superior to MP in diminishing T 
cell infiltration by induction of T cell apoptosis in spinal cord. Mϕ infiltration was clearly 
decreased only by PL. The rate of tumor necrosis factor-a (TNF-α) positive T cells or Mϕ was 
strongly reduced by PL and by MP. No adverse effects on glial cells were detected. A single 
injection of PL clearly ameliorated the course of adoptive transfer EAE and EAE induced by 
immunization. In conclusion PL is a highly effective drug in treatment of EAE, and is superior 
to a five fold higher dose of free MP, possibly by means of drug targeting. These findings 
may have implications for future therapy of autoimmune disorders such as MS. 
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INTRODUCTION 
 
Multiple sclerosis (MS) is one of the most common inflammatory disorders of the CNS. Its 
pathological hallmarks are demyelination and cellular infiltration of T cells (TC) and 
macrophages (Mϕ). The most favored pathophysiological hypothesis includes a TC 
dominated autoimmune reaction (1). 
Despite long-term immunotherapy relapses occur, which are commonly treated by 
repeated i.v. injections of high doses (‘pulse’) glucocorticoid (GC) as potent anti-
inflammatory drug. The main goal is to prevent ongoing tissue destruction with loss of 
oligodendrocytes, axons and neurons leading to permanent functional deficits. In MS a pulse 
therapy with 10 mg/kg methylprednisolone (MP) for 3-5 days is the standard regimen in 
relapse therapy (2, 3). The optimal dosage of the pulse GC is still under debate. Recently, it 
was reported that treatment with ultra high dose 2 g MP i.v. per day is superior to 500 mg 
per day for 5 days with regard to reduction of disease activity as measured by MRI criteria 
(4). In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, we have 
previously shown, that an ultra high dose of 50 mg/kg MP i.v. is superior to eliminate 
inflammatory infiltrates than a ‘standard’ dose of 10 mg/kg MP i.v. and is associated with 
much higher tissue levels of MP (5). 
The pharmacological effects of GC are based on a wide range of mechanisms of 
action (6). At a lower concentration GC-effects are mainly mediated by the classical GC 
receptor, yet at a higher concentration additional, non-genomic mechanisms may be 
operative, such as through membrane receptors and activation of a second messenger 
system (7, 8). These pathways are thought to be one possible explanation for the observed 
superiority of high and ultra high doses in the treatment of some autoimmune disorders (6). 
The goal of this study was to investigate the effects of long-circulating prednisolone-
liposomes (PL), a novel formulation for drug targeting, in treatment of EAE. These PL have 
been shown to exert a clear beneficial effect in an experimental rat model of arthritis (see 
Chapter 3). The objective of drug targeting with this formulation is to achieve ultra high 
tissue concentrations of GC in the inflamed target organ as compared to an equivalent dose 
given as free drug, and at the same time a much lower concentration systemically with a 
reduction of unwanted side effects.  
Here we show that drug targeting by PL is highly effective in restoring the blood-
brain-barrier (BBB)-integrity and in reducing cellular inflammation by induction of TC 
apoptosis, thereby ameliorating the disease activity of active and adoptive transfer (AT)-EAE 
without detectable side effects. Moreover, in contrast to free GC, Mϕ infiltration was 
diminished after PL. The effects may be explained by ultra high tissue levels of GC, achieved 
by means of drug targeting. Our results may have implications for a more efficient therapy of 
relapses in MS and of other autoimmune disorders.  
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MATERIALS AND METHODS 
 
Animals, cell culture and EAE 
Female Lewis rats (Charles River, Sulzfeld, Germany) were 6-8 weeks old. All culture media 
and supplements were obtained from Gibco BRL (Eggenstein, Germany). Encephalitogenic 
TC for in vivo experiments were generated and maintained as previously described in detail 
(9). Briefly, primed TC (3 ∗ 105/ml) were restimulated with guinea pig myelin basic protein 
(MBP, 20 µg/ml) in culture medium (RPMI 1640) supplemented with 1% normal rat serum, 
100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, using freshly isolated and 
irradiated (3000 rad) thymocytes (1.5 ∗ 107/ml) as antigen presenting cells. 
 AT-EAE was induced by tail vein injection of 10-12 ∗ 106 freshly activated, MBP 
specific TC. Animals were inspected daily by an observer masked to the respective 
treatment, using a 6 grade score: 0, healthy; 1, weight loss, limp tip of tail; 2, limp tail, mild 
paresis; 3, moderate paraparesis, ataxia; 4, tetraparesis; 5, moribund; 6, dead (5). Disease 
onset in all animals was at day 2, maximum at day 5. Active EAE was induced in rats by 
immunization with 75 µg guinea pig MBP in 100 µg complete Freund's adjuvant (CFA) per 
animal by s.c. injection in the hind paws. Disease onset was at day 10 to day 12 with 100% 
incidence, maximum was at day 13/14. 
 
Preparation of long-circulating PEG-liposomes 
Liposomes were prepared by the film-extrusion method (10). Briefly, a lipid solution was 
prepared in ethanol, containing dipalmitoyl phosphatidylcholine (DPPC, from Lipoid GmbH, 
Ludwigshafen, Germany), poly(ethylene glycol) (PEG) 2000–distearyl 
phosphatidylethanolamine (DSPE) and cholesterol (Sigma Chemical Co., Poole, UK) in a 
molar ratio of 1.85:0.15:1.0. A lipid film was created by rotary evaporation. The film was 
hydrated with a solution of 100 mg/ml prednisolone phosphate (Bufa, Uitgeest, The 
Netherlands) in sterile water. The resulting lipid dispersion was sized by multiple extrusion 
through polycarbonate filter membranes to a diameter of 90-100 nm. Mean particle size was 
determined by dynamic light scattering with a Malvern 4700 system (Malvern Ltd., Malvern, 
UK). Phospholipid content was determined with a phosphate assay (11) and prednisolone 
phosphate concentrations by reversed-phase HPLC (12). Each one ml liposomal preparation 
contained around 4.5 mg prednisolone phosphate and an average of 60 µmol phospholipid. 
 Colloidal gold-containing PEG-liposomes (13) were prepared accordingly except for 
the hydration step, which was performed with a freshly prepared tetrachloroaurate solution 
in citrate buffer. Immediately after extrusion, colloidal gold was formed by incubation of the 
liposomal dispersion at 37 °C.  
 3H-labeled liposomes were prepared similarly except for the lipid composition: to the 
lipids dissolved in ethanol [3H]-cholesteryloleylether (Amersham, Uppsala, Sweden) was 
added as a non-degradable liposome lipid phase marker. After rotary evaporation under 
reduced pressure, the lipid film was hydrated with PBS at an initial total lipid concentration 
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of 50 µmol/ml. Radioactivity of the liposomal dispersions was assayed in a liquid 
scintillation cocktail purchased from Ultima Gold (Groningen, The Netherlands) and counted 
in a Philips PW 4700 liquid scintillation counter. Lipid content of the liposomal dispersion 
was determined by assessing the loss of radioactivity of the liposomes during preparation. 
This mixture contained approximately 2.5 mg/ml prednisolone phosphate and 75 kBq/ml 
radioactivity. 
 
Treatment protocol and tissue sampling 
For therapeutic studies we used prednisolone PEG-liposomes (PL) and free prednisolone-
phosphate or methylprednisone hemisuccinate (MP) (Urbason solubile®, Aventis, Frankfurt, 
Germany). Treatment regimen for AT-EAE essentially followed the protocol used in previous 
studies (5, 14). All experiments, except for gold-labeled liposomes (n=4), and 3H-labeled 
liposomes (n=4), were performed in groups of 6 animals each and reproduced at least once. 
10 mg/kg body weight PL was injected i.v. in a tail vein at 2, 6, 18 and/or 42 hr before 
perfusion at day 5. As positive control another group received 50 mg/kg body weight MP 18 
and 6 hr prior to sacrifice (5).  
 In a separate experiment colloidal gold-labeled liposomes were applied once at 18 hr 
or 42 hr. In active EAE in rats 10 mg/kg body weight PL were injected once i.v. at beginning 
of disease at day 12. 50 mg/kg body weight MP was administered twice i.v. at days 12 and 
13. Controls received empty liposomes and/or saline i.v. 
 For tissue preparation anesthetized animals were perfused with HAES-steril® 6% 
(Fresenius, Bad Homburg, Germany), followed by paraformaldehyde 4% in 0.1 M phosphate 
buffer. Spinal cord was removed, postfixed, dehydrated and embedded in paraffin. 
 For [3H] analysis in EAE vs. healthy rats lethal CO2-anesthesia was applied and blood 
was drawn by cardiac puncture and centrifuged. Subsequently, spinal cord, brain, spleen, 
liver, one sciatic nerve and one 5∗5 mm lower back muscle as non-inflamed control tissue 
were taken out. All samples were stored at -80 °C until analysis. The organs of one non-
treated rat were used for background radioactivity determination. 
 [3H]-concentrations was measured after homogenization, addition of Solvable tissue 
solubilizer (NEN, Dreieich, Germany) and 35% hydrogen peroxide. After overnight incubation 
the samples were assayed in Ultima Gold scintillation cocktail (Packard BioScience B.V., 
Groningen, The Netherlands). Counting time was to a statistical precision of ± 0.2% or a 
maximum of 5 min whichever comes first. The scintillation counter was programmed to 
automatically subtract background and convert counts per min to disintegrations per min. 
Besides tissue samples also the radioactivity of the injected dose was counted. The ratio 
tissue samples radioactivity over radioactivity of the injected dose yielded the rate of the 
injected dose value in percent.  
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Immunohistochemistry 
Five µm cross-sections of spinal cord, spleen or liver were deparaffinized and rehydrated. 
Pretreatment with hydroxylamine (0.9%, from Sigma-Aldrich Chemicals, Deisenhofen, 
Germany) was required for albumin stain, and with protease 24 (0.4%, from Sigma-Aldrich) 
for Kupffer cells. As primary reagents we used: mouse mAb to a pan TC antigen (B 115-1, 
dilution 1:500, from HyCult biotechnology, via Sanbio, Beutelsbach, Germany) for TC; 
mouse mAb ED1 (diluted 1:500, from Serotec, via Biozol, Eching, Germany) for Mϕ; mouse 
mAb ED2 (diluted 1:300, from Serotec) for Kupffer cells; rabbit polyclonal Ab to the glial 
fibrillary acidic protein (GFAP) from cow (diluted 1:500, from DAKO, Hamburg, Germany), 
incubated at 4 °C over night, for astrocytes; mouse mAb to 2', 3'-cyclic nucleotide 
phosphohydrolase (CNPase, diluted 1:200, from Chemicon, Hofheim, Germany) for 
oligodendrocytes; lectin histochemistry with a biotinylated Griffonia simplicifolia isolectin B4 
(GSA-I-B4, concentration 100 µg/ml, Sigma-Aldrich Chemicals), incubated 24 hr at room 
temperature, for microglial cells; anti-albumin Ab (diluted 1:200, from Nordic, Bochum, 
Germany) for detection of BBB-disruption (15). All primary reagents/antibodies were 
incubated for one hr at room temperature unless stated otherwise. Primary 
reagents/antibodies were detected using the ABC-system (DAKO), and with 3,3’-
diaminobenzidine (DAB) tetrahydrochloride as chromogenic substrate. Sections were 
counterstained with hematoxylin for 30 sec.  
 Colloidal gold was visualized with a silver-enhancing solution (Sigma-Aldrich 
Chemicals) for 16 min in the dark. Sections were fixed by immersing in 2.5% aqueous 
sodium thiosulfate for 2-3 min, followed by immunohistochemistry for detection of glial or 
immune cells. Double labeling of apoptotic TC was performed by TUNEL as described before 
with nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) as 
chromogenic substrate (16). Double staining for TNF-α positive TC or Mϕ was performed as 
previously established (13). In brief, TNF-α was detected by a rabbit polyclonal Ab (diluted 
1:100, from Serotec), visualized with Vector Red (Vector) as chromogenic substrate, 
followed by detection of TC or Mϕ, using DAB-nickel (black, from Vector) as chromogenic 
substrate. All sections were dehydrated and mounted in Vitro-clud® (R. Langenbrinck, 
Emmendingen, Germany). Analysis of inflammatory infiltrates was performed by an observer 
masked to the respective treatment rating 1.6-3.2 mm2 of lumbar spinal cord at 250 ∗ 
magnification. Apoptosis was assessed by morphological criteria (17) or TUNEL. BBB-
disruption was quantified by a computer-aided grey scale measuring (Scion Image software, 
Scioncorp., Maryland, USA) with an Axiovert 100 microscope (Zeiss, Göttingen, Germany) 
and a CCD DXC 950P camera (Sony, Köln, Germany). We measured the maximal signal 
intensity of half a spinal cord cross section at 100 ∗ enlargement. 
 
Statistical analysis 
Statistical analysis of the data was performed by the Student t test (Excel, Microsoft, 
Germany), considering *P < 0.05, **P < 0.01, ***P < 0.001 as significant P values. 
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RESULTS 
 
3H-labeled PL accumulate in CNS. 
Selective accumulation of PL in the inflamed CNS was measured by 3H-labeled PL, which 
were injected at time points indicated in Figure 1 A. The serum level was highest 2 hr after 
injection and then gradually decreased about 50%, but even 42 hr after injection 3%/g 
organ of the injected dose was found to be circulating in AT-EAE rats as well as in healthy 
control animals. In the livers of the rats 1.5%/g organ were achieved after 6 hr, which 
remained basically unchanged until 42 hr after injection and was similar to levels of a 
healthy control animal. In spleen 2.7%/g organ were obtained 2 hr after the injection. 
Furthermore, [3H]-PL accumulated in spleen, reaching 20.3%/g organ 42 hr after injection, 
which was similar to healthy animals (Figure 1 A). These levels of 3H-labeled liposomes were 
in accordance with observations in experimental rat arthritis reported by Metselaar et al. 
(Chapter 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3H-labeled PL at indicated time points measured in serum, liver and spleen (A) or spinal cord, brain 
and control tissues nerve and muscle (B). Radioactivity is given as percentage of the injected dose per gram 
organ of 3H-labeled PL in AT-EAE vs. healthy control rats (n= 4 per group). 
 
 The [3H]-values in spinal cord, brain, peripheral nerve and muscle were lower 
compared to serum, spleen and liver. However, compared to the 42 hr-value in control 
animals without inflammation, there was a 3-fold higher [3H]-PL accumulation in CNS, in 
spinal cord with the highest number of inflammatory lesions and BBB-damage (18) even up 
to 4.5-fold (Figure 1 B). Also, in contrast to nerve and muscle from EAE-rats, only in the 
inflamed CNS we could observe a gradual increase of the rate of [3H]-PL, indicating an 
accumulation of PL. In the control nerve and muscle tissue we found no clear difference 
between EAE-rats and healthy control animals, except for the early time points in the nerve, 
where a decreasing curve similar to serum was observed. This may be best explained by 
contamination of the small tissue sample with blood (Figure 1 B). 
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Single injection of PL is effective in AT-EAE. 
First we investigated the optimal timing of the PL injections. We applied a single dose of 10 
mg/kg PL i.v. at 6 hr, 18 hr, or 42 hr or empty liposomes at 42 hr before perfusion at day 5 
in AT-EAE. 42 hr after PL the rate of TC apoptosis was increased compared to all other 
groups (***P < 0.001 vs. control or 6 hr; **P < 0.01 vs. 18 hr) (Table 1) and TC infiltration 
was clearly reduced (**P < 0.01 vs. all groups). PL given at 18 hr before perfusion increased 
TC apoptosis (**P < 0.01 vs. 6 hr or control), with only slight effect on TC infiltration (Table 
1). Only with treatment at 42 hr the disease course was ameliorated, which was repeated 
once (*P < 0.05 compared to all other groups) (data not shown). 
 
 
Table 1. Treatment of AT-EAE with a single 
i.v. injection of 10 mg/kg PL at indicated time 
points compared to empty liposomes and 
perfusion on day 5. Immunohistochemical 
staining for TC in spinal cord: rate of apoptotic 
TC (%) rated by morphological criteria and 
double labeling with TUNEL and number of 
infiltrating TC (per mm2) (n=5 per group, data 
are mean ± SD). P-values explained in text. 
 
 
PL is superior to free GC in AT-EAE. 
We then chose the two effective treatments with 10 mg/kg PL at 42 hr and at 18 hr as 
therapeutic regimen with two injections. This was compared to our previous regimen of two 
injections of 50 mg/kg MP at 18 hr and 6 hr (5). We investigated the BBB-integrity by an 
immunohistochemical staining for albumin, followed by a computerized grey-scale analysis. 
PL (density: 114 ± 1.5) was superior to MP (density: 121 ± 1.9, ***P < 0.001 PL vs. MP); 
MP also restored the BBB-function as compared to controls (density: 127 ± 2.3, **P < 0.01 
MP vs. controls) (2 d-f). PL clearly increased TC apoptosis (***P < 0.001 vs. control, P = 
0.07 vs. MP) and reduced TC infiltration (*P < 0.05 vs. all groups) (Figures 3 A,B; 2 a-c). MP 
augmented the rate of TC apoptosis (**P < 0.01 vs. control), but only marginally reduced TC 
infiltration. In one experiment we added another group, receiving two injections of 10 mg/kg 
free prednisolone phosphate. Free prednisolone was less effective than 50 mg/kg MP with 
regard to TC apoptosis and –infiltration, which is well in accord with previous results (5) 
(data not shown). Since liposomes are mainly taken up by Mϕ as revealed in situ by 
detection of gold-labeled liposomes, we also characterized Mϕ infiltration. The number of 
infiltrating Mϕ in spinal cord was strongly reduced by PL (*P < 0.05 vs. control, ***P < 0.001 
vs. MP), whereas MP had no effect. (Figures 3 C; 2 g-i). There was no increase in the rate of 
apoptotic Mϕ, which was in the range of 0 – 5.5% (data not shown). Then we investigated 
the TNF-α production by TC and Mϕ in situ by immunohistochemical double labeling. The 
rate of TNF-α positive TC in  
 Apoptosis (%) Infiltration (TC/mm2) 
Control     12.9 ±4.5         177 ±50 
PL 6 hr     15.8 ±2.5         180 ±53 
PL 18 hr     22.2 ±3.0**         132 ±24 
PL 42 hr     33.2 ±4.2**           42  ± 4** 
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Figure 2. Immunohistochemical detection of TC infiltration, BBB-disruption, Mϕ infiltration, and gold-
localization in astrocytes and Mϕ in 5 µm paraffin sections of spinal cord from AT-EAE rats at day 5. (a-c) 
Staining of TC (DAB, dark spots) with the mAb B115-1 and hematoxylin counterstaining (gray), in control (a), 
PL 10 mg/kg (b), or MP 50 mg/kg treatment (c). (d-f) Detection of BBB-disruption with anti-albumin Ab (DAB, 
dark) and hematoxylin counterstain, in control (d), PL 10 mg/kg (e), or MP 50 mg/kg treatment (f). (g-i) Staining 
of Mϕ (Vector Red, dark spots) with the mAb ED1 and hematoxylin counterstaining (gray) in control (g), PL 10 
mg/kg (h), or MP 50 mg/kg treatment (i). (j, k) Detection of gold liposomes by silver-enhancing technique (black 
dots, indicated by arrows), in combination with staining for Mϕ (j, ED1-mAb, Vector Red), or astrocytes (k, anti-
GFAP, Vector Red), and hematoxylin. Scale bar=100 µm (a-c, g-i), 200 µm (d-f), 10 µm (j, k). 
   control treatment      10 mg/kg PL   50 mg/kg MP 
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spinal cord was strongly diminished by PL (32.1 ± 7.8% vs. 55.6 ±8.0% in controls, ***P < 
0.001), and was equally effective as MP (34.4 ± 5.9%, ***P < 0.001 vs. controls). Also, the 
rate of TNF-α positive Mϕ was clearly reduced by PL (31.1 ± 7.4% vs. 52.3 ± 4.2 % in 
controls, ***P < 0.001), and showed the same efficacy as MP (31.1 ± 13.1%, **P < 0.01 vs. 
controls). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Treatment of AT-EAE with two i.v. injections of 10 mg/kg PL 42 hr and 18 hr, or 50 mg/kg MP 18 hr 
and 6 hr prior to perfusion on day 5 compared to controls. (A, B) Immunohistochemical staining for TC or Mϕ in 
spinal cord. (A) Percentage of apoptotic TC rated by morphological criteria and double labeling with TUNEL. 
(B) Number of infiltrating TC per mm2. (C) Number of infiltrating Mϕ per mm2. Each symbol represents one 
animal (n=6 per group), numbers and bars indicate mean ± SD. P values explained in text. 
 
 
Even though our study was designed to look for short-term mechanisms in situ, we 
could also observe a clinical benefit from PL (**P < 0.01 vs. all groups at day 5) (Figure 4 A). 
However, there was no beneficial effect by MP treatment, which can be explained by the 
start of treatment at day 4 instead of day 3 in PL. All experiments were reproduced at least 
once with similar results. 
 
PL ameliorates active EAE. 
Since PL appeared to be superior to MP in the different mechanisms investigated and 
beneficial clinical effects were observed in AT-EAE even with a single injection, we studied if 
PL could ameliorate the disease activity in an active EAE model. MBP immunized Lewis rats 
received one injection of i.v. 10 mg/kg PL at beginning of disease on day 12. This was 
compared to treatment with two injections of i.v. 50 mg/kg MP at days 12 and 13. In this 
experiment a single PL injection (*P < 0.05 vs. control at day 14) appeared to be equally 
effective as twice MP at a five fold higher dosage (*P < 0.05 vs. control at day 16) (Figure 4 
B). 
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Figure 4. Therapeutic effect on clinical scores (A) Treatment of AT-EAE with a two i.v. injections of 10 mg/kg 
PL 42 hr and 18 hr, or 50 mg/kg MP 18 hr and 6 hr prior to perfusion on day 5 compared to controls. (B) 
Treatment of active EAE with one i.v. injection of 10 mg/kg PL at day 12, or two i.v. injections of 50 mg/kg MP 
at days 12 and 13 compared to controls. Clinical course of disease indicated as mean +/- SD (n=6 per group). 
 
 
Apoptosis in spleen or liver 
We qualitatively investigated apoptosis of phagocytes and TC in spleen and liver by 
immunohistochemistry. We observed an induction of TC apoptosis in spleen in all PL treated 
groups, which was stronger as compared to free prednisolone. The frequency of apoptotic 
TC after injection of free prednisolone compared to controls was elevated after 2 hr and 6 hr, 
but not after 18 hr and 42 hr. There was no induction of apoptosis or notable change in 
number of Mϕ in spleen and Kupffer cells in liver in any of the treatment groups compared to 
controls (data not shown).  
 
Gold-labeled liposomes are detected in spinal cord. 
To detect the cellular localization of extravasated liposomes, we injected gold-labeled 
liposomes in AT-EAE rats once 18 hr or 42 hr before perfusion at day 5 compared to 
unlabeled empty liposomes. As revealed by silver-enhancing technique, gold-labeled 
liposomes were mostly located within phagocytic cells. Most of the cells were Mϕ in the 
inflamed spinal cord tissue, especially around the blood vessels (Figure 2 j). However, gold 
label could also be detected in astrocytes and microglia, speaking for a penetration of 
liposomes through disrupted BBB without the help of Mϕ (Figure 2 k). No gold particles were 
observed in oligodendrocytes. Also, a high amount of gold-labeled liposomes could be 
detected in Mϕ in spleen and in Kupffer cells in liver, which is in accord with other recent 
findings (Chapter 4). In EAE rats we observed no uptake of gold-liposomes in TC in spinal 
cord or spleen. There was no silver-enhanced signal in rats treated with unlabeled empty 
liposomes. 
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No detectable side effects on glial cells. 
Since glial cells can undergo apoptosis, we wanted to examine possible side effects by the 
high tissue levels achieved by PL. This was especially of note for astrocytes and microglial 
cells, which appeared to take up liposomes, as revealed by the experiments with gold-
labeled liposomes. We characterized astrocytes (GFAP), oligodendrocytes (CNPase), and 
microglia (GSA-I-B4) immunohistochemically. There was no induction of apoptosis in any of 
these glial cells and their total number per mm2 remained basically unchanged after 
treatment with PL or MP compared to controls (data not shown). 
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DISCUSSION 
 
Our experiments presented here demonstrate the beneficial effects by drug targeting of 
prednisolone with a new therapeutic liposomal formulation in the treatment of EAE as a 
model for MS. Radioactive labeling showed the accumulation of liposomes in the inflamed 
target organ. By a gold-labeling technique liposomes could clearly be located at the site of 
inflammation. These results also had functional implications: a dose of i.v. 10 mg/kg PL was 
superior to a five fold higher dose of i.v. free MP with regard to improvement of BBB-
disruption, induction of TC apoptosis, and amelioration of cellular infiltration. Only with PL a 
clear reduction of inflammatory Mϕ in the lesion could be achieved. In addition we observed 
a reduced rate of TNF-α expressing TC and Mϕ in situ after PL treatment. As a consequence 
of the reduced inflammation the disease course of AT-EAE and of active EAE were 
ameliorated. There were no detectable side effects on glial cells in situ.  
The therapeutic goal in treatment of MS-relapses is to reduce cellular inflammation 
as efficient as possible to prevent ongoing tissue destruction and axonal loss. The dosing of 
GC as mainstay of therapy in MS relapses is still a matter of debate. With regard to our 
previous findings in EAE (5) one of the major issues of dosing of steroids is to reach very 
high tissue levels, exerting multiple pathways of steroid actions according to a new model of 
steroid mechanisms (6). In the present study higher tissue levels of prednisolone were 
achieved by encapsulation of the steroid in long-circulating liposomes, which delivered the 
drug to the site of inflammation without a high serum concentration of the free drug. 
Conventional liposomes with a relatively short circulation half-life containing 
hydrocortisone have been developed in the late 70ies for i.a. treatment of arthritis in 
experimental models and patients (19, 20). In the early 90ies the principle of selective 
targeting inflamed tissue was reported with cholesterol/lecithin liposomes, which showed an 
improved stability in the circulation. These liposomes reached the joints after i.v. injection in 
rats with experimental arthritis (21). Recently it could be demonstrated that a similar 
formulation could penetrate the BBB in EAE (22). I.v. injected liposomes encapsulating 
dichloromethylene diphosphonate, which suppresses Mϕ activity, were beneficial in EAE and 
experimental autoimmune neuritis (EAN) (23, 24). For significant accumulation of the 
encapsulated drug in inflamed extravascular tissue it appears to be crucial that liposomes 
exhibit a long-circulating behavior, and it seems likely that the effects reported by de Silva et 
al. and Dingle at al. in the late 70ies were either mediated by a change of the 
pharmacokinetics of the encapsulated drug or by an indirect effect via 
monocytes/macrophages in liver, spleen or blood.  
Prolonged circulation behavior can be accomplished with small-sized liposomes (< 
150 nm) composed of neutral, saturated phospholipids and cholesterol. Often water-soluble 
polymers like PEG are attached to the surface of long-circulating liposomes to reduce 
adhesion of opsonic plasma proteins that would otherwise induce recognition and rapid 
removal from the circulation by the mononuclear phagocyte system in liver and spleen (25-
27). Using this approach PEG-coated long-circulating liposomes can remain in the 
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circulation with a half-life as long as 50 hrs in humans (28). The improved pharmacokinetics 
and target localization has led to several successful applications of this formulation in 
antitumor therapy (28, 29). Studies with liposome-associated radiolabels have indicated that 
PEG-liposomes can also successfully be employed to selectively target pathological sites in 
inflammatory disorders (30, 31). For our study here we encapsulated prednisolone-
phosphate as active drug into long-circulating liposomes, since methylprednisolone-
succinate, which we used in previous studies (5, 13), did not yield a stable formulation when 
encapsulated in PEG-liposomes. 
To investigate whether target localization of liposomes is a direct process or a result 
of uptake by monocytes in blood or spleen followed by infiltration of such monocytes at the 
target site, we employed gold-labeled liposomes, which could be detected in spinal cord 
within vascular endothelium and perivascular areas non-phagocytosed as well as in 
inflammatory Mϕ. Additionally, there was direct uptake of liposomes by resident astrocytes 
and microglia. Also, our radioactive data support a rapid penetration of liposomes into the 
CNS, where an accumulation of the injected liposomes was seen, reaching values of up to 
4.5-fold higher than in healthy control animals. In contrast, non-inflamed control tissue 
showed similar amounts of radioactive liposomes in healthy animals and EAE-rats. Taken 
together these data support the hypothesis of selective targeting of PL to inflamed sites. 
The theoretical prednisolone concentrations calculated based on concentrations of 
radioactive PL found in the spinal chord are in the range of non-genomic effects according to 
a new model of steroid mechanisms of action (6). These expected high levels of prednisolone 
after PL may have been responsible for the direct effects at the site of inflammation, such as 
the superior induction of TC apoptosis and the superior improvement of the BBB function. 
The TNF-α expression of TC and Mϕ was reduced comparably to a 5-fold higher dose of free 
MP. However, besides clear direct effects, the reduced infiltration of TC and Mϕ in the spinal 
cord may additionally be due to effects of PL in peripheral immune organs. We could not 
detect augmentation of apoptosis of Mϕ in spleen. Despite high organ concentrations of PL 
we could not detect apoptosis in resident cells like Kupffer cells in liver or astrocytes, 
oligodendrocytes, or microglia in spinal cord, which rules out some important unwanted side 
effects. One could even speculate that the immune cells playing an active role in the disease 
are more susceptible to a high-dose steroid treatment than resident or resting immune cells. 
Also recent observations in exp. arthritis did not reveal unwanted side effects of PL. 
Taken together we show that long-circulating PL given at 10 mg/kg accumulate in the 
inflamed organ of EAE rats. Augmentation of TC apoptosis in situ occurs rapidly and the BBB 
function is improved. The reduced infiltration of TC and Mϕ ultimately leads to an 
ameliorated disease activity of active and AT-EAE. Especially the reduced Mϕ infiltration, 
which was only seen after PL, might help to prevent ongoing tissue destruction. Thus, PL 
could be a therapeutic alternative to free MP, which even at a 5-fold higher dose remains 
less effective. Finally, employing the principle of drug targeting may reduce systemic side 
effects. These findings may have implications for the treatment of inflammatory disorder of 
the CNS such as multiple sclerosis and other autoimmune diseases. 
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ABSTRACT  
 
Glucocorticoids can inhibit solid tumor growth, which has been suggested to be caused by 
an inhibitory effect on angiogenesis. Several mechanisms have been proposed to explain 
their anti-angiogenic action, ranging from inhibition of endothelial cell proliferation and 
migration, modulation of basement membrane turnover, and/or inhibition of production of 
pro-angiogenic factors. The anti-tumor effects of the free drugs have only been observed 
using treatments schedules based on high and frequent dosing for prolonged periods of 
time. As long-circulating liposomes (LCL) accumulate at sites of malignancy, we investigated 
the tumor-inhibiting potential of LCL-encapsulated prednisolone phosphate. It appeared that 
liposomal prednisolone phosphate could inhibit tumor growth dose-dependently. 80-90% 
tumor growth inhibition was achieved in s.c. B16 melanoma and C26 colon carcinoma 
murine tumor models at a dose of 20 mg/kg by single or weekly doses. Prednisolone 
phosphate in the free form was completely ineffective at this low frequency treatment 
schedule, even at a dose of 50 mg/kg. Histological evaluation revealed that liposomal PLP-
treated tumors were surrounded by a layer of connective tissue, whereas the tumor center 
contained areas of apoptotic cells. In addition, blood clots were observed in some of the 
larger blood vessels in these tumors. In conclusion, the present study shows the potent anti-
tumor efficacy of a new, liposomal, formulation of glucocorticoids. 
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INTRODUCTION 
 
Glucocorticoids (GC) have a wide spectrum of activities on cell trafficking, cell-cell 
interactions and cell communications, leading to pronounced anti-inflammatory and 
immunosuppressive effects. GC exert their effects by diffusion through the cell membrane 
and binding to their cytosolic receptors. Subsequently, these receptors become activated 
and translocate to the nucleus where they directly modulate DNA transcription of a variety of 
genes. In addition, GC-receptors may directly or indirectly antagonize the activity of several 
transcription factors, most notably nuclear factor kappa-B (1,2). GC also exert rapid non-
genomic effects on cells by interacting non-specifically with cellular membranes, or 
specifically with membrane bound GC-receptors (3). 
In tumor therapy, GC have been used for their anti-inflammatory and anti-emetic 
effects and for the treatment of hematological malignancies based on their efficient cytolytic 
activity on cells of lymphoid origin (4). Reports in the last two decades demonstrated that 
GC could also decelerate solid tumor growth in experimental animal models (5-8). However, 
one of the drawbacks of GC in tumor therapy, as shown in these pre-clinical studies, is the 
need for high or frequent dosing. In mice, doses of 100-200 mg/kg per day need to be 
administered for prolonged periods of time to obtain significant tumor growth inhibition (5-
8). Moreover, these doses have been shown to cause considerable morbidity and mortality 
as a result of severe immune suppression in experimental animals (6,7).  
Targeted delivery of GC to tumor tissue could be an attractive strategy to increase 
intratumoral drug concentrations, thereby reducing the overall dose decreasing the 
likelihood of side effects (9). In the present study, we investigated the use of long-circulating 
liposomes (LCL) to deliver GC selectively to tumor tissue. LCL have previously been shown to 
accumulate at sites of malignancy as a result of the enhanced permeability of tumor 
vasculature as compared to healthy endothelium (10). Furthermore, in previous studies in 
our group, the therapeutic activity of encapsulated in LCL was shown to be strongly 
increased in experimental models of arthritis (Chapter 3 and 4). In the present study, anti-
tumor activity of liposomal prednisolone phosphate (PLP) was investigated in s.c. C26 colon 
carcinoma and B16F10 melanoma models and compared to the anti-tumor activity of free 
PLP in different dosing schemes. 
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MATERIALS AND METHODS 
 
Liposome preparation 
LCL were prepared as described previously (11). In brief, appropriate amounts of dipalmitoyl 
phosphatidylcholine (DPPC) (Lipoid GmbH, Ludwigshafen, Germany), cholesterol (Sigma, St. 
Louis, USA), and poly(ethylene glycol) 2000-distearoyl phosphatidylethanolamine (PEG-
DSPE) (Lipoid GmbH) in a molar ratio of 1.85:1.0:0.15, respectively, were dissolved in 
chloroform:methanol (2:1 vol:vol) in a round-bottom flask. A lipid film was made under 
reduced pressure on a rotary evaporator and dried under a stream of nitrogen. Liposomes 
were formed by addition of an aqueous solution of 100 mg/ml PLP. A water-soluble 
phosphate ester of prednisolone was used to ensure stable encapsulation in the liposomes. 
For labeling of the liposomes with 0.5 mCi 111In-oxine (Mallinckrodt Medical, Petten, The 
Netherlands), the lipid film was hydrated in 5 mM diethylene-triamine penta-acetic acid 
(DTPA) in 10 mM N-(-2 hydroxyethyl) piperazine-N’-ethane sulfonic acid (HEPES)/135 mM 
NaCl-buffer pH 7 to a final lipid concentration of 10 µmol/ml, according to a procedure 
described by Boerman et al. (12). The liposome size was reduced by multiple extrusion 
steps through polycarbonate membranes (Nuclepore, Pleasanton, USA) with a final pore size 
of 50 nm. 
 Short-circulating liposomes (SCL) were prepared similarly, only PEG-DSPE was 
replaced by egg phosphatidylglycerol (EPG). SCL were used to determine the dependency of 
anti-tumor effects on the degree of liposome localization in the tumor, which is positively 
correlated to liposomal circulation time (10). Therefore, PEG-DSPE was exchanged, as it is 
responsible for the prolonged circulation of the LCL by providing a layer of steric 
stabilization around the liposome surface, decelerating MPS uptake. Moreover, exchanging it 
for EPG introduced a negative charge on the liposome surface, which promotes MPS-uptake 
and thereby reduces circulation time of the SCL even further (13). The SCL were formed by 
addition of 10 mg/ml PLP in 10 mM HEPES/135 mM NaCl-buffer pH 7.4 to the lipid film, 
and extrusion took place through polycarbonate membranes of 400 nm. Unencapsulated 
material was removed by dialysis with repeated changes of buffer against 10 mM 
HEPES/135 mM NaCl-buffer pH 7.4 at 4 °C. 
Mean particle size of the LCL was determined by dynamic light scattering and found 
to be 0.1 µm with a polydispersity value of around 0.1, whereas the SCL had a mean particle 
size of 0.5 µm with a polydispersity value of around 0.3. The low polydispersity values 
indicate limited variation in particle size. The large size of the SCL also reduces circulation 
time as compared to the LCL and also prevents efficient extravasation at the target site 
(13,14). Taken together, the changes in lipid composition and liposome size strongly reduce 
the degree of liposome localization in the tumor for SCL as compared to LCL.   
Phospholipid content was determined with a phosphate assay, performed according 
to Rouser (15), on the organic phase after extraction of liposomal preparations with 
chloroform. The aqueous phase after extraction was used for determining the PLP content 
by high performance liquid chromatography using a mobile phase of acetonitril-water with 
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pH of 2 and monitoring the eluens with a UV-detector, which was set at 254 nm. The 
liposomal preparation contained around 2 mg PLP/ml and 60 µmol/ml phospholipid. Using 
this setup it was established that liposomes contained 25-35 µg PLP/µmol lipid. 
 
Cells 
B16 murine melanoma and C26 murine colon carcinoma cells were cultured at 37 °C in a 
5% CO2-containing humidified atmosphere in culture medium (DMEM) (Gibco, Breda, The 
Netherlands) supplemented with 10% (v/v) heat-inactivated fetal calf serum (Gibco), 100 
IU/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Gibco). To 
determine whether prednisolone (phosphate) had a direct cytotoxic effect on tumor cells, 
104 cells/well were plated in a 96-well plate. Prednisolone (PL) was added dissolved in 
ethanol, using corresponding concentrations of ethanol as controls, whereas PLP was added 
in HEPES/NaCl-buffer. Cell viability was determined after 24 h and 48 h of incubation by 
XTT-assay (Sigma, St. Louis, USA) according to manufacturer’s instructions.     
 
Murine tumor models 
Male Balb/c and C57Bl/6 mice (6 – 8 weeks of age) were obtained from Charles River (the 
Netherlands) kept in standard housing with standard rodent chow and water available ad 
libitum, and a 12 h light/dark cycle. Experiments were performed according to national 
regulations and were approved by the local animal experiments ethical committee. For 
tumor induction, 1 x 106 B16 melanoma or C26 colon carcinoma cells were inoculated 
subcutaneously in the flank of syngeneic C57Bl/6 or Balb/c mice, respectively. 
 
Tissue distribution of 111In-labeled LCL in tumor bearing mice 
At a tumor volume of approximately 1 cm3, mice were injected i.v. with 25 µmol lipid/kg 
(corresponding to 30 x 106 cpm/mouse) of 111In-labeled LCL. At 6 h and 24 h after injection 
animals were sacrificed, a blood sample was taken and tumor, lungs, liver, spleen and 
kidneys were dissected, the tissues were weighed and radioactivity was counted with a a 
Philips PW 4700 liquid scintillation counter 
 
Tumor growth inhibition  
Effect of dose. Mice received a single intravenous injection of an indicated dose of free PLP or 
liposomal PLP at the time when the tumor became palpable. At 7 days after treatment 
tumor size was measured and tumor volume calculated according to the formula V = 0.5 ∗ 
a2 ∗ b, in which a is the smallest and b the largest superficial diameter. 
Effect of tumor size. Free PLP or liposomal PLP were i.v. administered at a dose of 20 mg/kg 
at day 1, 7, and 14 or by single injection at day 7 or day 14 after tumor cell inoculation. As a 
reference, B16F10 tumors became palpable around 7 days and C26 tumors around 11 days 
after tumor cell inoculation. Tumor size was measured regularly, and tumor volume was 
calculated as described above. 
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Analysis of amount of PLP or prednisolone in tissues 
At a tumor volume of approximately 1 cm3, mice were injected i.v. with 20 mg/kg liposomal 
PLP or free PLP. At 24 h after injection animals were sacrificed and tumor, liver, and spleen 
were dissected. The tissues were weighed and homogenized. 2 µg methylprednisolone was 
added as an internal standard. PLP and free prednisolone were extracted from the tissue 
with ethylacetate at pH 2, and concentrated under a nitrogen flow. Samples were diluted in 
ethanol:water 1:1 vol/vol and analyzed by HPLC as described above. Standard lines were 
prepared by extracting known amounts of PLP and prednisolone from control organs from 
untreated mice. The detection limit for the HPLC setup was 20 ng/ml 
 
Histology 
Tumors were dissected at 72 h after a single i.v. injection of either free PLP or liposomal PLP 
20 mg/kg. Tumors were fixed in 10% PBS-buffered formaldehyde and embedded in paraffin. 
5 µm slides were cut and stained with hematoxilin/eosin and evaluated by light microscopy. 
 
Statistical analysis 
Data were analyzed by one-way ANOVA with Dunnett's post-test using GraphPad InStat 
version 3.05 for Windows, GraphPad Software (San Diego, USA). Data were logarithmically 
transformed to correct for significant differences between SD of groups, when appropriate 
according to Bartlett’s test. Spearman rank correlation coefficient was calculated to identify 
dose-response. 
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RESULTS 
 
Tissue distribution of LCL 
Figure 1 presents tissue distribution data of the LCL at 6 h and 24 h after intravenous 
injection in C26 or B16-tumor bearing mice. Approximately 60% of the injected dose (ID) 
was still present in the circulation at 6 h after administration in both mouse models, whereas 
15% ID was still circulating at 24 h post-injection. These values correspond to previous data 
on circulation kinetics of LCL (10). Approximately 7-10% ID could be recovered from tumor 
tissue in both the C26 and B16F10 model at 24 h after injection, which was approximately 
two-fold higher than the levels at 6 h post-injection. At both time-points approximately the 
same amount was present in the livers of both strains of tumor-bearing mice. Relatively low 
amounts of LCL were recovered from spleen, kidney and lung in the two mouse models both 
at 6 h and 24 h after injection. 
 
 
 
 
 
Figure 1. Tissue distribution of 111In-labeled 
liposomes at 6 h and 24 h after intravenous 
administration in B16F10-tumor bearing C57Bl/6 
mice or C26-tumor bearing Balb/c mice. Tumors 
weighed approximately 1 g. Mean ± SD, n=5 
animals/experimental group. 
 
 
Anti-tumor activity of liposomal PLP versus free PLP: dose–response relationship 
To compare the effect of different doses of liposomal PLP to free PLP on tumor growth, B16 
or C26-tumor bearing mice received a single injection of either formulation at the moment 
that the tumor became palpable. At 1 week after injection the tumor volume was smaller 
with an inverse relationship to the dose of injected liposomal PLP in both mouse models as 
shown in Figure 2 (B16: Spearman correlation coefficient r=-0.92 (p<0.001); C26 Spearman 
correlation coefficient r=-0.82 (p<0.01)). 20 mg/kg PLP was the maximum dose that could 
be administered for the liposomal formulation in view of the maximal injection volume. 
Treatment of B16 or C26 tumor bearing mice with 20 mg/kg or 50 mg/kg free PLP did not 
result in significantly different tumor volumes compared to buffer treated control animals 
(Figure 2). 
To evaluate whether the anti-tumor effect was due to a direct cytotoxic effect of 
prednisolone or PLP on the tumor cells, B16 and C26 cells were incubated in vitro with 
increasing concentrations of prednisolone and PLP. No decrease in cell viability was noted 
up to the maximum concentration tested of 10 µg/ml (data not shown). 
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Figure 2. Effect of dose of liposomal (left) or free PLP on tumor growth in B16F10 or C26 bearing mice. Mice 
received a single injection with the indicated dose and formulation of PLP on the day tumors became palpable 
(= day 7 after inoculation). Tumor volume after 1 week is reported. Mean ± S.D, n=5 animals/experimental 
group. 
  
Analysis of level of PLP or prednisolone in tissues 
PLP and prednisolone levels at 24 h after i.v. injection of liposomal PLP in liver, spleen and 
tumor tissue were determined by HPLC analysis. Figure 3 shows that the highest amount of 
PLP (± 5 µg) was present in the tumor and a similar amount was present in the form of PL. 
The level of PLP in the spleen was relatively low, whereas the prednisolone level was similar 
to that in the tumor. Hardly any PLP could be detected in liver tissue, but approximately 20 
µg was present in the form of PL. Neither PLP nor prednisolone was detected in any of these 
tissues at 24 h after injection of free PLP (data not shown). 
 
 
 
 
 
Figure 3. Amount of PLP and PL recovered 
from mouse tissues. Mice received a single 
injection of 20 mg/kg liposomal PLP and 
tissues were excised 24 h later. Mean ± SD, 
n=5 animals/experimental group. 
 
 
 
Dependence of anti-tumor effect on tumor size 
To determine if, and to what extent the anti-tumor effect depends on the tumor size at day of 
treatment, liposomal and free PLP were injected at a dose of 20 mg/kg at day 1, 7, and 14 
or a single dose at day 7 or day 14. The results are shown in Figure 4.  
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Figure 4. Effect of tumor size on the antitumor effect of free and liposomal PLP. The formulations were 
injected at a dose of 20 mg/kg at day 1, 7, and 14 (A and B) or single injection at day 7 (C and D) or day 14 (E 
and F) in B16F10-bearing C57Bl/6 mice (A, C, and E) or C26-bearing Balb/c mice (B, D, and F). Mean ± SD, 
n=5 animals/experimental group.  
tum
or 
vol
um
e (
mm
3 )
tum
or 
vol
um
e (
mm
3 )
tum
or 
vol
um
e (
mm
3 )
0 5 10 15 20 
0 
1000 
2000 
3000 
0 5 10 15 20
0
1000
2000
3000
Control
Free
Liposome
0 5 10 15 20
0
1000
2000
3000
Time (days)
0 5 10 15 20 25
0 5 10 15 20 25
0 5 10 15 20 25
Time (days)
B16      C26 
A B
C D
E F
20 mg/kg day  1, 7, 14 
20 mg/kg day 7 
20 mg/kg day 14 
chapter 6 
100 
B16-model. The tumor volumes of B16-tumor bearing mice that received either no treatment, 
or treatment with free PLP or liposomal PLP at day 1, 7, and 14 are shown in Figure 4 A. 
Tumors became palpable at day 7 in all treatment groups indicating that neither of the 
treatments delayed tumor growth between day 1 and day 7. A second dose of liposomal PLP 
at day 7 resulted in 92% tumor growth inhibition between day 7 and day 14 as compared to 
controls (p<0.05), whereas free PLP did not affect tumor volume. On day 14, mice received 
a third injection. At day 17, some of the mice in the free PLP and control group had to 
euthanized because of large tumor sizes (>2 cm3), whereas average tumor volume in the 
liposomal PLP group was approx. 79% smaller (p<0.01). 
After a single injection of liposomal or free PLP at day 7, a significantly smaller tumor 
volume was only seen after treatment with liposomal PLP with average inhibition of tumor 
growth of 89% at day 14 and 67% at day 17 as compared to controls (p<0.05, both time-
points) (Figure 4 C). A single injection of liposomal PLP at day 14 produced 58% tumor 
growth inhibition at day 17 compared to controls (p<0.05) (Figure 4 E). 
 
C26 model. C26-bearing mice received the first of the three doses of liposomal PLP or free 
PLP on day 1 and a second on day 7 after tumor cell inoculation. As tumors in all treatment 
groups became palpable around day 10, the effect on tumor growth of the first injections 
appeared to be minimal, although tumor volume was 89% smaller in liposomal PLP-treated 
animals than in controls at day 14. At day 21, 1 week after the third dose at day 14, average 
tumor volume in liposomal PLP-treated animals was 89% smaller than that in controls 
(p<0.01) (Figure 4 B).  
Although a single dose of liposomal PLP on day 7 resulted in 66 % tumor growth 
inhibition at day 14 and 67% inhibition at day 21, these differences were not statistically 
significant from the control and free drug-treated groups (Figure 4 D). A single injection of 
liposomal PLP at day 14 resulted in 78% tumor growth inhibition (p<0.05) (Figure 4 F). 
 
 
 
 
Figure 5. Effect of short-circulating or long-
circulating PLP-liposomes on tumor growth. 
Mice received a single injection of 20 mg/kg of 
the indicated formulation of PLP on the day 
tumors became palpable. Mean ± SD, n=5 
animals/experimental group. 
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Importance of the long-circulation property of liposomes for tumor growth inhibition 
To determine whether liposomal circulation time is critical for achieving anti-tumor efficacy 
we tested a SCL and LCL formulation of PLP for anti-tumor activity in C26 tumor-bearing 
mice. Both formulations were injected at day 14 after tumor cell inoculation in C26-tumor 
bearing mice. Tumor volume of SCL-encapsulated PLP-treated animals was not significantly 
different from saline-treated animals, whereas animals treated with LCL-encapsulated PLP 
experienced a significantly reduced tumor growth rate (Figure 5). 
 
Histological examination of tumor tissue 
Histological examination of tumor tissue at 3 days after treatment with a single dose of 20 
mg/kg liposomal PLP or free PLP revealed 3 prominent differences between treatment 
groups as is illustrated in Figure 6 A. Firstly, tumors treated with liposomal PLP were 
smaller and surrounded by a layer of connective tissue, which was absent in the tumors 
treated with free PLP. Secondly, liposomal PLP-treated tumors showed areas of apoptotic 
tumor cells, which were not noted in the free PLP-treated animals. And finally, large fibrin 
clots were present in some of the larger blood vessels in liposomal PLP-treated tumors, 
which were not observed in free PLP-treated tumor tissue. A large, leukocyte infiltrated clot 
is shown in Figure 6 B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Micrographs of C26 tumor tissue dissected at 3 days after treatment with a single dose of 20 mg/kg 
of liposomal PLP. Pictures show an overview (A) and an occluded blood vessel (B). Tissues were stained with 
hematoxilin/eosin. Legend of figure A: x layer of connective tissue, + apoptotic region, arrows point to 
occluded blood vessels. 
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DISCUSSION 
 
The present study demonstrates for the first time anti-tumor effects of LCL-encapsulated GC. 
Strong anti-tumor effects were observed when liposomal PLP was administered in a low 
frequency (single dose or weekly) dosing schedule and at substantially lower doses than 
reported for free GC (conjugates) (5-7).  
LCL have been previously used to increase the delivery of a variety of drugs to tumor 
tissue (16-18). Probably, the best-known formulation in this respect is LCL-encapsulated 
doxorubicin, marketed as Doxil® or Caelyx® (17). The long-circulating property allows 
liposomes to extravasate as a result of the enhanced vascular permeability in solid tumor 
tissue leading to their accumulation at the malignant site (16-18). In both the B16 and C26 
tumor models used in this study, 7 to 10% of the injected dose of LCL had localized in the 
tumor at 24 h after injection, which is similar to previously reported data (10,16-18). At this 
time-point approximately 15% of the injected dose was still circulating in the blood stream, 
which is consistent with a long-circulatory behavior. 
Furthermore, LCL encapsulation increased levels of the drug in the tumor, liver and 
spleen at 24 h after injection compared to administration of the free drug. Approximately, 
2% of the injected dose of PLP was recovered from the tumor tissue as PLP or prednisolone. 
This percentage is substantially lower than the 7-10% of the ID of LCL that accumulate at 
the site of the malignancy. Probably, intratumoral conversion of PLP to prednisolone leads 
to a redistribution of the drug over the body as prednisolone can easily pass membranes. 
Conversion of PLP to prednisolone likely forms also the explanation for the virtual absence of 
PLP in liver tissue.   
Administration of LCL-encapsulated PLP resulted in a dose-dependent anti-tumor 
effect in both the B16 and C26 s.c. tumor model. The maximum dose of 20 mg/kg 
(determined by the maximal injection volume) resulted in approximately 90% tumor 
inhibition over a 1 week period, when administered as a single dose at the moment that the 
tumor became palpable, in both tumor models. Free PLP did not inhibit tumor growth even 
at a dose of 50 mg/kg in this treatment schedule.  
The underlying mechanism of tumor inhibition is at present unclear. Several studies 
showed that an anti-tumor effect of GC was not directly aimed at the tumor cells, but rather 
mediated by interference with the tumor vascularization (19-23). Also in the present study 
PLP or prednisolone did not inhibit the proliferation of the murine tumor cells in vitro. It has 
been suggested that GC’s anti-angiogenic effect is mediated by inhibition of endothelial cell 
proliferation and migration (20) or effects on basement membrane turnover (21). 
Furthermore, inhibition of production and/or release of pro-angiogenic factors (like 
plasminogen activator and vascular endothelial growth factor) may play a role (22,23). In 
addition, the hypothesis that inflammatory processes in and around the tumor are important 
in the angiogenic cascade suggests that GC’s immunosuppressive action may also be of 
relevance in this respect (24,25). Likely, these mechanisms act together leading to the 
observed anti-tumor effects. 
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Regardless of the proposed underlying mechanism, these studies report a 
concentration-dependent inhibition of the angiogenic process in vitro or in vivo by GC (19-23). 
The dose-dependent inhibition of angiogenesis is further illustrated by a study in rats 
demonstrating that local administration of GC in sponge implants was more effective in 
inhibiting angiogenesis than systemic treatment (26). Also in the clinical treatment of 
hemangiomas, intralesional injection of GC is often used (27). The importance of prolonged 
high local drug levels is further supported by the observation in this study that the same 
dose of liposomal PLP in SCL inhibited tumor growth to a much lower extent. SCL are 
rapidly taken up by macrophages mainly in liver and spleen and are therefore unable to 
accumulate at the tumor. Consequently, the limited localization of SCL in the tumor is 
paralleled by a decrease in activity.  
The lack of an inhibitory effect of liposomal PLP against small, not-yet palpable, 
tumors as observed in this study, is indicative of the importance of tumor localization of the 
liposomes for anti-tumor efficacy. Both in the B16 and C26 model, liposomal PLP injection 
at 1 day after tumor cell inoculation did not delay the time-point at which the tumor became 
palpable. At 24 h after tumor cell inoculation, the tumor mass is still minimal and vascular 
integrity is hardly affected yet. Therefore the circulating liposome particles are not able to 
extravasate at this time point. Once a tumor mass has formed, however, administration of 
liposomal PLP reduced tumor growth rate significantly, irrespective of the size of the tumor 
at the time of liposome injection. 
Histological evaluation indicates that apoptosis of tumor cells in the core of the tumor 
occurs, which could be the result of inhibition of angiogenesis as the cells at this location are 
most dependent on intratumoral blood supply. Another observation, which was made solely 
in some of the liposomal PLP treated tumors, was the presence of blood clots inside the 
larger blood vessels in the tumor tissue. As thrombosis has been suggested to precede 
angiogenesis, we may be dealing with tissue that is again in or converting to a pro-
angiogenic state (28,29). 
In conclusion, the present study shows for the first time potent anti-tumor efficacy of 
LCL-encapsulated PLP. This formulation yields high intratumoral levels of PLP for a 
prolonged period of time. The advantage that the current system may offer for clinical use is 
the relatively low dose and low frequency schedule with which PLP needs to be administered 
to produce anti-tumor efficacy.  
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CHAPTER THERAPEUTIC INDEX OF GLUCOCORTICOIDS CAN BE 
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ABSTRACT 
 
Long-circulating liposomes (LCL) may be useful as drug-targeting vehicles for anti-
inflammatory agents in arthritis, since they selectively home at inflamed joints after i.v. 
administration. Previously we showed in experimental arthritis that encapsulation of 
glucocorticoids (GC) as water-soluble phosphate esters in PEG-liposomes resulted in a 
strong improvement of the anti-inflammatory effect as compared to the free drug. In the 
present study, we compared the therapeutic activity and adverse effects induced by 3 
different GC encapsulated in LCL in an attempt to further optimize the therapeutic index of 
liposomal GC in arthritis. Our data show that with GC (dexamethasone, budesonide) of 
higher potency than prednisolone, the therapeutic activity of liposomal GC can be increased. 
However, side effects at the level of body weight and hyperglycemia were noted, related to 
the sustained free GC level observed after injection of the liposomal GC. An inverse 
relationship with the clearance rate of the GC in question was shown. This study stresses the 
importance of a high clearance rate of the GC to be encapsulated for achieving a maximal 
therapeutic index with liposomal GC. Therefore high-clearance GC, which until now are only 
applied in local treatment approaches, may be very useful for the development of novel, 
highly effective anti-inflammatory preparations for systemic treatment of inflammatory 
disorders. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder, involving joint inflammation 
and progressive cartilage destruction (1). Glucocorticoids (GC) are highly effective anti-
inflammatory drugs but their use in arthritis therapy is controversial due to a high incidence 
of serious adverse effects occurring during chronic treatment (2-4). As a result of rapid 
elimination from the circulation and unfavorable tissue distribution, systemic treatment with 
GC results in poor target localization of the drug, which often necessitates the use of high 
doses and intensive dosing schedules (5,6). Targeted delivery of GC can greatly increase the 
concentration of the drug in the inflamed joints and therefore a less intensive dosing regimen 
may be sufficient for an adequate therapeutic response with minimal risk for side effects. 
Long-circulating liposomes have been extensively studied as targeted drug carrier 
systems in oncology and infectious diseases. They have been shown to selectively 
accumulate at the corresponding sites of pathology (7-10). The phenomenon of selective 
targeting to pathological sites can be attributed to locally enhanced permeability of the 
vascular endothelium, allowing small-sized liposomes to extravasate and accumulate in the 
extravascular tissue (11,12). 
In a previous study we showed that a single i.v. injection of GC in long-circulating 
liposomes yielded a rapid, complete and durable disease remission in a rat model of 
adjuvant arthritis (AA). We selected prednisolone as model GC and encapsulated the water-
soluble inactive phosphate ester prednisolone phosphate (PLP) to achieve a stable liposome 
formulation as PLP in free form is quickly converted into active prednisolone in blood or 
tissues. Intensive treatment with repeated daily injections of free PLP could by far not match 
the effect of a single dose of the liposomal drug (see Chapter 3). Pharmacokinetic analysis of 
blood samples taken after administration of liposome-encapsulated PLP revealed not only 
the presence of liposome-bound PLP but also a low, sustained level of unencapsulated 
prednisolone in the circulation. The low, sustained level of free prednisolone did not 
contribute to the therapeutic activity of liposomal PLP. 
A drawback for the translation of therapeutic effects observed in rat models, to 
humans is that the pharmacokinetic behavior of prednisolone in rats is strongly different 
from that in human beings. Therefore, in the present study, we selected dexamethasone 
phosphate (DXP) for incorporation in liposomes, as the pharmacokinetics of dexamethasone 
in rats is similar to its pharmacokinetics in humans.  
First, we investigated whether incorporation of DXP in liposomes is also 
therapeutically beneficial in the AA model. In view of the stronger potency of dexamethasone 
over prednisolone higher therapeutic efficacy was anticipated.  
Second, it was evaluated whether the sustained free drug level observed after i.v. 
administration of liposomal GC is related to the occurrence of systemic side effects. As 
parameters for systemic side effects, treatment-induced loss of body weight and increase of 
blood glucose concentration were measured as these parameters can be quickly, frequently 
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and accurately be measured (as shown by Kaur et al., 1989 (13) and Ogawa et al., 1992 
(14), respectively).  
Third, it was investigated whether the sustained free drug level correlates with the 
clearance rate of the free GC that appears in the circulation after injection of the 
corresponding liposomal formulation. If the clearance rate is an important determinant of 
the free drug level, the chance for side effects may be minimized by encapsulation of high-
clearance GC. We compared PEG-liposomes with dexamethasone (relatively slow clearance 
rate) to PEG-liposomes containing GC with a higher clearance rate (prednisolone, 
budesonide), with respect to pharmacokinetics, therapeutic response in the AA model, and 
systemic side effects, such as body weight loss and increased blood glucose values. With 
budesonide as an example, the results suggest that topical high-clearance GC are interesting 
candidates for encapsulation in long-circulating liposomes and application in the treatment 
of arthritis. This study is the first to report the use of topical high-clearance GC in a systemic 
drug-targeting approach. 
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MATERIALS AND METHODS 
 
Preparation of liposomal GC 
Basically, the same long-circulating poly(ethylene glycol) (PEG) liposomes were used as in 
previous studies, in which was shown that this type of liposomes can selectively accumulate 
in inflamed joints and induce strong local anti-inflammatory activity (Chapter 3 and 4). The 
liposomes were prepared by the film-extrusion method (15). Briefly a lipid solution was 
prepared in ethanol, containing dipalmitoyl phosphatidylcholine (DPPC) (Lipoid GmbH, 
Ludwigshafen, Germany), cholesterol (Sigma Chemical Co., Poole, UK) and distearoyl 
phosphatidylethanolamine-PEG 2000 (PEG-DSPE) (Avanti Polar Lipids, Alabaster, AL, USA) 
in a molar ratio of 1.85 : 1.0 : 0.15 respectively. The lipid solution was transferred to a 
round-bottom flask and a lipid film was created by rotary evaporation. The film was hydrated 
with a solution of 100 mg/ml of prednisolone disodium phosphate (PLP), dexamethasone 
disodium phosphate (DXP) (both obtained from Bufa, Uitgeest, The Netherlands) or 
budesonide disodium phosphate (BUP) (synthesized by Syncom, Groningen, The 
Netherlands) dissolved in sterile water. The resulting lipid dispersion was sized to a diameter 
between 90 and 100 nm by multiple extrusions through polycarbonate filter membranes. 
The unencapsulated GC-phosphate was removed by dialysis against 0.9% phosphate 
buffered saline using Slide-A-Lyzer dialysis cassettes with a molecular weight cut-off of 
10,000 (Pierce, Rockford, IL, USA). The mean particle size was determined by dynamic light 
scattering with a Malvern 4700 system (Malvern Ltd., Malvern, UK). The phospholipid 
content was determined with a phosphate assay (16) in the organic phase after extraction of 
liposomal preparations with chloroform. The aqueous phase after extraction was used for 
determining the GC-phosphate content by high performance liquid chromatography with a 
mobile phase of acetonitril-water with a pH of 2, followed by UV-detection at 254 nm. The 
liposomal preparations contained between 3.5 and 4.5 mg GC-phosphate and an average of 
60 µmol phospholipid/ml. 
 
Rat adjuvant arthritis 
The Dutch Committee of Animal Experiments approved all animal studies. Male inbred Lewis 
rats between 7 and 9 weeks of age (170-200 g) were obtained from Maastricht University, 
Maastricht, the Netherlands. To induce arthritis, 100 ml of incomplete Freund’s adjuvant 
(IFA) containing 10 mg/ml of heat-inactivated Mycobacterium tuberculosis (Mt) (both 
purchased from DIFCO laboratories, Detroit, MI, USA) was injected intracutaneously at the 
base of the tail (17). At day 10 after the immunization, the first signs of joint inflammation 
became visible, together with a loss of body weight as a result of the disease. 20 days post-
immunization the disease reached maximal severity, after which the inflammation process 
gradually resolved. Starting at day 10, the rats were daily examined for the visual signs of 
inflammation and the disease-induced weight drop. The severity of the joint inflammation 
was graded by assigning a score to each paw from 0 to 4, based on erythema, swelling and 
deformation of the joints. The sum of these four grades for each animal is the clinical score 
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and can vary from zero up to 16. Besides the development of paw inflammation, the disease 
results in a loss of body weight that can easily be monitored by daily weighing of the rats. 
 
Therapeutic activity 
All rats were treated on day 14 or 15 post-immunization, when the average score of all rats 
in the experiment reaches 7, which was approximately half the maximal scores reached in 
these experiments. At the day of treatment, groups of five rats were formed with equal 
average clinical scores. All preparations were given intravenously in the tail vein. As the 
pharmacokinetics of PEG-liposomes have been shown to be lipid dose-independent, the 
administered dose of phospholipid was allowed to vary with the different liposomal GC 
preparations (18). When multiple injections of free GC were required, each following day 
treatment was repeated at the same time. The effect of treatment on clinical scores and 
body weight loss was monitored daily from day 10 until day 30 post-immunization. Control 
rats were treated with 150 µmol total lipid/kg empty PEG-liposomes. 
 
Systemic adverse effects 
As parameters for systemic activity loss of body weight and increase in blood glucose 
concentrations were evaluated. Loss of body weight is a phenomenon that is generally 
observed upon systemic GC treatment in rats (13). In this study the loss of body weight 
because of treatment with GC is clearly additional to the weight loss resulting from the 
induction of experimental arthritis. Besides the induction of body weight loss, systemic GC 
treatment can induce hyperglycemia (14). Monitoring the increase of blood glucose was 
performed by using a blood glucose meter (EuroFlash, LifeScan Inc, Miltiplas, USA). 
 
Determination of liposomal GC-phosphate and free GC in the circulation 
In a previous study we showed that PLP remained stably entrapped in PEG-liposomes upon 
i.v. injection (Chapter 3), since at different time-points post-injection PLP was detected in the 
same quantities as a liposome bilayer marker (assuming that unencapsulated PLP is quickly 
and completely converted to prednisolone after entering the circulation). To evaluate the 
stability of the other liposomally encapsulated GC-phosphates (DXP and BUP), plasma 
concentration-time curves of the different liposomal GC-phosphates were measured after 
injection of a dose of 10 mg/kg in healthy rats and were compared to PLP-PEG-liposomes. 
Concentrations of liposomal GC-phosphates were determined by plasma extraction followed 
by HPLC-determination (19). Concentrations as low as 200 ng/ml could be measured 
accurately. Quantities of free GC after injection of 10 mg/kg liposomal GC-phosphate in 
healthy rats could simultaneously be detected with the same assay in one single run with the 
phosphate ester. Concentrations of free GC in the extracts could be determined accurately 
down to a concentration of 50 ng/ml. 
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Statistical analysis 
For statistically assessing and comparing therapeutic efficacy in different groups the 
nonparametric Wilcoxon/Kruskal-Wallis test (rank sums) was used. For evaluating 
differences between groups regarding other parameters, a one-way analysis of variance or a 
Students T-test was performed. P-values of less than 0.05 were considered significant. 
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RESULTS 
 
Therapeutic activity in rat AA: DXP-PEG-liposomes vs. free DXP 
Figure 1 shows the anti-inflammatory effect of 2 mg/kg dexamethasone phosphate (DXP) i.v. 
in free form and encapsulated in PEG-liposomes. A single dose of 2 mg/kg free DXP 
significantly suppressed paw inflammation during three days. The same dose encapsulated 
in PEG-liposomes resulted in complete disappearance of the clinical signs of AA within two 
days. Complete remission of the disease symptoms lasted until day 20 (6 days post-
treatment) after which joint inflammation gradually reappeared, reaching the inflammation 
score of the saline control group around day 24. The same therapeutic response could be 
realized by 5 daily injections of 2 mg/kg free DXP. 
 
 
 
 
 
 
Figure 1. Therapeutic activity in rat AA of 2 
mg/kg DXP-PEG-liposomes versus 2 mg/kg 
free DXP given as single or multiple daily 
treatment. Means of 5 rats are shown. Vertical 
bars show SEM. Arrow indicates first day of 
treatment. 
 
 
 
Adverse effects: DXP-PEG-liposomes vs. free DXP 
Figure 2 A shows the effect of the treatment on the total body weight of AA rats. Both 
liposomal DXP as well as single and multiple treatment with free DXP resulted in treatment-
induced weight loss additional to the body weight loss as a result of the disease (saline 
treatment). Although equally effective at a therapeutic level, repeated administration of 2 
mg/kg free DXP generated a stronger treatment-induced loss of body weight than a single 
injection of 2 mg/kg liposomal DXP (p < 0.05 at day 18 post-immunization). In Figure 2 B it 
is shown that 2 mg/kg DXP in liposomal and in free form (single and repeated injections) 
enhanced blood glucose levels to a similar extent during the first days after treatment. 
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Figure 2. Systemic effects as a result of 2 mg/kg unencapsulated DXP (single and multiple dose), and 2 mg/kg 
DXP-PEG-liposomes. (A) Effect on total body weight. Vertical bars show SEM. (B) GC-induced hyperglycemia. 
The percentage of the blood glucose concentration at day of treatment is shown. Vertical bars show SD. In 
both A. and B. means of 5 rats are shown. Arrows indicate treatment days. 
 
Therapeutic activity and adverse effects: PLP-PEG-liposomes vs. DXP-PEG-liposomes 
To investigate the role of clearance rate in the therapeutic index of liposomal GC, 
prednisolone phosphate (PLP) was encapsulated, as prednisolone is a GC, which has in rats 
a much higher clearance rate than dexamethasone. However, as these two GC are known to 
differ in potency, first the therapeutic activity of liposomal PLP was compared with liposomal 
DXP. Figure 3 A shows the comparative effect of a single dose of 2 mg/kg and 10 mg/kg of 
PLP-PEG-liposomes and DXP-PEG-liposomes on rat adjuvant arthritis scores. A clear dose-
response relation is observed with both liposomal GC. A dose of 10 mg/kg PLP-PEG-
liposomes was equally effective as 2 mg/kg DXP-PEG-liposomes, indicating that liposomal 
PLP is approximately 5 times less potent than liposomal DXP.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Relative potency of PLP-PEG-liposomes vs. DXP-PEG-liposomes. (A) Effect on joint inflammation in 
rat adjuvant arthritis, and (B) effect on body weight. Body weight is shown as percentage of the body weight at 
day of treatment. Means of 5 rats are shown. Vertical bars show SEM. Arrow indicates treatment (day 15). 
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Figure 3 B shows that 10 mg/kg PLP-PEG-liposomes reversed the disease-induced 
process of body weight loss between day 2 and 7 post-treatment. A dose of 2 mg/kg DXP-
PEG-liposomes produced a similar response, however, body weight gain started 2 days later, 
between day 19 and day 24. In the period between day of treatment (day 15) and body 
weight gain, an additional loss of body weight was observed with liposomal DXP, which was 
not significant with liposomal PLP. Rats treated wit 2 mg/kg liposomal DXP showed an 
additional weight loss of up to 5.5% as compared to rats in the control group over a period 
of 4 days before body weight gain was observed. With 10 mg/kg liposomal DXP, this 
additional body weight loss even reached 9.2%, lasting for more than a week. 
 
Therapeutic activity and adverse effects: BUP-PEG-liposomes vs. DXP-PEG-liposomes 
The anti-inflammatory effect of a dose of 1 mg/kg BUP-PEG-liposomes was compared to the 
effect of 1 mg/kg and 2 mg/kg DXP-PEG-liposomes in the rat AA model (Figure 4). Both 
liposomal DXP and liposomal BUP are highly effective in AA, causing a complete remission 
of joint inflammation at a 10-fold lower dose as compared to liposomal PLP. Importantly, 
Figure 5 B shows that 1 mg/kg liposomal BUP induces an almost complete regain of the 
disease-induced loss of body weight as a result of its therapeutic effect. However, the 
opposite is observed after both 1 mg/kg and 2 mg/kg liposomal DXP, which induced an 
additional treatment-induced body weight loss. The reversal of disease-induced body weight 
loss as a result of the therapeutic effect was also seen with liposomal DXP, but this was 
occurring after the period of additional treatment-induced body weight loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Relative potency and systemic activity of BUP-PEG-liposomes vs. DXP-PEG-liposomes. (A)Effect on 
joint inflammation, and (B) effect on body weight of 1 mg/kg liposomal BUP and 1 and 22 mg/kg liposomal 
DXP. Body weight is shown as percentage of the body weight at day of treatment. Means of 5 rats are shown. 
Vertical bars show SEM. Arrow indicates treatment (day 15) 
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Plasma concentrations: liposomal GC vs. free GC 
Figure 5 A shows the plasma concentration-time profile of the three different GC-phosphates: 
PLP, DXP and BUP, after injection of a dose of 10 mg/kg encapsulated in PEG-liposomes. 
All three liposomal GC follow the same plasma concentration-time profile. As in a previous 
study PEG-liposomal PLP was shown to be completely contained within the liposome 
particles in the circulation, based on these data, complete retention in the liposomes may 
also be expected with both DXP and BUP in PEG-liposomes. 
Despite equal dose and identical plasma concentration-time profile of the three 
liposomal GC-phosphates, strong differences are observed regarding the plasma 
concentration-time profile of the free (i.e. not bound to liposomes) parent drug detected in 
the circulation after treatment with the liposomal formulations. Treatment with liposomal 
DXP yielded the highest free drug levels, whereas treatment with liposomal BUP and PLP 
resulted in similar, but much lower levels of free GC. Roughly, the areas under the plasma 
concentration-time curves of free GC in the circulation appeared to be inversely correlated 
with the reported clearance values (in rats: approx. 0.2 L·h-1kg-1 for dexamethasone (20), 1.5 
L·h-1kg-1 for budesonide (21) and 2.3 L·h-1kg-1 for prednisolone (22)). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Plasma concentrations of liposomal glucocorticoid phosphate (A) and released free glucocorticoid (B) in the 
circulation upon injection of 10 mg/kg glucocorticoid phosphate-PEG-liposomes. Data represent means of 4 rats, Vertical 
bars show SD. 
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DISCUSSION 
 
In previous studies we showed that long-circulating liposomes extravasate into inflamed 
joints in experimental rat and murine models of arthritis. Liposomal encapsulation of PLP 
enhanced the local anti-inflammatory activity to such an extent that even a single i.v. 
injection of 10 mg/kg liposomal PLP yielded complete, rapid and long-lasting remission of 
joint-inflammation. In the present study, we compared the therapeutic activity and adverse 
effects of 3 different GC, encapsulated in water-soluble phosphate form in long-circulating 
liposomes in an attempt to further optimize the therapeutic index of liposomal GC in 
arthritis. However, increased efficacy is only clinically relevant when the adverse effects are 
not increased such that the therapeutic index of the drug is not improved upon liposomal 
encapsulation. In the present study we focus on possible adverse effects of liposomal GC 
and evaluate how the therapeutic index of liposomal GC can be optimized. 
Dexamethasone was chosen as model GC, as its pharmacokinetics in rats are quite 
similar to that in humans. As the potency of dexamethasone is higher than that of 
prednisolone, which was used in our previous study, the first objective was to find the dose 
at which liposomal dexamethasone phosphate (DXP) induced complete remission of joint 
inflammation. In rat AA, it appears that a single i.v. injection of 2 mg/kg liposomal DXP can 
induce a full disease remission for almost a week. This therapeutic response roughly equals 
the previously observed response in AA of 10 mg/kg liposomal PLP (Chapter 3), indicating 
that liposomal DXP is approximately 5 times more potent than liposomal PLP. Therapeutic 
benefit could also be realized with free DXP. However, 5 daily injections of 2 mg/kg were 
required to produce the same response as a single treatment with 2 mg/kg liposomal DXP, 
indicating that liposomal encapsulation strongly enhances the therapeutic activity of the 
drug (Figure 1). 
The second objective of this study was to evaluate possible systemic side effects of 
induced by sustained level of free GC in the circulation after injection of liposomal GC. Such 
levels were observed in our first study with liposomal PLP. We showed that these levels were 
not contributing to the increased therapeutic effect. However, they may contribute to the 
induction of systemic adverse effects. First, the effect on body weight was evaluated. Besides 
paw inflammation, induction of AA in rats generally leads to a gradual fall of body weight. 
Therapeutic activity in the model is not only detectable by reversal of paw inflammation, but 
also by reversal of disease-induced body weight fall (17). Reversal of body weight fall was 
clearly observed in our previous study with PLP-PEG-liposomes. In the present study, 
however, instead of a reversal, liposomal DXP induced an extra drop in body weight 
occurring during the first five days after treatment (Figure 2 A). This treatment-induced body 
weight loss was additional to the disease-induced body weight drop and could be 
reproduced in healthy rats (data not shown). Body weight loss as a result of i.v. GC has been 
earlier reported for rats (13) and can be considered as a relevant parameter for systemic 
adverse events. As in our study the treatment-induced body weight fall was also seen with 
therapeutic index can be optimized by encapsulating high-clearance glucocorticoids in liposomes 
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free GC, it is likely that liposomal DXP induced this adverse effect as a result of the presence 
of free dexamethasone in the circulation. 
Besides the effect on body weight also the effect on blood glucose levels of GC can be 
used as a parameter for systemic activity (14). In our study, monitoring blood glucose levels 
during the course of the disease showed that both liposomal DXP and free DXP caused a 
limited, but significant hyperglycemia during the first days after treatment (Figure 2 B). This 
observation again points to the presence of free dexamethasone in the systemic circulation 
after injection of liposomal DXP. Interestingly, an equipotent dose of liposomal PLP did not 
result in significant systemic adverse effects. Instead of a treatment-induced body weight 
loss, a strong regain of body weight was revealed in the first week after treatment with 10 
mg/kg liposomal PLP, which clearly corresponded with the remission of paw inflammation 
(Figure 3). Furthermore, no significant rise of blood glucose concentration was revealed upon 
10 mg/kg liposomal PLP (data not shown). These observations suggest that the fraction of 
the i.v. administered dose of liposomal GC-phosphate that becomes available in the 
circulation as free GC may be much lower with liposomal PLP than with liposomal DXP. 
The third objective of the study was to evaluate whether there is a relation between 
the clearance rate of the encapsulated GC-phosphate ester and the quantity of free parent 
drug that becomes available in the circulation after i.v. administration of liposome-
encapsulated GC-phosphate. In our previous study injection of liposomal PLP yielded 
detectable levels of free prednisolone in the circulation. As the liposome particles appeared 
not to leak PLP in the circulation, it was suggested that in particular phagocytes in liver and 
spleen release the encapsulated GC-phosphate after uptake and degradation of the 
liposomes (23,24), after which the phosphate ester is converted into active GC. With a higher 
clearance rate of the free drug, one would expect the quantity of GC present in the 
circulation in free form to be less, as clearance rate and area under the plasma 
concentration-time curve of drug in the circulation are inversely related. In rats, there is a 
clear difference between prednisolone and dexamethasone regarding their clearance rate. 
The clearance rate of prednisolone is reported to be approximately 2.3 L·h-1kg-1 (21), 
whereas for dexamethasone the clearance rate is not higher than 0.2 L·h-1kg-1 (19,25). 
Therefore, the absence of systemic activity of liposomal PLP regarding body weight loss 
(Figure 3b) and hyperglycemia may indeed be explained by its high clearance rate in rats. 
Our results show that liposomal encapsulation of PLP results in a stronger 
improvement of the therapeutic index than liposomal encapsulation of DXP. However, this 
observation may only apply to the rat. In humans, the clearance rate of prednisolone from 
the circulation is quite similar to that of dexamethasone. To optimize the therapeutic index 
of i.v. liposomal GC in RA patients, other GC should be selected with high clearance rates 
after i.v. administration in humans without forming active metabolites. Such may be found 
among the GC that are used for local treatment of asthma and rhinitis (26,27). From this 
group we selected budesonide, one of the GC reported to have a high clearance rate forming 
metabolites that are almost completely devoid of systemic activity (28). To successfully 
encapsulate budesonide in PEG-liposomes, the water-soluble phosphate ester was 
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synthesized (BUP), a derivative, which has not yet been commercialized. The results show 
that the liposomal form of this novel budesonide derivative is at least as effective as 
liposomal DXP in rat AA (Figure 4 A) while showing less systemic side effect (Figure 4 B). 
Comparing the plasma concentration-time curves of liposomal BUP with liposomal 
DXP and liposomal PLP after i.v. injection of equal doses revealed identical profiles for all 
three liposomal GC. As we showed before that no leakage of PLP from PEG-liposomes 
occurred, such may also be assumed for liposomal DXP and liposomal BUP. In contrast, the 
sustained free drug levels after injection of the three liposomal GC formulations greatly 
differed from each other with an inverse relationship with the clearance rate of the GC in 
question (Figure 5 B). The observation that free budesonide levels were slightly higher than 
free prednisolone is in agreement with the slightly lower clearance rate of budesonide 
reported in rats (1.5 L·h-1kg-1 as compared to 2.3 L·h-1kg-1 for prednisolone) (20,21). 
However, this does not reflect the human situation, as in humans the clearance rate of 
prednisolone is much lower than that of budesonide (29,30). 
In conclusion, our data show that with the use of GC (dexamethasone, budesonide) of 
higher potency than prednisolone, the therapeutic activity of liposomal GC can be increased. 
However, sustained free GC levels were observed after injection of the 3 liposomal GC-
phosphates, which showed an inverse relationship with the clearance rate of the GC used. As 
the sustained free GC levels can cause systemic side effects, this study stresses the 
importance of a high clearance rate of the free GC in question for achieving a maximal 
therapeutic index with liposomal GC. Therefore high-clearance GC, which until now are only 
applied in local treatment approaches, may be very useful for the development of novel, 
highly effective anti-inflammatory preparations for systemic treatment of inflammatory 
disorders. 
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CHAPTER COMPLEMENT ACTIVATION - RELATED HYPERSENSITIVITY 
REACTIONS CAUSED BY PEGYLATED LIPOSOMES 
SEARCH FOR AN ALTERNATIVE LONG-CIRCULATING LIPOSOME 
FORMULATION WITHOUT COMPLEMENT ACTIVATION 
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ABSTRACT 
 
PEGylated long-circulating liposomes have been reported to cause immediate 
hypersensitivity reactions in 5-10% of the patients treated. These reactions may be 
explained by liposome-induced complement activation. The aim of this study was to design a 
long-circulating liposome formulation that does not induce complement activation. We 
monitored the formation of complement terminal complex SC5b-9 in vitro in human serum 
samples as well as hemodynamic changes in pigs upon i.v. injection of several PEGylated 
and non-PEGylated liposome formulations. 
It was found that Doxil (PEG-liposomal doxorubicin), similar PEG-liposomes without 
drug as well as size-matched (90 nm) empty non-PEG-liposomes, all caused significant in 
vitro complement activation as well as hypersensitivity reactions in pigs, indicating that PEG-
PE and/or its negative charge cannot be the sole underlying cause. Smaller (<70 nm) non-
PEG-liposomes composed of DSPC and cholesterol caused no complement activation and 
completely lacked the induction of hemodynamic changes in pigs, suggesting that size is an 
additional major factor in complement activation responses. 
To evaluate the usefulness of these small non-PEG-PEGylated DSPC-cholesterol 
liposomes for passive targeting purposes, dexamethasone phosphate was encapsulated and 
this liposomal formulation was given to rats with experimental arthritis. Interestingly, our 
data show that these liposomes can circulate at least as long as PEG-liposomes. The 
therapeutic activity of the liposomally encapsulated drug was similar for the PEG-liposomes 
and non-PEG-liposomes in this study, indicating that small-sized (<70 nm) non-PEGylated 
liposomes may be preferred over PEG-liposomes as carrier for passive drug targeting 
purposes, as they appear not to induce complement activation. 
complement activation-related hypersensitivity reactions caused by PEGylated liposomes 
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INTRODUCTION 
 
PEG-liposomes have extensively been studied as potential carriers for targeted drug delivery 
to tumors, infections and sites of inflammation, as they have been shown to selectively 
accumulate at these sites (1-4). The success of PEG-liposomes in the field of oncology has 
led to a growing use of this formulation in the clinic. One preparation is currently on the 
market for the treatment of solid tumors: Doxil (Caelyx in Europe), a PEGylated long-
circulating liposome (LCL) formulation of doxorubicin, while others are in clinical trials. 
The therapeutic value of PEG-liposomes in infection has been shown in a range of 
preclinical studies (5). Evaluation in experimental models of infection revealed that the 
therapeutic activity of antibacterial drugs can be improved by encapsulation in PEG-
liposomes. In rat and murine models of experimental arthritis encapsulation in PEG-
liposomes strongly improved the anti-inflammatory activity of glucocorticoids (see Chapter 3 
and 4). Such promising results warrant clinical studies in patients in a short term. 
However, PEG-liposomal formulations such as Doxil can cause immediate allergic 
reactions in patients. These reactions have been observed in a significant proportion of 
patients. The symptoms occur upon the first infusion and include dyspnea, tachypnea, facial 
swelling, headache, chills, hypo- and/or hypertension, chest pain and back pain (6-9). They 
are generally mild and quickly resolve after interruption and resumption of the infusion at a 
slower rate. Most patients can receive further infusions without any complications. The 
reactions have been dubbed “pseudoallergic”, as no prior sensitization is needed to induce 
them. Clinical studies performed with radioactively labeled PEG-liposomes without drug for 
diagnostic purposes also revealed pseudoallergic reactions, supporting the suggestion that 
the observed effects are due to the liposomal carrier rather than the drug (10). 
In recent reports it was hypothesized that PEGylated liposome formulations induced 
these phenomena as a result of complement activation (11,12). A key argument for this 
hypothesis came from experiments in a porcine model of liposome-induced cardiopulmonary 
distress (13,14), which showed that the PEG-liposome-induced hemodynamic reactions in 
pigs are a consequence of complement activation (15). A relationship between complement 
activation and pseudoallergic reactions was recently confirmed in a clinical study in patients 
treated with Doxil (16). Possibly the use of PEG-phosphatidyl ethanolamine (PEG-PE) is a 
key factor in the induction of complement activation. 
The ultimate aim of this study was to design LCL, which do not induce complement 
activation. To this end, different types of PEGylated and non-PEGylated liposomes were 
evaluated regarding complement activation in human serum, pseudoallergic reactions in 
pigs, and long-circulating properties and therapeutic benefit in a rat model of experimental 
arthritis. For the two latter purposes, the anti-inflammatory glucocorticoid dexamethasone 
phosphate (DXP) was encapsulated as a model drug, as a previous study revealed that 
encapsulation of glucocorticoids in PEG-liposomes, resulted in a strong increase of the 
therapeutic benefit of the glucocorticoid in question by selective targeting to inflamed joints 
(Chapter 3). 
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MATERIALS AND METHODS 
 
Liposomes 
Liposomes were prepared by the film-extrusion method (17). Briefly, a lipid solution was 
prepared in ethanol, containing the phospholipid dipalmitoyl phosphatidylcholine (DPPC) or 
distearoyl phosphatidylcholine (DSPC) (Lipoid GmbH, Ludwigshafen, Germany) and 
cholesterol (Sigma Chemical Co., Poole, UK) in a molar ratio of 2:1. For PEG-liposomes, 7.5 
mole % of the amount of total lipid in the mixture of poly(ethylene glycol)2000 coupled to 
distearoyl phosphatidylethanolamine (PEG-DSPE) (Avanti Polar Lipids, Alabaster, AL, USA) 
was added. The lipid solution was transferred to a round-bottom flask and a lipid film was 
created by rotary evaporation. The film was hydrated with 0.9% saline buffered with 10 mM 
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH: 7.4) in sterile water. DXP 
was encapsulated by dissolving 100 mg/ml in the hydration buffer before hydration. The 
resulting lipid dispersion was sized to the desired diameter by multiple extrusions through 
polycarbonate filter membranes. Non-encapsulated DXP was removed by dialysis with Slyde-
A-Lyzer dialysis cassettes with a molecular weight cut-off of 10,000 (Pierce, Rockford, IL, 
USA). Mean particle size was determined by dynamic light scattering with a Malvern 4700 
system (Malvern Ltd., Malvern, UK). Zeta potentials were measured with a Zetasizer 
(Malvern Ltd., Malvern, UK). Phospholipid content of the organic phase after extraction of 
liposomal preparations with chloroform was determined with a phosphate assay (18). DXP 
was determined by a reversed phase HPLC assay in the aqueous fraction after extraction.  
 
In vitro complement activation assay in human serum samples 
Blood samples from healthy volunteers were collected and serum was prepared and stored 
(at –20 °C) as described earlier (19). Complement activation was assessed by ELISA kits 
(Quidel Co., San Diego, CA, USA) measuring protein S (vitronectin)-bound C terminal 
complex (SC5b-9). The assay has been used in clinical studies to quantify complement 
activation with high sensitivity and specificity (20). Liposome dispersions containing 60 mM 
total lipid were diluted 5-fold in human serum and were incubated for 30 min at 37 °C with 
shaking at 80 rpm. After incubation the samples were diluted 20-fold in the "sample diluent" 
of the kit and 100 µl aliquots from this mixture were applied into the wells of the ELISA 
plate, usually in duplicate. The assay was validated by repetitive measurement of randomly 
selected samples at different times with >1 year separation, using different batches of the 
SC5b-9 kit, and blinding the assayer(s) with regard to the identity of samples. In agreement 
with the manufacturer’s specification of the SC5b-9 kit, these experiments revealed 
approximately 10-20% variation of SC5b-9 readings (16).  
All liposome formulations were tested in serum samples of 4 to 5 different subjects. 
For each subject the % increase of SC5b-9 concentration was calculated and compared to 
the person’s own baseline, referred to as “PBS control”. Complement activation is presented 
as the mean % increase observed in the 4 – 5 subjects in which the formulations were 
tested. 
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In vivo porcine model of complement-related pseudoallergy 
Experiments were performed in accordance with guidelines of the Committee on Animal 
Care of the Uniformed Services University of the Health Sciences. Castrated male Yorkshire 
swine (48-215 LB) were sedated with intramuscular ketamine, anesthetized with isoflurane 
and instrumented as described previously (13). In brief, a catheter was advanced via the 
right internal jugular vein into the pulmonary artery to measure pulmonary artery pressure 
(PAP), central venous pressure (CVP) and cardiac output (CO); another catheter was 
advanced through the left femoral artery into the proximal aorta to measure systemic arterial 
pressure (SAP). Systemic vascular resistance (SVR), left ventricular end-diastolic pressure 
(LEVDP) and pulmonary vascular resistance (PVR) were calculated from SAP, PAP, CO, and 
CVP by standard formulas. Cerebral blood flow, pCO2 and ECG were recorded continually. 
Liposomes were diluted in 1 ml PBS and injected into the pulmonary artery of pigs, 
via the pulmonary arterial catheter. Liposomes were flushed into the circulation with 10 ml 
PBS. Based on our previous finding that the hemodynamic effects of small liposome boluses 
were non-tachyphylactic and quantitatively reproducible in the same animal, we injected 
increasing amounts of the same type of liposomes in each pig until a reaction developed, or, 
in the absence of reaction, until a certain predetermined top dose was tested. The doses 
applied were in the 0.15-1.5 µmol lipid/kg (pig) range except for Doxil, which, because of 
the severity of the reactions, had to be given at an almost 10-fold lower dose. The responses 
were graded as follows: none, no significant alteration in ECG or any hemodynamic 
parameters; mild, transient (< 2 min) <50 % changes in at least one of the following 
parameters: heart rate, ECG, SAP, PAP, pCO2; severe, up to 10 min and >50% changes in at 
least one of the above parameters plus bradyarrhythmia; lethal, circulatory collapse within 2 
min requiring epinephrine and cardiac massage for resuscitation. Typically mean SAP falls 
from 110 to <40 mm Hg, mean PAP rises from 18 to a maximum (60 mm Hg), pCO2 in 
expired gas drops from 32 to <20 mm Hg, tachycardia is followed by severe bradycardia 
with arrhythmia, leading to cardiac arrest and death. 
 
Pharmacokinetics and therapeutic activity non-PEG-liposomes vs. PEG-liposomes 
For comparative assessment of the pharmacokinetics of PEG-liposomes versus non-PEG 
liposomal formulations, DXP was encapsulated in liposomes composed of PEG-DSPE, DPPC 
and cholesterol (90 nm) and in two liposome types composed of DSPC and cholesterol (90 
nm and 65 nm in size). 
DXP can easily be detected in plasma and has the attractive property of being almost 
immediately and fully converted into dexamethasone when free in the circulation. As in a 
previous study liposomal glucocorticoid was shown to not leak encapsulated drug in the 
circulation, plasma levels of DXP could be regarded as a measure of liposome-associated 
drug (see Chapter 3). For assessment of DXP in plasma samples, plasma was extracted 
according to a method reported by Derendorf et al. and assayed with a reversed-phase HPLC 
method, using UV-absorption detection at 254 nm (21). 
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Rat experimental model of adjuvant arthritis 
The Dutch Committee of Animal Experiments approved these animal studies. Male inbred 
Lewis rats between 7 and 9 weeks of age (170-200 g) were obtained from Maastricht 
University, Maastricht, The Netherlands. Adjuvant arthritis was induced according to Koga 
and Pearson (22). Briefly, incomplete Freund’s adjuvant containing heat-inactivated 
Mycobacterium tuberculosis was intracutaneously injected at the base of the tail. Paw 
inflammation started around day 10 after the immunization, reached maximal severity 
around day 20, after which the inflammation process gradually resolved. The rats were 
scored daily for the visual signs of inflammation. The severity of the joint inflammation was 
graded by assigning a score to each paw from 0 to 4, based on erythema, swelling and 
deformation of the joints. All rats were treated on day 15 post-induction with DXP in free 
form or DXP encapsulated in PEG-liposomes or DSPC-cholesterol liposomes (90 or 65 nm), 
when the average sum score of all paws of the rats in the experiment was around 7. The 
effect of treatment on clinical scores and body weight was monitored up to 4 weeks post-
treatment. 
 
Statistical Analysis 
SC5b-9 values were expressed as mean ± SD of 4 – 5 subjects. One-sample t tests were 
used to determine whether the mean was significantly different from 100% (PBS value). 
Scores in the in vivo pig model were statistically evaluated with the nonparametric 
Wilcoxon/Kruskal-Wallis test (rank sums). For evaluation of pharmacokinetics one-way 
analysis of variance was used, whereas for evaluation of the therapeutic activity also the 
Wilcoxon/Kruskal-Wallis test was applied. P values of less than 0.05 were considered 
significant. 
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RESULTS 
 
Liposome characteristics 
Table 1 shows the characteristics of the different liposome types used in this study. In 
general, the size of the liposomes ranged between 80 and 100 nm except for the DSPC-
cholesterol liposomes of 65 nm. Polydispersity was always lower than 0.1 except in the case 
of Daunoxome, which had a polydispersity of >0.2. The zeta-potential of PEG-liposomes 
was negative. Non-PEG-liposomes proved to be around neutral. Each liposome formulation 
contained around 40 µmol phospholipid/ml. The formulations prepared with DXP contained 
between 5 and 10 mg DXP/ml. 
 
Table 1. Liposome composition and characteristics 
Composition Molar ratio 
Mean diameter 
(nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
DPPC PEG-DSPE Chol 1.85 : 0.15 : 1.0 88 <0.1 -37 
DSPC PEG-DSPE Chol 1.85 : 0.15 : 1.0 87 <0.1 -28 
DSPC Chol 2.0 : 1.0 90 <0.1 -1 
DSPC Chol 2.0 : 1.0 66 <0.1 -1 
DSPC PEG-DSPE Chol 
+ doxorubicin (Doxil) 
1.85 : 0.15 : 1.0 85 <0.1 -43 
DSPC Chol + daunorubicin 
(Daunoxome) 
2.0 : 1.0 74 >0.2 -2 
 
 
In vitro complement activation in human plasma 
Fig 1 shows the % increase of the human serum SC5-b9 concentration after addition of 
liposomal formulations as compared to the baseline concentration. All liposome 
formulations induced a significant increase of SC5-b9 levels except for 65 nm DSPC-
cholesterol liposomes. 
 
In vivo porcine model of complement-related pseudoallergy 
Table 2 shows that 5 out of the 6 formulations tested caused pseudoallergic reactions in the 
pigs. Liposomes without drug roughly induced reactions in half of the pigs that were tested. 
Both Doxil and Daunoxome caused severe to lethal reactions in the majority of the pigs in 
which they were tested. Especially Doxil proved to be a strong inductor of pseudoallergy, as 
the reactogenic dose range was an order of magnitude lower than that of other liposomes. 
The only formulation, which did not induce complement activation and pseudoallergy, was 
the DSPC-cholesterol liposome formulation of 65 nm.  
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Figure 1. In vitro complement activation in 
human serum as measured by % increase of 
SC5-b9 levels as a result of addition of 
liposomes as compared to baseline SC5-b9 
levels (addition of PBS). * = significant 
complement activation (p <0.05, single 
sample t test). Data represent means of 4 – 5 
subjects + SD. 
 
 
 
 
Table 2. Hypersensitivity reactions in porcine model  
liposomes lipid dose (µmol/kg) 
frequency of 
reactions 
severity of reactions 
DPPC PEG-DSPE Chol 0.17-1.39 4/6 
None (2), Mild (1), 
Severe  (1),    Lethal  (2) 
DSPC PEG-DSPE Chol 0.16-1.97 2/4 
None (2), Mild (0), 
Severe  (1),    Lethal  (1) 
DSPC Chol (90 nm) 0.16-1.85 5/11 
None (6), Mild (3), 
Severe  (2),    Lethal  (0) 
DSPC Chol (65 nm) 0.16-1.54 0/8 
None (8), Mild (0), 
Severe  (0),    Lethal  (0) 
Doxil 0.02-0.27 12/14 None (2), Mild (3), 
Severe  (8),    Lethal  (1) 
Daunoxome 0.18-0.73 7/8 None (1), Mild (2), 
Severe  (1),    Lethal  (4) 
 
 
Circulation kinetics: non-PEG-liposomes vs. PEG-liposomes 
Fig 2 shows that non-PEG-liposomes composed of DSPC and cholesterol can behave as long-
circulating as PEG-liposomes. DSPC-cholesterol liposomes of <70 nm had an even longer 
circulation half-life (appr. 36 hrs) as compared to PEG-liposomes (22 hrs). 
 
 
 ∗
0
100
200
300
400
500
DPPC
PEG-DSPE
Chol
DSPC
PEG-DSPE
Chol
    DSPC    
Chol        
(100 nm)
   DSPC     
Chol         
(60 nm)
Doxil Daunoxome
re
la
tiv
e 
SC
5-
b9
 c
on
c 
(P
BS
 =
 1
00
%
)
DPPC
PEG-DSPE
Chol
DSPC
PEG-DSPE
Chol
DSPC  
Chol    
(10 nm)
     
Chol         
(60 nm)
Doxil Daunoxo e
 ∗ 
∗ ∗ 
∗ 
(90 nm) (65 n ) 
complement activation-related hypersensitivity reactions caused by PEGylated liposomes 
  131 
 
 
 
 
Figure 2. Plasma concentration-time curves 
of liposomal DXP after injection of 10 mg/kg 
DXP incorporated in DPPC-PEGDSPE-
cholesterol liposomes (closed squares), 
DSPC-cholesterol liposomes of 90 nm (gray 
circles) and DSPC-cholesterol liposomes of 
<70 nm (gray triangles) in healthy rats. Data 
represent means +/- SD of groups of 4 rats. 
 
 
 
 
Therapeutic activity of DXP-liposomes in rat adjuvant arthritis 
Figure 3 A shows the effect of liposomal encapsulation of DXP on the therapeutic activity of 
the drug.  Non-encapsulated DXP at 2 mg/kg reduced inflammation scores during one day, 
after which paw inflammation intensified again. In contrast, an equal dose of DXP 
encapsulated in PEG-liposomes led to complete remission of paw inflammation up to one 
week post-treatment. In Figure 3 B the effect of 1 mg/kg DXP in 90 nm and 65 nm DSPC-
cholesterol liposomes without PEG is compared to an equal dose DXP-PEG-liposomes. 
Clearly, no difference in therapeutic activity is observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Therapeutic effect in rat adjuvant arthritis. (A) 2 mg/kg i.v. DXP in free form (open squares) given at 
day 15 (arrow), and 2 mg/kg DXP in PEG-liposomes (closed squares), both given as a single injection, and (B) 
1 mg/kg DXP encapsulated in PEG-liposomes (closed squares), DSPC-cholesterol liposomes of 90 nm (gray 
circles) and DSPC-cholesterol liposomes of <70 nm (gray triangles) in adjuvant arthritis rats. Saline treated rats 
are used as controls (A and B) (open circles). Data represent means +/- SEM of groups of 5 rats. 
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DISCUSSION 
 
Complement activation-related pseudoallergy in patients has been reported to occur with 
several lipid formulations (23). The most extensively studied liposome formulation in this 
respect is PEGylated liposomal doxorubicin (Doxil, Caelyx) (6-9). Of the formulations 
tested in the present study Doxil indeed appeared to be the strongest inductor of 
complement activation. On the average, Doxil caused a more than 3-fold increase of SC5-b9 
in serum samples as compared to baseline values. Also, in the in vivo pig model, Doxil 
caused reactions in 12 out of 14 pigs at 5- to 10-fold lower doses as compared to the other 
formulations tested. 
This study confirms earlier observations that PEG-liposomes, also when doxorubicin 
is not encapsulated, can activate complement and cause hypersensitivity reactions in pigs 
(24). It is also in line with a report by Brouwers et al. on hypersensitivity reactions to 99Tc-
labeled empty PEG-liposomes in 3 out of 9 patients with Crohn’s disease (10). Both the 
results of the in vitro SC5-b9 assay and the in vivo pig data reveal a response in roughly 50% 
of the test cases with PEG-liposomes. Remarkably, quite similar results were obtained with 
liposomes without PEG, indicating that PEG-PE and/or its negative charge cannot be the 
sole underlying cause of complement activation and subsequent hypersensitivity reactions.  
In our studies, only the smallest size (mean diameter: 65 nm) DSPC-cholesterol 
liposome formulation was completely lacking complement-activating properties. Liposomes 
with the same composition but a somewhat larger mean diameter (90 nm) did show 
complement-activating activity, which indicates that size is an important factor in 
complement activation. Nevertheless, the presence of PEG-PE and/or its negative charge, 
and a relatively large size (i.e. ≥90 nm) may not represent the full list of risk factors for 
induction of complement activation. We found that Daunoxome, a neutral, non-PEGylated 
DSPC-cholesterol formulation of daunorubicin, in our study showing a mean diameter of 74 
nm, caused responses both in vitro and in vivo with a relatively high frequency. This 
observation is in line with the finding that Daunoxome caused hypersensitivity reactions in 4 
out of 15 of patients involved in a clinical phase II trial (25). Considering that Daunoxome 
differed from the reaction-free empty control (DSPC-cholesterol) liposomes only in that it 
had substantially greater polydispersity index (see Table I), these observations suggest that 
the relatively large size distribution, probably caused by the presence of a fraction of larger 
liposomes or liposome aggregates among the small ones, is an additional major risk factor.  
We have previously shown that Doxil is a more effective complement activator than 
the corresponding empty PEGylated liposomes (24). Taken together with the present 
observations with Daunoxome, it seems likely that the encapsulated doxorubicin and 
daunorubicin do play a role in C activation, despite the fact that both drugs are located 
within the liposome particles, apparently shielded from plasma. It has been observed that 
aggregates are present within these formulations (unpublished observations). Liposome 
aggregates, might be superior complement activators even in negligible quantities.  
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As small DSPC-cholesterol liposomes appeared to lack complement activating 
properties, it was of interest to evaluate whether these non-PEG-liposomes could also be 
used for passive drug targeting purposes. Therefore, we assessed the circulation time of 
DXP encapsulated in these liposomes in healthy rats. In addition, we evaluated the 
therapeutic activity of these liposomes in rat experimental arthritis. Our data showed that 
non-PEGylated DSPC-cholesterol liposomes circulated at least as long as PEG-liposomes. 
Interestingly, decreasing the size of DSPC-cholesterol liposomes from 90 nm to <70 nm 
extended the half-life to approximately 36 hrs in rats. In addition the therapeutic 
performance of these small non-PEGylated liposomes was similar to that of the PEG-
liposomes.  
In conclusion, the results presented in this study show that complement-related 
hypersensitivity reactions can occur either with or without the incorporation of PEG-PE in the 
liposomal formulation, indicating that PEG and/or a net negative surface charge may not be 
the (sole) key factor in the activation of complement by liposomes. Avoidance of 
complement activation may be achieved by sizing liposomes down to <70 nm with minimal 
polydispersity. The small, neutral DSPC-cholesterol liposome formulation, which in this 
study was completely lacking complement activation and hypersensitivity reactions, proved 
to be as valuable for targeting glucocorticoids to inflamed areas as 90 nm PEG-liposomes, 
which we used in most of the experimental work presented in this thesis. Therefore, the 
small non-PEGylated liposome formulation may be preferred over PEG-liposomes as carrier 
for passive drug targeting purposes. 
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CHAPTER A NOVEL FAMILY OF L-AMINO ACID-BASED 
BIODEGRADABLE POLYMER-LIPID CONJUGATES FOR THE 
DEVELOPMENT OF LONG-CIRCULATING LIPOSOMES WITH 
EFFECTIVE DRUG TARGETING CAPACITY 
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ABSTRACT 
 
Purpose. The objective of this study was to develop biodegradable polypeptide-lipid 
conjugates for the design of polymer-coated long-circulating liposomes (LCL).  
Methods. Lipid conjugates of poly(hydroxyalkyl L-asparagine/L-glutamine) were synthesized 
and incorporated into 0.15 µm dipalmitoyl phosphatidylcholine (DPPC) - cholesterol 
liposomes. Circulation times and biodistribution were assessed in rats using a radioactive 
lipid marker. Evaluation of the therapeutic activity of prednisolone phosphate loaded in 0.1 
µm PHEA-DPPC-cholesterol liposomes in a rat experimental arthritis model was performed 
to demonstrate the drug-targeting potential of the polymer-coated liposomes. 
Results. Coating of liposomes with poly(hydroxyethyl L-asparagine) (PHEA) and 
poly(hydroxyethyl L-glutamine) (PHEG) extended the circulation half-life to a similar extent 
as poly(ethylene glycol) (PEG), which is normally used for the preparation of LCL. Glutamine 
polymers with a hydroxypropyl or a hydroxybutyl group instead of hydroxyethyl group also 
yield prolonged circulation, however, not to the same extent as PHEA/G. The 
pharmacokinetic properties of PHEA-liposomes were independent of the lipid dose even at 
very low lipid doses of around 50 nmol per rat. PLP was successfully entrapped in PHEA-
liposomes. These liposomes were shown to be stable in the circulation and equally effective 
in rat experimental arthritis as PLP encapsulated in PEG-liposomes. 
Conclusions. PHEA and PHEG are attractive alternative polymers for the design of LCL: their 
performance is similar to that of PEG-liposomes but they have the advantage of being 
biodegradable. 
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INTRODUCTION 
 
Liposomes are small spherical particles that consist of one or more lipid bilayers enclosing 
an aqueous interior (1). Liposomes are highly suitable as drug carriers as they are 
composed of natural lipids and offer the opportunity to incorporate a wide variety of 
therapeutic agents for the purpose of drug-targeting (2). Biodistribution studies in laboratory 
animals showed that intravenously (i.v.) injected liposomes predominantly home to cells of 
the mononuclear phagocyte system (MPS) that is present in liver, spleen and bone marrow. 
As a result, liposomes show generally a short circulation half-life after i.v. administration 
(3,4). 
The development of bilayer surface modifications that were able to reduce rapid 
uptake by the MPS, represented a major step forwards to the successful clinical application 
of liposomes (5). Incorporation of a lipid conjugate of the water-soluble polymer 
poly(ethylene glycol) (PEG) results in a polymeric layer around the liposome, which reduces 
the adhesion of plasma proteins that would otherwise cause rapid recognition of the 
liposomes by MPS-phagocytes. With a PEG-coating, liposomes oppose rapid uptake by the 
MPS and acquire a prolonged circulation property. With these so-called ‘long-circulating 
liposomes’ (LCL) drug targeting to tissues other than liver, spleen and bone marrow became 
possible. Indeed, LCL were shown to selectively accumulate at sites of enhanced vascular 
permeability as found in tumors and inflamed areas in the body (6,7). This form of targeted 
drug delivery resulted in increased therapeutic efficacy and/or reduced toxicity of several 
cytostatic, antifungal and antibacterial drugs and led to the market approval of liposomal 
doxorubicin as the first commercially available liposomal cytostatic agent (8-11). 
 Besides PEG a few other polymers have also been shown to induce prolonged 
circulation behavior of liposomes upon attachment to their surface (12). Woodle and 
coworkers investigated oxazoline-derived polymers, Maruyama et al. designed poly(glycerol)-
coated liposomes, while Torchilin and coworkers developed several water-soluble vinyl-based 
polymers for the creation of long-circulating liposomes. All groups reported circulation half-
lives comparable to PEG-liposomes (13-18). Up to now PEG-liposomes are the only polymer-
coated liposomes that have been approved for clinical use. However, despite the fact that 
low-molecular weight PEG has been shown to be non-toxic and to be readily excreted by the 
kidneys, the biological fate of (liposome associated) PEG after cellular uptake is not known 
(19,20). Since PEG is expected not to be easily intracellularly degraded, it cannot be 
excluded that PEG may affect cell functioning at the long term (21). 
It was the objective of this study to design a biodegradable and biocompatible 
polymer-lipid conjugate for the development of LCL. To achieve minimal toxicity of the 
polymer as well as the compounds that are formed upon biodegradation, we selected natural 
L-amino acids as starting material for the synthesis of polymer-lipid conjugates in this study. 
Besides the advantage of being intracellularly degradable, such poly(L-amino acid)-lipid 
conjugates are expected to be degraded by proteolytic enzymes that are present at 
pathological target tissues such as tumors and sites of inflammation. Therefore, these 
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polymer-lipid conjugates may allow the incorporation of bilayer functionalities that have to 
remain shielded in the circulation until arrival at the pathological target sites where they can 
perform their specific function. 
 The present study investigates the feasibility of polymers based on hydroxyalkyl 
derivatives of L-glutamine and L-asparagine as monomers. Poly(hydroxyethyl L-glutamine) 
(PHEG) was selected as a starting polymer as PHEG is known to be water-soluble, 
biocompatible and biodegradable by lysosomal peptidases from the papain family (22). 
Subsequently, structure-activity relationships were established by replacing the hydroxyethyl 
side group with other hydroxyalkyl groups and selecting L-asparagine as backbone monomer 
instead of glutamine. Different lipid molecules were evaluated to ensure stable anchoring of 
the polymer-lipid conjugates in the liposome bilayer. In addition, the effect of the polymer 
grafting density on the liposome surface and the effect of lipid dose on the circulation half-
life were assessed. Finally, the feasibility of liposomal incorporation and targeting an anti-
inflammatory glucocorticoid to inflamed sites in an experimental animal model of arthritis 
was evaluated. 
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MATERIALS AND METHODS 
 
Synthesis and characterization of different PEG-lipid conjugates 
PEG5000-lipid conjugates were synthesized from methoxy-PEG5000-isocyanate, 
commercially available from Shearwater Polymers, Huntsville Al, USA), and long-chain 
alkylamines: octadecyl amine (stearylamine) NH2-C18H37 (ODA), having a single C18-tail, 
dioctadecyl amine (distearylamine) NH-(C17H35)2 (DODA), and 1-heptadecyl-octadecylamine 
NH2-CH-(C17H35)2 (HOA) both with a double alkyl tail. Isocyanate groups reacted with these 
primary and secondary alkyl amines rapidly at room temperature to form ureas of a general 
formula: mPEG-NH-CO-NH-R in case of a primary amine (ODA, R=C18H37 or HOA, 
R=CH(C17H35)2) or mPEG-NH-CO-N-R2 in case of a secondary amine (DODA , R being a C18-
tail). 
All three PEG5000 derivatives were synthesized in exactly the same way. For the 
synthesis of the PEG5000-stearyl derivative a solution of 300 mg methoxyPEG-isocyanate 
(0.06 mmol, MW 5000, Shearwater Polymers) and 18 mg (0.07 mmol) ODA in 1.5 ml 
chloroform was stirred at room temperature for ca. 0.5-1 hour. The solution was then 
precipitated into 20-30 ml petroleum-ether. A fine white powder (220 mg, 75 %) was 
obtained after filtration and drying. 
 
Characterization: 
1H-NMR (CDCl3, δ in ppm relative to TMS):  
PEG: 3.6 (CH2-O) 
Stearyl anchor: 1.2 (CH2) & 0.8 (CH3) 
The ratio of PEG and stearyl peak integrals confirms the presence of one stearyl group per 
PEG moiety. 
 
Synthesis and characterization of PHEA-DODASuc 
Synthesis of poly(L-hydroxyethyl asparagine)-N-succinyl-dioctadecylamine (PHEA-DODASuc) 
is schematically represented in Figure 1 A. To a solution of 3 g β-benzyl L-aspartate N-
carboxy anhydride (NCA) (synthesized as described by Fuller et al. (23)) dissolved in 9 ml 
dry dimethylformamide (DMF) (Aldrich-Chemie, Steinheim, Germany) was added 0.3 ml of a 
2 M solution of methylamine in tetrahydrofurane (THF) (Aldrich) as initiator. The solution 
(initially clear, after ca. 2 hrs cloudy) was stirred for one day under a nitrogen atmosphere at 
room temperature and then precipitated into water (150 ml), collected by filtration and 
dried. Yield: 2 g poly(benzyl-L-aspartate) (PBLA).  
Polymer-lipid coupling was performed to obtain the PBLA-DODASuc-conjugate. 
Briefly, a solution of 2 g PBLA in 5 ml chloroform containing ca. 150 ml triethylamine 
(Merck, Darmstadt, Germany) was added to a solution of 200 mg dicyclohexylcarbodiimide 
DCC (Acros Chimica, Geel, Belgium), 15 mg 4-(dimethylamino) pyridinium-4-toluene 
sulfonate (DPTS) (Acros) and 350 mg N-succinyl-dioctadecylamine (DODASuc; for synthesis 
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see (24)) in 6 ml chloroform, that had been stirred for 1 hour. The mixture was stirred for 
one day and then precipitated into methanol. The polymeric product was filtered off and 
dried in vacuo. Yield: 1.4 g PBLA-DODASuc. Aminolysis of 1.4 g PBLA-DODASuc was 
performed with ca. 4 ml ethanolamine (Aldrich), using 0.4 g 2-hydroxypyridine (Aldrich) as a 
catalyst, in 10 ml DMF solution at 40 °C for 1 day yielding PHEA-DODASuc. Yield: 0.8 g after 
dialysis (molecular weight cut off 500) and freeze-drying. 
 
NMR (DMSO-d6) (δ in ppm relative to TMS): 
distearyl: 0.8 (CH3), 1.2 (CH2), 1.4 (CH2-N) 
PHEA: 2.4-2.8 (β-CH2), 3.2 & 3.4 (hydroxyethyl), 4.6 (α-CH + OH), 7.8-8.5 (NH) 
From the ratio of integrals of the distearyl signals and the α-CH signal the molecular weight 
of the polymer part of the conjugate was calculated to be ca. 3000 g/mol. 
 
Synthesis and characterization of poly(L-hydroxyalkyl glutamine)-DODASuc-conjugates 
Synthesis of poly(hydroxyethyl glutamine) (PHEG)-lipid conjugates is schematically shown in 
Figure 1 B. To a solution of 3 g γ-benzyl-L-glutamate NCA (for synthesis see (23)) in 8 ml dry 
DMF was added a solution of 0.1 g N-BOC-1,4-diaminobutane (Fluka, Zwijndrecht, The 
Netherlands) in chloroform as initiator. This solution was stirred for 1 day under a nitrogen 
atmosphere at room temperature. After precipitation into ca. 100 ml methanol the polymer 
was filtered off and dried, yielding 2 g PBLG with a BOC-protected amino end group. To 
remove BOC, a solution of 1.7 g PBLG-diaminobutane-BOC in 12 ml 2 M HCl/dioxane was 
stirred for 4 hrs and then added dropwise to ca. 150 ml water in which appr. 10 g NaHCO3 
was dissolved. The product was filtered off, washed with water and dried in vacuo. Yield: 1.4 
g PBLG-diaminobutane. Deprotection was complete as demonstrated by NMR analysis. 
To obtain the PBLG-DODASuc-conjugate, 340 mg DODASuc, 180 mg DCC and 15 mg 
DPTS were dissolved in 5 ml chloroform. The solution was stirred for 1 hour at room 
temperature. Next, a solution of 1.4 g PBLG-diaminobutane and 120 mg triethylamine in 8 
ml chloroform was added. After stirring overnight at room temperature the obtained solution 
was added dropwise to an excess of methanol (ca. 150 ml). The polymeric product was 
filtered off, washed and dried. Yield: 1.2 g PBLG-DODASuc. 
 
1H-NMR (CDCl3) (δ in ppm relative to TMS):  
distearyl signals at 0.8-0.9 (CH3) and 1.2-1.4 (methylene protons) 
PBLG: 2.2 & 2.6 (β,γ-CH2), 4.0 (α-CH), 5.0 (benzyl CH2), 7.3 (phenyl) 
 
Aminolysis with ethanolamine was performed to obtain PHEG-DODASuc: 1.2 g PBLG-
DODASuc (see above) and 0.5 g 2-hydroxypyridine were dissolved in 10 ml DMF. Then ca. 4 
ml ethanolamine was added dropwise. After stirring for 24 hrs at 40 °C under a nitrogen 
atmosphere the solution was precipitated into ca. 200 ml diethylether. The precipitate was 
dissolved in water, dialyzed (molecular weight cut off 500) and subsequently freeze-dried 
yielding 0.8 g PHEG-DODASuc conjugate.  
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Figure 1. Synthesis of poly(hydroxylalkyl L- asparagines/glutamine)-lipid conjugates. (A) Schematic 
representation of PHEA-DODASuc synthesis strategy. (B) Schematic representation of the synthesis of 
PHEG-DODASuc. Note that DODASuc is attached to PHEA at the amino end group (on the right) of the 
poly(amino acid) back bone, whereas to PHEG it is attached to the carboxylic end (on the left, using 
diaminobutane to connect the poly(amino acid) back bone to DODASuc). 
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1H-NMR (DMSO-d6) (δ relative to TMS): 
distearyl signals at 0.8-0.85 (CH3) and 1.2-1.5 (methylene protons) 
PHEG: 1.7-2.2 (β,γ-CH2), 3.1 & 3.3 (hydroxyethyl), 4.2 (α-CH), 4.7 (OH), 7.8 & 8.2 (NH) 
From the ratio of integrals of the distearyl signals and the α-CH signal molecular weight of 
PHEG was calculated to be ca. 4000.  
By varying the monomer/initiator ratio similar conjugates with different PHEG molecular 
weights (3000 and 8000) were synthesized.  
 
Maldi-TOF confirms the molecular structure of the PHEG-DODASuc conjugate as depicted in 
Figure 1 A. 
Na+-adduct: m/z 3064.5 (n=13), 3236.1 (n=14), 3408.7 (n=15), 3580.6 (n=16), 3752.9 
(n=17), 3924.7 (n=18), 4096.7 (n=19), 4268.4 (n=20), 4441.1 (n=21), 4613.3 (n=22), 
4785.1 (n=23), etc.  
 
The same procedure of aminolysis but with 3-propanol amine instead of ethanolamine 
yielded PHPG-DODASuc:  
 
NMR (DMSO-d6) (δ in ppm relative to TMS):  
distearyl signals at 0.8-0.85 (CH3) and 1.2-1.5 (methylene protons) 
PHPG: 1.7-2.2 (β,γ-CH2), 1.5 & 3.1 & 3.3 (hydroxypropyl), 4.2 (α-CH), 4.6 (OH), 7.8 & 8.2 (NH) 
 
Maldi-TOF: 
Na+-adduct: m/z 3623 (n=15), 3810 (n=16), 3996 (n=17), 4182 (n=18), 4368 (n=19), 
4555 (n=20), etc. 
 
To obtain PHBG-DODASuc, the same procedure of aminolysis of PBLG-DODASuc was 
repeated with 4-butanolamine (Merck). Stirring was performed for 48 hrs instead of 24 hrs 
at 40 °C. 
 
NMR (DMSO-d6) (δ in ppm relative to TMS): 
distearyl signals at 0.8-0.85 (CH3) and 1.2-1.5 (methylene protons) 
PHBG: 1.7-2.2 (β,γ-CH2), 1.4 & 3.1 & 3.3 (hydroxybutyl), 4.2 (α-CH), 4.5 (OH), 7.8 & 8.2 (NH) 
 
Preparation of radiolabeled liposomes for comparative pharmacokinetics 
Liposomes were prepared as described previously (25). Briefly, a lipid mixture in ethanol 
with a molar ratio composition of 1.85:0.15:1.0 (DPPC:polymer-lipid conjugate:cholesterol) 
was prepared. Such molar ratio results in liposomes containing 7.5% polymer-lipid 
conjugate as a percentage of the total amount of phospholipid. To the mixture [3H]-
cholesteryl oleylether was added as a non-degradable liposome lipid phase marker. A lipid 
film was created by rotary evaporation under reduced pressure. The lipid film was hydrated 
with phosphate buffered saline (PBS) at an initial total lipid concentration of 20 µmol/ml. 
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The liposomes were sized by multiple extrusion using a medium pressure extruder equipped 
with two stacked polycarbonate membrane filters, one with a pore size of 200 nm on top of 
one with 100 nm pores. Components that were not incorporated in liposomes were removed 
by gel filtration on a PD-10 column (Pharmacia, Uppsala, Sweden) eluted with PBS. 
 
Characterization of liposome preparations 
Radioactivity of the liposomal dispersions was assayed in an Ultima Gold liquid scintillation 
cocktail purchased from Hewlet Packard (Groningen, The Netherlands) and counted in a 
Philips PW 4700 liquid scintillation counter. Lipid content of the liposomal dispersion was 
determined by assessing the radioactivity of the liposomes before and after preparation. The 
mean particle size of the liposomes was determined by dynamic light scattering with a 
Malvern 4700 system (Malvern, UK). The mean size ranged between 140 and 160 nm. In 
addition to the mean particle size, the system reports a polydispersity index (a value 
between 0 and 1; 0 indicating that a complete monodisperse system is obtained, whereas 1 
indicates maximal variation in particle size). All liposome preparations used had a 
polydispersity index of below 0.15. In Table I the composition and characteristics of the 
different liposome types are summarized. Liposome preparations were stored under 
nitrogen at 4 ºC and used within one week after preparation. 
 
Table I. Liposome composition and characteristics. Means of 3 measurements are shown. 
 
Grafting density 
(%) 
Composition 
DPPC:Chol:PLC* 
Mean diameter 
(nm) 
Polydispersity 
index 
BARE(no polymer) 0 2:1 151 ± 2 0.13 ± 0.02 
PEG-DSPE 7.5 1.85:1.0:0.15 139 ± 2 0.11 ± 0.01 
PHEG-DODASuc 1 1.98:1.0:0.02 151 ± 2 0.09 ± 0.01 
 2.5 1.95:1.0:0.05 156 ± 2 0.08 ± 0.01 
 7.5 1.85:1.0:0.15 151 ± 2 0.07 ± 0.02 
 15 1.85:1.0:0.30 160 ± 1 0.07 ± 0.01 
 
PHEA-DODASuc 
 
7.5 1.85:1.0:0.15 146 ±  2 0.09 ± 0.02 
 
PHPG-DODASuc 
 
7.5 1.85:1.0:0.15 153 ± 1 0.09 ± 0.02 
 
PHBG-DODASuc 
 
7.5 1.85:1.0:0.15 148 ± 2 0.07 ± 0.04 
 
* PLC: Polymer-lipid conjugate 
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Comparative pharmacokinetics of polymer-coated 3H-labelled liposomes in rats 
Male Wistar rats with an approximate body weight of 200 g were used (outbred, SPF-quality, 
Utrecht University, The Netherlands). Besides the different poly(hydroxyalkyl L-amino acid)-
coated liposomes, non-polymer-coated (‘bare’) liposomes and liposomes coated with 
PEG2000 coupled to distearoyl phosphatidylethanolamine (PEG-DSPE) were prepared and 
evaluated as ‘negative’ and ‘positive’ controls respectively. Single-dose intravenous injections 
of liposomal preparations containing 5 µmol total lipid and approximately 50 kBq of 
radioactivity, were given in the tail vein. Blood samples of 100 µg were collected from the 
opposite tail vein of each rat at the following time points post-injection: 5 minutes and 1, 4, 
8, 24 and 48 hours. Radioactivity in blood samples was determined by adding Solvable 
tissue solubilizer (NEN, Dreieich, Germany) and 35% hydrogen peroxide. After overnight 
incubation the samples were assayed in Ultima Gold scintillation cocktail (Packard 
BioScience B.V., Groningen, The Netherlands) and counted for radioactivity with a Philips 
PW 4700 liquid scintillation counter. At 48 hrs post-injection liver and spleen were dissected, 
homogenized and processed according to the same method as described for the blood 
samples. Besides tissue and blood samples also the radioactivity of the injected dose was 
counted. The % injected dose in the organs was calculated by dividing the total radioactivity 
of the organs by the injected dose. To obtain the %injected dose values in the circulation, the 
radioactivity of the blood samples was multiplied with a factor 10 times the total mass of the 
blood in grams (calculated as 7% of the total body weight) and divided by the injected dose. 
The results are presented as the mean ± standard deviation of the percentage of the injected 
dose of 4 rats. 
 
Liposome preparation for assessing drug targeting potential 
Liposomes containing the anti-inflammatory glucocorticoid prednisolone phosphate (PLP) 
were prepared as described previously (see Chapter 3). In brief, a lipid film containing 7.5% 
PHEA-DODASuc or PEG-DSPE was created by rotary evaporation and hydrated with a 
solution of 100 mg/ml prednisolone phosphate (PLP) (Bufa, Uitgeest, The Netherlands) in 
water at a initial lipid concentration of 100 µmol lipid per ml dispersion. Liposomes were 
sized to approximately 90 nm by multiple extrusion. A smaller size than the liposomes used 
in the comparative pharmacokinetic studies was chosen, as this may further increase target 
localization of the liposomes. PLP and was removed by repeated dialysis using Slide-A-Lyzer 
dialysis cassettes with a molecular weight cut off of 10.000 (Pierce, UK) against PBS. 
Phospholipid content was determined with a phosphate assay in the organic phase after 
extraction of the liposomal preparations with chloroform (26). The aqueous phase after 
extraction was used for determining the PLP content by HPLC. Each ml liposomal 
preparation contained around 5 mg PLP and approximately 60 µmol phospholipid. 
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Pharmacokinetics of PLP encapsulated in polymer-coated liposomes 
For assessment of in vivo stability in the circulation and pharmacokinetic behavior of PLP in 
polymer-coated liposomes, the PLP plasma concentration was measured at the time of 
injection, at 24 and 48 hrs post-injection. The PLP-plasma concentration was compared with 
PLP in PEG-liposomes, as the latter has been shown to be completely stable in the 
circulation by comparing the plasma concentration of a radioactive liposome marker to the 
plasma concentration of encapsulated PLP (see Chapter 3). In the same study plasma levels 
of PLP could hardly be detected after i.v. injection of free PLP, which strongly suggests that 
all PLP measured in plasma after injection of liposomal PLP must be liposome-associated. 
To measure PLP in plasma samples, plasma was extracted according to a method reported 
by Derendorf et al. (27). The extracts were assayed with a reversed-phase HPLC method, 
using UV-absorption detection at 254 nm.  
 
Therapeutic activity of PLP-containing polymer-coated liposomes in adjuvant arthritis 
The Dutch Committee of Animal Experiments approved the animal studies. Male inbred 
Lewis rats between 7 and 9 weeks of age (170-200 g) were obtained from Maastricht 
University, Maastricht, The Netherlands. Adjuvant arthritis was induced according to Koga 
and Pearson (28). Briefly, incomplete Freund’s adjuvant containing heat-inactivated 
Mycobacterium tuberculosis was subcutaneously injected at the base of the tail. Paw 
inflammation started around day 10 after the immunization, reached maximal severity 
around day 20, after which the inflammation process gradually resolved. The rats were daily 
scored for the visual signs of inflammation. All rats were treated on day 15 post-
immunization, when the average score of all rats in the experiment is about half the maximal 
scores reached in these experiments. The effect of treatment on clinical scores and body 
weight was monitored up to 4 weeks post-treatment.  
 
Statistical analysis 
For statistically assessing and comparing therapeutic efficacy in different groups the 
nonparametric Wilcoxon/Kruskal-Wallis test (rank sums) was used. For evaluating 
differences between groups regarding other parameters, one-way analysis of variance was 
used. P values of less than 0.05 were considered significant. 
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RESULTS 
 
Synthesis of PHEA and PHEG-DODASuc-conjugates 
Poly(hydroxyethyl L-asparagine) (PHEA) and poly(hydroxyethyl L-glutamine) (PHEG) were 
synthesized starting from benzyl L-aspartate NCA and benzyl L-glutamine NCA, respectively, 
as shown in Figure 1. Polymerization of these L-amino acid benzyl ester NCA monomers was 
followed by aminolysis with alkanolamines. Molecular weights in the range of 2000-5000 
were obtained via a primary amine initiated polymerization of these side group-protected 
amino acid NCA monomers. The molecular weight of the polymer is controlled by the molar 
ratio of monomer/initiator. N-succinyl-dioctadecylamine (DODASuc) (lipid anchor) could be 
coupled to the polypeptide’s amino end group. Polymerization of benzyl-L-aspartate initiated 
by a primary amine (e.g. methylamine) yields a polypeptide (PBLA) with an amino end 
group. In contrast, polymerization of benzyl-glutamate NCA initiated by a primary amine 
results in the formation of a polypeptide (PBLG) without an amino end group. As could be 
concluded from Maldi-TOF, a 5-membered lactam end group is formed by an intramolecular 
reaction of the amino end group with the benzyl ester group. The terminal amino group is 
lost.  
Conjugation of DODASuc to PBLG, therefore, requires a slightly modified approach: 
first, benzyl-L-glutamate NCA is polymerized using BOC-butanediamine (one amino group is 
BOC (tertiary butoxycarbonyl)-protected; the other amino group is not) as an initiator. The 
resulting PBLG containing a protected amino group is deprotected and then coupled to 
DODASuc using dicyclohexyl carbodiimide (DCC). Amphiphilic conjugates resulted after the 
polypeptides were made water-soluble by the aminolysis reaction of the benzyl ester side 
groups with alkanolamines (e.g., ethanolamine).  
 
Preparation and characterization of polymer-coated liposomes 
In Table I the characteristics of the polymer-coated liposomes are presented. The resulting 
mean diameter and polydispersity of PHEG-, PHPG-, PHBG- and PHEA-coated liposomes are 
comparable to those of PEG-liposomes. All preparations appeared to be physically stable 
upon storage and no signs of aggregation were found. 
 
Selection of suitable anchor molecules  
Figure 2 A shows the plasma concentration-time profiles of liposomes coated with different 
PEG5000-conjugates after i.v. injection. For the evaluation of the anchor molecules PEG5000 
was chosen instead of PEG2000 as a molecular mass of PEG5000 more closely resembles 
the molecular mass of most of the polymers tested in this study. We coupled PEG5000 to a 
series of lipid anchor molecules and compared liposomes coated with these conjugates to 
liposomes without PEG (‘bare’ liposomes). Clearly, octadecyl amine (ODA) as a lipid anchor 
results in little prolongation of circulation time, suggesting that one single C18-tail is not 
sufficient for stable grafting. Dioctadecyl amine (DODA) and heptadecyl octadecyl amine 
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(HOA) yield improved prolongation of circulation behavior, similar to the phospholipid 
anchor distearyl phosphatidylethanolamine (DSPE), which is generally used for stable 
grafting of PEG on the liposome bilayer. Apparently, two alkyl tails are required for sufficient 
grafting stability. We selected DODA as the standard anchor molecule for synthesis of PHEA-
and the different poly(hydroxyalkyl L-glutamine)-lipid conjugates. 
 Figure 2 B shows the tissue distribution to the MPS organs. The DODA- and HOA-PEG 
conjugates significantly reduce the hepatosplenic uptake of liposomes. As hepatosplenic 
uptake is the main cause of liposome elimination from the circulation, these data are in 
agreement with plasma concentration-time profiles shown in Figure 2 A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pharmacokinetics and distribution to the MPS of PEG5000 conjugated with different anchor 
molecules incorporated with a grafting density of 7.5% in 150 nm DPPC-cholesterol liposomes. (A) %-injected 
dose in blood-curves of PEG5000–ODA (closed diamonds),PEG5000–DODA (closed squares), PEG5000–
HOA (closed triangles), PEG5000–DSPE (closed circles), and bare liposomes without polymer-lipid conjugate 
(open circles). (B) Distribution to spleen (open bars), liver (gray bars) and total distribution to the MPS (liver 
and spleen) (black bars). Results are expressed as the mean percentage of the injected dose of 4 rats ± SD. 
 
 
 
Successful prolongation of circulation half-life with PHEG- and PHEA-DODASuc 
In Figure 3 A it is shown that coating liposomes with 7.5% PHEG4000 or PHEA3000 and 
PHEA5000 all coupled to N-succinyl-DODA (DODASuc) results in almost similar circulation 
behavior as compared to 7.5% PEG2000-DSPE, the conjugate which is most often used for 
the preparation of LCL. These results are in line with the tissue distribution data shown in 
Figure 3 B, which shows that all four polymer-lipid conjugates significantly reduce MPS 
uptake from the circulation. 
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Figure 3. Pharmacokinetics and distribution to the MPS of PHEA and PHEG versus PEG incorporated with a 
grafting density of 7.5% in 150 nm DPPC-cholesterol liposomes. (A) %-injected dose in blood-curves of 
PEG2000–DSPE (closed circles), PHEG4000–DODASuc (gray diamonds), PHEA5000–DODASuc (gray 
triangles), PHEA3000–DODASuc (gray squares, and bare liposomes without polymer-lipid conjugate (open 
circles). (B) Distribution to spleen (open bars), liver (gray bars) and total distribution to the MPS (liver and 
spleen) (black bars). Results are expressed as the mean percentage of the injected dose of 4 rats ± SD. 
 
 
Selection of optimal grafting density with PHEG-DODASuc 
In Table II the effect of different grafting densities of PHEG4000 on circulation behavior and 
hepatosplenic uptake is shown. Although plasma concentration-time profiles show little 
differences at 4 and 24 hrs, hepatosplenic uptake at 48 hrs indicates that decreasing the 
grafting density to 2.5% and 1% or increasing the density to 15% leads to enhanced 
removal of liposomes by the MPS.  
 
Table II. Percentage of injected dose of PHEG-liposomes in the circulation at 4 and 24 hrs post-injection and 
uptake by MPS organs at 48 hrs. Mean ± SD of 4 rats per group 
Blood circulation Liver uptake Spleen uptake  
PHEG 
Grafting density 4 h 24 h 48 h 48 h 
1% 55 ± 2 22 ± 1 52 ± 9 11 ± 6 
2.5% 56 ± 8 22 ± 1 38 ± 7 15 ± 2 
7.5% 61 ± 6 23 ± 4 23 ± 5   7 ± 2 
15% 49 ± 4 17 ± 3 32 ± 5   9 ± 1 
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Effect of the side group 
Introduction of longer hydroxyalkyl side groups to the poly(L-glutamine) back bone, such as 
hydroxypropyl and hydroxybutyl instead of hydroxyethyl, results in reduced prolongation of 
circulation time and enhanced MPS uptake to the level of ‘bare’ liposomes (Figure 4). The 
hydroxyethyl side group appears to be the optimal side group for the poly(hydroxyalkyl L-
glutamine)-lipid conjugates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Pharmacokinetics and distribution to the MPS of different poly(hydroxyalkyl L-glutamine)s 
incorporated with a grafting density of 7.5% in 150 nm DPPC-cholesterol liposomes. (A) %-injected dose in 
blood-curves of PEG2000–DSPE (closed circles), PHEG4000–DODASuc (gray squares), PHPG5000–
DODASuc (gray diamonds), PHBG5000–DODASuc (gray triangles), and bare liposomes without polymer-lipid 
conjugate (open circles). (B) Distribution to spleen (open bars), liver (gray bars) and total distribution to the 
MPS (liver and spleen) (black bars). Results are expressed as the mean percentage of the injected dose of 4 
rats ± SD. 
 
 
Table III. Percentage of the injected dose of liposomes in circulation at 4 and 24 hrs post-injection. Mean ± SD 
of 4 rats per group. 
PEG-liposomes PHEA-liposomes  
 
Lipid dose 4 h 24 h 4 h 24 h 
5 µmol 66 ± 7 29 ± 6 57 ± 4 27 ± 9 
0.5 µmol 71 ± 10 26 ± 5 57 ± 5 18 ± 2 
0.05 µmol 46 ± 7 12 ± 3 61 ± 4 20 ± 1 
0.005 µmol 5 ± 3 1 ± 1 33 ± 5   9 ± 2 
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Effect of lipid dose 
Table III shows the % injected dose of liposomes still present in the circulation at 4 and 24 
hrs post-injection of PEG-coated liposomes and PHEA-coated liposomes, both at 4 different 
dose levels ranging from 0.005 to 5 µmol lipid per rat. At a dose of 0.05 µmol and especially 
at 0.005 µmol PHEA-liposomes show improved circulation behavior as compared to PEG-
liposomes. PEG-liposomes are very rapidly eliminated at the 5 nmol dose level, they are 
hardly present in the circulation at 24 hrs post-injection, whereas still 9% of the injected 
PHEA-liposomes circulates at 24 hrs at the same dose level.  
 
Drug targeting potential 
Prednisolone phosphate (PLP) was encapsulated in both PEG- and PHEA-liposomes and 
injected in adjuvant arthritis rats. In this experimental arthritis model we previously showed 
that the therapeutic activity of PLP was dramatically increased by encapsulation in PEG-
liposomes. Figure 5 A shows the plasma concentration of liposomally encapsulated PLP. The 
% fractions of the injected dose of PLP in PHEA-liposomes in the circulation at 24 and 48 
hrs equals PLP in PEG-liposomes. As PLP-PEG-liposomes composed of DPPC and 
cholesterol have been shown not to leak PLP in the circulation, such may therefore also be 
assumed for PLP-PHEA-liposomes. The circulation half-life of these liposomes is somewhat 
longer than reported with the radiolabeled liposomes in this study. However, this is most 
likely a result of a relatively small diameter of approximately 90 nm as compared to the 
radiolabeled liposomes (between 140 and 160 nm). Figure 5 B shows that 10 mg/kg PLP-
PHEA-liposomes induces a similar reversal of the inflammation reaction as 10 mg/kg PLP-
PEG-liposomes. Both preparations induce a strong anti-inflammatory effect lasting for two 
weeks. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Pharmacokinetics and therapeutic activity of PHEA- versus PEG-liposomal PLP in rat experimental 
arthritis. A) Plasma concentration at 0, 24, and 48 hrs post-injection of 10 mg/kg PLP in PHEA-liposomes 
(open bars) and PEG-liposomes (closed bars). Results are expressed as the mean concentration (µg/ml) of 5 
rats + SD. B) Daily arthritis score after induction of adjuvant arthritis at day 0 and treatment at day 15 (arrow) 
with 10 mg/kg PLP (120 µmol/kg phospholipid) in PHEA-liposomes (closed circles), 10 mg/kg in PEG-
liposomes (closed squares), and saline (open diamonds). Results are expressed as the mean of 5 rats ± SEM.
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DISCUSSION 
 
In this paper biodegradable polymer-lipid conjugates based on amino acids are evaluated 
regarding their capacity to confer a long-circulation property to liposomes upon attachment 
to their lipid bilayer surface. Besides the polymer itself, also the choice of the lipid bilayer 
anchor deserves attention, as stable grafting of a polymer to the liposome bilayer is essential 
for achieving long-circulating behavior. Therefore, in this study the suitability of different lipid 
anchor molecules was evaluated with PEG5000 as a model polymer (Figure 2). The results 
show that successful prolongation of liposome circulation time can only be realized with 
anchor molecules with two stearyl chains. PEG coupled to DODA and HOA resulted in similar 
prolongation of circulation behavior as PEG-DSPE, which is at present most often used in 
liposome technology. In agreement with the findings of Webb et al., coupling of the polymer 
to a single alkyl chain yielded inferior results, most likely due to insufficient grafting stability 
(29). As DODA was easier to obtain from commercial sources than HOA, all polypeptides 
were tested in subsequent experiments with DODA as liposome anchor molecule. 
 The approach of L-amino acid-based polymer-lipid conjugates proved to be successful 
with PHEG4000, PHEA3000 and -5000, all coupled to DODASuc. The plasma concentration-
time profiles as well as uptake by liver and spleen showed that these polymer-lipid 
conjugates prolonged the circulation time and reduced the uptake by the MPS to the same 
extent as PEG2000-DSPE (Figure 3). As has been shown in literature for PEG, lowering the 
grafting density of PHEG to 1 mol % resulted in increased uptake by the MPS (30). 
Interestingly, also a grafting density of 15 mol % PHEG increased MPS-uptake. However, the 
circulation times of liposomes grafted with 1, 2.5, 7.5, and 15 mol % PHEG did not differ 
significantly. 
 The results in this study show that coating the liposomes with poly(L-glutamine) with 
longer hydroxyalkyl side chains (PHPG and PHBG) instead of PHEG resulted in decreased 
circulation half-lives (Figure 4). An explanation for this observation may be found in the 
conformation of the polymers when dissolved in water. It has been suggested that suitable 
stealth polymers should be flexible and adopt a random conformation (31). E.g. dextran has 
a lower chain flexibility than PEG due to its carbohydrate backbone. When grafted on 
liposomes dextran is not able to prolong circulation times (32). Altschuler et al. showed that 
for poly(hydroxyalkyl-L-glutamine)s the degree of conformational freedom is optimal with 
hydroxyethyl as a side group and conformational freedom decreases for longer hydroxyalkyl 
groups. The use of hydroxypropyl and, even more so, hydroxybutyl resulted in the formation 
of α-helices in the polymer (33). The decrease in flexibility of these polymers correlates with 
the observed decrease of circulation half-life. 
 An important advantage of polymer-coated LCL over LCL without polymer-lipid 
conjugates is that incorporation of PEG leads to dose-independent pharmacokinetics over a 
broad dose range (34). To evaluate whether this phenomenon also applies to liposomes 
coated with poly(hydroxyalkyl L-amino acid)-lipid conjugates, pharmacokinetics of PHEA-
liposomes were compared with PEG-liposomes at four different lipid doses ranging from 
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0.005 to 5 µmol total lipid per rat. The lowest dose level at which the PEG-liposomes 
appeared to show dose-independent kinetics was around 500 nmol/rat (Table III) which 
corresponds with earlier reported data (35). Interestingly, with PHEA-liposomes dose-
dependency of the pharmacokinetics was less pronounced even at a 10-fold lower dose. 
PHEA-liposomes may therefore offer an additional advantage over PEG-liposomes in cases 
when very low lipid doses are preferred, such as in scintigraphic detection of sites of 
pathology (7). 
 The final aim of this study was to show that successful drug targeting is possible, with 
liposomes exposing biodegradable polypeptide-lipid conjugates. Within the scope of this 
thesis a PEG-liposomal formulation of prednisolone phosphate (PLP) was developed that 
was shown to efficiently contain the drug in the circulation and to highly effectively deliver 
the encapsulated drug to inflamed joints in experimental arthritis models (Chapter 3 and 4). 
Incorporation of PEG increased the circulation half-life of the liposomal formulation from 6 
hrs to 18 hrs, which was shown to be necessary to achieve sufficient local delivery for 
complete reversal of the development of joint inflammation in these models (Chapter 3). The 
present study shows that the use of PHEA-liposomes as PLP carrier results in a similar 
pharmacokinetic profile of encapsulated PLP. Also, the therapeutic activity of 10 mg/kg 
PLP-PHEA-liposomes in rat adjuvant arthritis was equal to that of 10 mg/kg PLP-PEG-
liposomes. In Chapter 3 and 4 we report that non-encapsulated PLP was inactive at this 
dose level. The observation that a dramatic improvement of the therapeutic effect of PLP can 
be achieved with PHEA-liposomes, clearly points to the drug targeting potential of this 
formulation. 
 In conclusion, we present a novel sterically stabilized liposome formulation 
performing similarly to PEG-liposomes regarding in vivo long-circulation behavior and drug 
targeting potential. These novel polymer-coated liposomes are the first that are sterically 
stabilized with a biodegradable polymer coating. 
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1. Introduction 
Glucocorticoids are highly effective anti-inflammatory drugs that are applied in a range of 
different pathologies varying from local allergic reactions to severe, chronic inflammatory 
disorders (1). However, successful application in the clinic is limited due to a high incidence 
of serious adverse effects (2-4). Besides a poor safety profile, also poor localization in 
pathological target sites limits the usefulness of corticosteroids in the patient (5). 
Targeted drug delivery with liposomal drug carriers that selectively accumulate at 
target tissues after i.v. injection may offer perspective (6). Targeted delivery may be 
considered a form of local treatment of all target sites by simply employing the systemic 
route (7,8). Chapter 1 presents the primary aim of the work described in this thesis: to 
design, evaluate and optimize long-circulating glucocorticoid-containing liposome 
formulations for the i.v. treatment of inflammatory disorders.  
Liposomes are small lipid bilayer vesicles with an aqueous interior that can be used 
to entrap water-soluble glucocorticoid derivatives. By introducing specific functionalities to 
the bilayer, liposomes can acquire the ability to selectively accumulate at pathological target 
tissues, such as sites of inflammation or tumors. Such functionalities include ligands (e.g. 
antibodies) that specifically recognize receptors at cell surfaces in target tissues (active 
targeting). However, simple modifications such as polymer coatings that impose long-
circulating behavior to liposomes can also introduce selectivity for the target site (passive 
targeting). Chapter 2 of this thesis provides an overview of both passive and active targeting 
strategies with liposomes. 
The first part of the work, as described in Chapter 3, 4, 5 and 6 focuses on the 
therapeutic activity of long-circulating glucocorticoid liposomes in a series of different 
experimental animal models. The second part, described in Chapter 7 and 8 and 9 
addresses the safety issues of liposomal glucocorticoid and approaches are proposed for 
further optimization of the formulation. 
 
 
2. Therapeutic activity of liposomal glucocorticoid 
 
2.1 Rheumatoid arthritis 
 In this thesis, the primary focus was directed towards the treatment of arthritis. Rheumatoid 
arthritis is a chronic autoimmune disorder, involving joint inflammation and progressive 
cartilage destruction (9). Rheumatoid arthritis is primarily an inflammatory disease of the 
connective tissue characterized by spontaneous remissions and exacerbations (flare-ups). 
Glucocorticoids can be highly effective in treating joint inflammation, but systemic 
application is only reserved for severe, refractive forms of inflammatory diseases in which 
other drugs are not sufficiently active (10). In rheumatoid arthritis local treatment can be 
realized by means of intra-articular injection. Nevertheless, this treatment approach is only 
attractive when single large joints are affected. In many cases rheumatoid arthritis involves a 
range of (smaller) affected joints and systemic therapy remains the only option (11). 
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In Chapter 3 of this thesis the therapeutic response to prednisolone phosphate 
encapsulated in long-circulating PEG-liposomes in rat adjuvant arthritis was evaluated. The 
results indicate that in this experimental arthritis model a single i.v. injection of 10 mg/kg 
prednisolone phosphate-PEG-liposomes can already induce a strong, rapid and long-lasting 
therapeutic effect. Complete remission of joint inflammation could be accomplished within 
two days of treatment, and the therapeutic benefit of the injection lasted for up to two weeks. 
Free prednisolone phosphate was not effective. Limited efficacy was observed only with a 
treatment regimen involving daily injections of free glucocorticoid. The results in this Chapter 
also show that the increased therapeutic activity results from drug targeting, as equal doses 
of prednisolone phosphate encapsulated in liposome types that home to the inflamed joint 
to a lesser extent also produce a weaker therapeutic response. 
Roughly the same results were obtained in the murine collagen induced arthritis 
model, as described in Chapter 4. A single injection of 10 mg/kg liposomal prednisolone 
phosphate proved to be sufficient for complete, long-lasting remission of joint inflammation, 
whereas free prednisolone phosphate could slightly inhibit the progression of the 
inflammation reaction only when given daily during 5 days. The therapeutic activity of 5 
times 10 mg/kg free prednisolone phosphate roughly corresponded to the effect of a single 
dose of 1 mg/kg liposomal prednisolone phosphate, illustrating the dramatic increase of the 
therapeutic effect conferred by liposomal encapsulation. Although 1 week post-treatment 
joint inflammation clearly recurred, cartilage erosion was still reduced in mice treated with 
prednisolone phosphate-PEG-liposomes, as witnessed by histological inspection of knee joint 
slides. Apparently, treatment with liposomal prednisolone phosphate resulted in a profound 
delay of the cartilage erosion process.  
The results presented in both chapters provide promising prospects for a novel 
treatment approach in rheumatoid arthritis. The fact that a single dose efficiently affects all 
inflamed sites for a prolonged period of time may not only improve the therapeutic benefit 
and safety of i.v. glucocorticoids, it may also be more patient friendly. It can be envisaged 
that a single i.v. dose of liposomal glucocorticoid could be sufficient for overcoming an 
exacerbation of joint inflammation. The finding that cartilage erosion could be significantly 
delayed by targeted delivery of liposomal glucocorticoid may be of importance as 
glucocorticoid treatment of rheumatoid arthritis is often criticized for the lack of ability to 
induce a delay in the progression of joint erosion (12,13). 
 
2.2 Multiple sclerosis 
Like rheumatoid arthritis, multiple sclerosis is also an autoimmune disease involving 
inflammation and progressive tissue degeneration, in this case in the central nervous system 
(14). Relapses frequently occur and attenuation of these active stages of the disease is 
currently realized with intravenous high doses of glucocorticoids (1 or 2 grams 
methylprednisolone or prednisolone, daily for 3 – 5 days) (15). There is a strong need for the 
development of new therapies, as for relapses of multple sclerosis there is no treatment with 
a proven long-term effect available. 
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 In Chapter 5 we describe the therapeutic effect of liposomal glucocorticoid 
formulations in two rat models of experimental encephalomyelitis. Like in experimental 
arthritis the results showed that long-circulating liposomes selectively enter the inflamed 
extravascular tissue in the spinal chord, which results in a higher local concentration of 
glucocorticoid. The improved target localization of liposomal glucocorticoid resulted in 
increased rate of T cell apoptosis and reduced infiltration of T cells and macrophages and 
completely resolved the disease-induced damage of the blood brain barrier. Furthermore, 
clinical signs such as paralysis of the limbs and tail were significantly reversed, which was 
not observed with free glucocorticoid treatment. 
 These data suggest that the added therapeutic benefit of liposomal encapsulation 
also applies to glucocorticoid treatment of inflammatory neurological disorders. Not only a 
superior anti-inflammatory effect but also significant benefit at the level of tissue destruction 
is achieved with liposomal glucocorticoid. 
 
2.3 Oncology 
Whereas surgery and radiation therapy can be successfully applied to treat patients with 
isolated primary and secondary tumors, in many cases chemotherapy is needed to eliminate 
metastases and/or non-resectable tumor tissue. Chemotherapy involves treatment with 
highly (cyto)toxic agents that pose a significant threat to healthy organs. An important 
limitation to the success of the current anti-cancer drugs is therefore the dose-limiting 
toxicity (16,17).  
For the same reason as in inflammatory disorders, long-circulating liposomes may 
offer perspective. Besides sites of inflammation, also tumors show vasculature with 
enhanced permeability, enabling long-circulating liposomes to selectively localize in the 
extravascular tumor tissue (18). Studies with doxorubicin, daunorubicin, cisplatin and taxol 
showed that encapsulation in long-circulating liposomes can result in enhanced and 
prolonged exposure of the tumor to the drug and clearly improved the therapeutic outcome 
(18-21). Nevertheless, treatment with cytotoxic agents implies a range of long-term risks 
such as mutagenicity and teratogenicity, also with liposomally encapsulated cytotoxic drugs. 
Furthermore, liposomal encapsulation may lead to new forms of toxicities, such as the 
induction of skin reactions by liposomal doxorubicin (22). A lot of attention has therefore 
been paid to therapeutic agents without direct cytotoxic activity that realize an indirect anti-
tumor effect by affecting (patho)physiological processes required for tumor growth. Current 
studies tend to focus on agents that intervene at the level of the blood supply and 
angiogenesis (neovascularization) in the tumor (23). 
 Glucocorticoids also belong to the group of non-cytotoxic agents shown to be able to 
inhibit angiogenesis. However, to become active against tumors, extremely high and 
frequent doses are necessary. Such doses were shown to induce morbidity and mortality in 
laboratory animals (24,25). In Chapter 6 we show that at a single dose level of 20 mg/kg, 
strong anti-tumor activity could be realized in two murine models of solid tumors. Tumor 
growth was almost fully inhibited by weekly injections of liposomal glucocorticoid. 
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Furthermore, tumor histology showed many interesting signs of strong beneficial effects, like 
massive apoptosis of tumor cells, obstruction of the tumor vascularization and 
encapsulation by fibrous tissue and isolation of the tumor nodule from healthy tissue. 
 Either alone or in combination therapy, liposomal glucocorticoid may show high 
therapeutic value in cancer treatment, potentially offering the advantage of strong anti-tumor 
activity without the acute and long-term side effects that are usually associated with 
chemotherapy. 
 
 
3. Mechanism of action 
 
3.1 Pharmacokinetics and localization at the target site 
The observation that liposomal encapsulation could lead to such a strong increase of the 
therapeutic activity of glucocorticoids was unexpected. In fact, it shows that the currently 
employed systemic treatment approach with free glucocorticoid may be highly inefficient. In 
free form, glucocorticoids show a large volume of distribution and a high clearance rate (5). 
The fraction of the injected dose that will actually reach the target site is therefore low and 
the majority of the administered drug may be either prematurely eliminated from the body 
or localize at healthy non-target tissues. The results in adjuvant arthritis rats (Chapter 3) 
clearly show the consequences of liposomal encapsulation for the pharmacokinetics of 
glucocorticoids. Estimations based on the plasma concentration-time curves of free and 
liposomal prednisolone phosphate shown in this chapter suggest that liposomal 
encapsulation can decrease the distribution volume in a rat from more than a liter to 
approximately 10 ml, which roughly equals the plasma volume. Also, the clearance rate is 
reduced from approximately 2 L·h-1kg-1 to less than 2 ml·h-1kg-1. 
In itself altered pharmacokinetic behavior does not imply increased target localization 
and/or enhanced therapeutic activity. Two additional requirements must be met: (1) the 
target site must be directly accessible for the liposomes residing in the circulation, and (2) 
as the liposomally encapsulated phosphate ester of the glucocorticoid is not therapeutically 
active, it must be released from the liposome and converted to the active form of the drug. 
1) Access to the target site. In rat experimental arthritis (Chapter 3), experimental 
encephalomyelitis (Chapter 5) and murine experimental tumors (Chapter 6) the organ 
distribution data of radioactively labeled liposomes clearly point to preferential accumulation 
at pathological sites. Also the data with gold-labeled liposomes show that liposome 
localization is clearly inflammation-driven. Both in murine experimental arthritis as well as in 
experimental encephalomyelitis gold is present at the inflamed sites whereas healthy tissues 
are largely devoid of gold. It has been suggested that liposomes localize at pathological 
tissues as a result of uptake by infiltrating monocytes/macrophages (26). However, in our 
case, the radioactivity that was found in the cell fraction after centrifugation of the blood was 
minimal. Therefore, it appears more likely that liposomes selectively localize at 
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inflamed/malignant sites as a result of enhanced vascular permeability. This phenomenon 
has been studied and described in many previous publications (26,27).  
2) Release of the encapsulated drug. The microscopic tissue slides obtained with 
gold-labeled liposomes in experimental arthritis (Chapter 4) and experimental 
encephalomyelitis (Chapter 5) point out that the liposomes become cell-associated after 
localization in the pathological target site. In both cases resident macrophages appear to 
take up the majority of the liposomes. Therefore, it seems likely that liposomal 
glucocorticoid ends up in the intracellular endosomal/lysosomal compartment. Liposomal 
glucocorticoid may be released by enzymatic degradation of the liposome and subsequently 
converted from the non-active phosphate form into the free (active) glucocorticoid. Free 
glucocorticoid is able to freely cross cellular membranes, enabling the drug to reach the 
cytoplasm of the macrophage and possibly also to the extracellular space. Such a 
macrophage-mediated release process has been described earlier for liposomal doxorubicin 
and liposomal 5-fluoro-2'-deoxyuridine (28,29). 
 
3.2 Role of macrophages at the target site 
In arthritis an important role in the pathology of arthritis is ascribed to macrophages present 
in the synovial lining layer that surrounds the connective tissue in the joints. They have been 
shown to produce many pro-inflammatory cytokines, attract new inflammatory cells and 
produce enzymes that can damage the cartilage (30,31). Generally, these functions can be 
effectively suppressed by glucocorticoids. Glucocorticoids bind to the cytosolic 
glucocorticoid receptor, which can then translocate to the nucleus where it directly 
modulates DNA transcription of a variety of genes that encode for pro-inflammatory 
cytokines or tissue-degenerating enzymes (32,33). GC also exert rapid non-genomic effects. 
These are thought to occur by intracellular signaling via second messengers (like protein 
kinases and cyclic AMP) upon binding to GC receptors, non-specific interactions with cellular 
membranes, or specific interactions with membrane bound GC-receptors (34). 
The observation that especially the macrophages in the synovial lining very actively 
internalized liposomes alerted our interest. The high intracellular concentrations of 
glucocorticoid are likely to account for a strong suppressive effect on synovial macrophages 
leading to amelioration of inflammation and reduction of joint erosion. Furthermore, as free 
glucocorticoid can easily pass cellular membranes, the drug may escape from the 
intracellular compartment and be released into the extracellular environment, also 
suppressing other cells in the synovium, such as T cells or endothelial cells. 
In experimental encephalomyelitis, liposome uptake by macrophages in the inflamed 
areas was also observed. Besides a direct suppressive effect on macrophages, as illustrated 
by reduced TNF-α production, liposomal glucocorticoid enhanced apoptosis of T cells, 
indicating that free glucocorticoid can indeed escape from macrophages affecting other cells 
at the inflamed site. The observed reduction of leukocyte infiltration may be a result of down-
regulation of the production of chemoattractants by macrophages and/or resulting from the 
restoration of the integrity of the blood-brain-barrier. Also, localization of glucocorticoid 
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liposomes in peripheral immune organs leads to a reduction of the number of circulating 
leukocytes. The reduced infiltration of macrophages was only seen with liposomally 
encapsulated glucocorticoid. Interestingly, this may help to prevent ongoing tissue 
destruction and thereby exert beneficial long-term effects on the disease course. 
Macrophages are known to also play a role in tumor growth. As the anti-tumor effect 
we observed with liposomal glucocorticoid proved to be indirect (no tumorcidal activity of 
glucocorticoid was noted in in vitro tumor cell cultures), it may be explained by the strong 
suppressive effect of liposomal glucocorticoid on activated macrophages. Several 
investigators report that tumor-associated macrophages indirectly promote tumor growth by 
either secreting pro-inflammatory cytokines that induce angiogenesis and/or producing 
tissue-degrading enzymes, such as matrix metalloproteinases, that enable the tumor to 
invade into healthy tissue. Tumors appear therefore to be dependent to some degree on the 
infiltration of macrophages for their own growth and survival (35,36). Down regulation of the 
production of proangiogenic factors and tissue-degrading enzymes by macrophages with 
liposomal glucocorticoid may be an attractive strategy to suppress tumor growth without the 
use of cytotoxic agents. 
 
 
4. Safety aspects of liposomal glucocorticoid 
 
4.1 Systemic adverse effects 
In addition to the affinity of liposomal glucocorticoid for macrophages at sites of pathology 
also macrophages in organs that are part of the mononuclear phagocyte system, such as 
liver, spleen and bone marrow, extensively take up liposomes. The fact that these 
macrophages are loaded with glucocorticoid may have two important consequences that 
relate to toxicity: first, liposomal glucocorticoid may be expected to be converted into free, 
active glucocorticoid entering the circulation and second, cellular functioning of these 
macrophages may be (temporarily) suppressed. The first phenomenon may result in 
systemic (adverse) effects of free glucocorticoid and is discussed below. The second aspect 
deals with the concern of unwanted suppression of the body’s immune defense against 
blood-born pathogens and is discussed under 3.2. 
The results presented in Chapter 7 reveal that adverse effects that are typical for 
systemic glucocorticoid treatment, such as body weight loss and hyperglycemia, can also 
occur upon injection of liposomal glucocorticoid (37,38). Interestingly, these adverse effects 
were observed with free and liposomal dexamethasone, but not with liposomal prednisolone. 
These results corresponded with the observation that upon injection of liposomal 
dexamethasone phosphate relatively high levels of free glucocorticoid in the circulation were 
observed, much higher than in the case of liposomal prednisolone phosphate. As both 
liposome formulations were shown to be non-leaky in the circulation, we hypothesize that the 
20 – 30% of the injected dose of liposomal drug that localized in liver and spleen may have 
been taken up by MPS macrophages, degraded, and subsequently released by the 
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macrophages as free drug back into the circulation (28,29). The observation that the plasma 
levels of free glucocorticoid after injection of liposomal dexamethasone phosphate were 
considerably higher than after liposomal prednisolone phosphate is likely the result of a 
higher clearance rate of prednisolone as compared to dexamethasone. In fact, the relatively 
high clearance rate of prednisolone in rats may have been the critical parameter preventing 
pharmacologically active plasma levels and corresponding systemic adverse effects.  
As a high clearance rate of the free glucocorticoid in the circulation appears to be 
crucial to optimize the therapeutic index of liposomal glucocorticoid, the group of 
inhaled/intranasal glucocorticoids may be of high interest. The success of these 
glucocorticoids in topical treatment of asthma and rhinitis can largely be attributed to their 
high local activity in combination with the fact that the liver highly efficiently eliminates the 
fraction of administered drug entering the circulation after inhalation and ingestion (39,40). 
By means of targeted delivery with long-circulating liposomes, patients with inflammatory 
disorders such as rheumatoid arthritis or multiple sclerosis may also benefit from this group 
of glucocorticoids. Data provided in Chapter 7 confirm the value of such an approach with 
budesonide as a representative of this group. 
 
4.2 Suppression of MPS-function 
The second type of potential adverse effects investigated is also related to the encapsulated 
glucocorticoid, but differs from the effects discussed above in the sense that it is not 
observed with free drug. The fact that liposomally encapsulated glucocorticoids cannot 
easily enter healthy tissues may reduce a range of adverse effects, but it should be realized 
that a significant fraction of the injected dose ends up in the liver, spleen and bone marrow. 
The majority of this fraction is taken up by macrophages and the latter cells may therefore 
become at risk for adverse effects induced by liposomally encapsulated glucocorticoid (41). 
As the MPS has an important function as a part of the immune system’s first line of defense 
against pathogens in the circulation, suppression of macrophages by liposomally 
encapsulated glucocorticoid may result in enhanced susceptibility for infections. 
To evaluate the extent to which liposomal glucocorticoid can suppress the phagocytic 
capacity of liver macrophages, blood clearance of bacteria was monitored after injection of 5 
∗ 105 K Pneumonia, 24 hrs after rats were pretreated with 10 mg/kg liposomal prednisolone 
phosphate and compared to control treatments (saline, free prednisolone phosphate, and 
empty liposomes). At 60 and 120 min after i.v. injection of the bacteria, blood was collected 
in which the number of viable bacteria was determined. 
At 2 hrs after injection of the bacteria, all control treatments (saline, free 
prednisolone phosphate and empty liposomes) showed 99.98 % removal of bacteria from 
the circulation, whereas after treatment with liposomal prednisolone phosphate 99.8% of the 
bacteria was removed  (p<0.05, One way ANOVA). This result suggests that liposomal 
glucocorticoid can affect the clearance capacity of MPS macrophages. However it should be 
realized that K Pneumonia is a highly encapsulated bacterial strain for which optimal MPS-
functioning is crucial. The fact that this is a highly sensitive test and that the majority of 
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bacteria is still rapidly cleared from the circulation may reduce concerns regarding MPS 
dysfunction. Dose escalation studies in patients are necessary to reveal whether suppression 
of MPS-macrophages will become a dose limiting form of toxicity. 
 
4.3 Complement-related hypersensitivity reactions 
Chapter 8 addresses a third type of potential adverse effects, not related to the 
glucocorticoid but rather a result of the liposomal carrier itself. Several studies revealed that 
liposomes, in particular PEG-liposomes, can cause hypersensitivity reactions in 5-10% of the 
patients upon i.v. injection. Although these reactions are generally mild and short lasting, 
they caused some turbulence in the liposome field as i.v. administration of long-circulating 
liposomes was thought to be safe within a broad dose range (43,44). Mechanistic studies 
showed that these hypersensitivity reactions are most likely a result of the activation of 
complement (45,46). 
In our study different liposome types were evaluated in an in vitro complement 
activation assay in human plasma and an in vivo pig model in which cardiopulmonary effects 
can be detected. All liposomes types tested caused complement activation and 
hypersensitivity reactions. Only a small-sized non-PEG-liposome (<70 nm) composed of 
rigid, neutral bilayers, lacked both complement activation and hypersensitivity reactions. As 
the same liposome type but with a mean size of 90 nm did induce reactions, to a similar 
extent as PEG-liposomes of approximately 90 nm, size seems to be an important additional 
parameter in complement activation besides composition-related aspects.  
As we were not able to size the PEG-liposomes down to <70 nm, it was decided to 
evaluate the small non-PEG-liposomes regarding their applicability for passive drug 
targeting. To our surprise, the small non-PEG-liposome type appeared to have a longer 
circulation time than the 90 nm PEG-liposomes, which have been used for most of the work 
presented in this thesis. Evaluation of glucocorticoids encapsulated in this type of liposome 
in experimental arthritis revealed a comparable therapeutic effect, indicating that 
glucocorticoid encapsulated in small, neutral non-PEG-liposomes may be preferred over 
glucocorticoid-PEG-liposomes in the clinic. 
 
 
5. Further development of glucocorticoid formulations 
 
5.1 Design of novel long-circulating liposome compositions 
Chapter 9 describes the development of novel liposome coating polymers, other than PEG 
and based on L-amino acids as monomers. With both poly(hydroxyethyl-L-glutamine) and 
poly(hydroxyethyl-L-asparagine) liposomes could be prepared that were as long-circulating 
as PEG-liposomes and also as effective as PEG-liposomes in targeted delivery of 
glucocorticoids to sites of inflammation in experimental arthritis. These liposomes are novel 
in that they are coated with biodegradable polymers that can be degraded by proteolytic 
enzymes, which may be abundant at sites of pathology. Interestingly, liposomes coated with 
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poly(hydroxyethyl-L-asparagine) could relatively easily be downsized to approximately 50 
nm, which was not possible with PEG-liposomes. This may offer perspective regarding the 
avoidance hypersensitivity reactions, as size appeared to be a crucial parameter to be taken 
into account in liposome-induced complement activation.  
 
5.2 Selection and encapsulation of new glucocorticoids 
We found that from the glucocorticoid, which is encapsulated in the aqueous interior, the 
water-soluble phosphate ester is required for stable encapsulation. Specific examples of 
water-soluble glucocorticoids that can be used in the liposomal approach are prednisolone 
disodium phosphate, dexamethasone disodium phosphate, betamethasone disodium 
phosphate, and triamcinolone acetate disodium phosphate. To minimize the systemic 
effects, the use of topical glucocorticoids with a high clearance rate seems advantageous, as 
shown by the work in this thesis. Success was booked with a newly synthesized phosphate 
ester of the asthma glucocorticoid budesonide.  
Two other interesting approaches for further optimization of liposomal glucocorticoid 
deserve attention. Recent research has revealed that certain glucocorticoids have a 
surprisingly potent direct effect on inflammatory cells that does not involve down-regulation 
of cytokine production at the level of gene transcription. Rather, this phenomenon is 
mediated at a non-genomic level and appears to be of importance when a high concentration 
of glucocorticoid is present at sites of inflammation (34). From this perspective, 
methylprednisolone, which is currently applied in high dose i.v. treatment of relapses of 
multiple sclerosis and rheumatoid arthritis, appears to be an interesting candidate for 
evaluation in the concept of targeted delivery by long-circulating liposomes. 
A second group of glucocorticoids of high interest are the 11-keto glucocorticoids. 
These glucocorticoids are in principle inactive and require a specific enzyme (11ß-
hydroxysteroid dehydrogenase) to be converted to the active form. As relatively high 
quantities of this enzyme are present selectively at sites of inflammation, incorporation of 
these glucocorticoids could lead to additional target specificity (47,48). An interesting 
candidate for encapsulation in long-circulating liposomes is prednisone. In future research 
both the above-mentioned approaches will be evaluated. 
Typically the hydration-extrusion method of preparation results in encapsulation of 5-
10% of the glucocorticoid inside the liposomes. The formulation can be stored at 4 ºC and 
remains stable for at least 1 year (less than 5% leakage and less than 5% increase of 
particle size). To further improve the encapsulation efficiency and long-term stability, at the 
moment an improved preparation method is being developed, using a ‘remote-loading’ 
technique. Up to 100 % of the added glucocorticoid can potentially be encapsulated by 
using this method, resulting in reduced loss of glucocorticoid during manufacturing of the 
preparation. Evaluation of such preparations in experimental arthritis revealed that remote 
loading does not result in loss of therapeutic activity.  
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Besides increased encapsulation efficiency, remote loading often enables successful 
lyophilization of liposomally encapsulated drugs, which increases the long-term stability of 
the product. Whether this also applies to remote-loaded liposomal glucocorticoid remains to 
be evaluated. All together these additional developments must lead to a product that besides 
strong therapeutic activity shows optimal safety in humans, with attractive properties 
regarding (large-scale) production and long-term storage. 
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SAMENVATTING IN HET NEDERLANDS 
 
 
1. Inleiding 
Glucocorticoïden zijn zeer effectieve ontstekingsremmende geneesmiddelen die kunnen 
worden toegepast bij een breed scala aan ontstekingsziekten, variërend van kleinschalige 
allergische reacties tot ernstige inflammatoire aandoeningen zoals reuma, de ziekte van 
Crohn en multiple sclerose. Een groot probleem bij behandeling met glucocorticoïden is dat 
deze stoffen zich na toediening snel over het gehele lichaam verspreiden, veel gezonde 
organen bereiken en zich slechts in beperkte mate concentreren in de ontstekingshaarden. 
Dit ongunstige gedrag maakt het noodzakelijk dat de dosis omhoog moet om de gewenste 
therapeutische werking te verkrijgen. Dat is niet alleen verspilling van de toegediende 
glucocorticoïden, het is met name ook een belangrijke oorzaak van allerlei (vaak ernstige) 
neveneffecten. 
 Een belangrijke vooruitgang werd geboekt met de introductie van lokale 
behandelingsstrategieën, waarmee zeer effectief ziekten zoals bijvoorbeeld astma en 
allergische huidreacties kunnen worden bestreden zonder dat de toegediende 
glucocorticoïden terecht komen op gezonde plaatsten waardoor ongewenste neveneffecten 
kunnen ontstaan. Helaas kunnen veel ontstekingsziekten moeilijk worden behandeld door 
middel van lokale toediening van glucocorticoïden, omdat de ontstekingshaarden slecht 
toegankelijk zijn en/of te veel verspreid zijn over het lichaam. Gestuurde aflevering van 
glucocorticoïden door liposomale geneesmiddeldragers die in de ontstoken plekken in het 
lichaam ophopen (‘targeting’) zou uitkomst kunnen bieden. Targeting kan zo worden 
beschouwd als een vorm van lokale behandeling van alle ontstekingen in het lichaam 
eenvoudigweg door de liposomen in de bloedbaan te injecteren (‘intraveneuze’ toediening). 
 Liposomen zijn minuscule vetblaasjes ter grootte van een duizendste tot een 
tienduizendste van een millimeter, waarin geneeskrachtige stoffen, zo ook glucocorticoïden, 
kunnen worden ingesloten. Liposomen worden veelal gemaakt door bepaalde vetten te 
dispergeren in een waterige oplossing van het geneesmiddel. De gewenste afmeting van de 
vetblaasjes die op deze wijze ontstaan wordt verkregen door de dispersie meerdere keren 
door filtermembranen te persen met de juiste poriegrootte. Door het oppervlak van de 
vetblaasjes te modificeren met stoffen die affiniteit vertonen met het aangedane weefsel, kan 
targeting met de liposomen gerealiseerd worden. Als hierbij gebruik wordt gemaakt van 
biologische stoffen zoals eiwitten en suikerverbindingen die specifieke interacties aangaan 
met zieke cellen op de aangedane plek, spreekt men van ‘actief gestuurd 
geneesmiddeltransport’ (‘active drug targeting’ in het Engels). 
Echter, soms kunnen synthetische stoffen zoals polymeren er al voor zorgen dat 
liposomen affiniteit krijgen met de aangedane plekken in het lichaam. Maar dit gebeurt dan 
eigenlijk op een indirecte manier. Normaal gesproken worden liposomen, net als bijvoorbeeld 
bacteriën en andere indringers, uit de bloedbaan verwijderd door macrofagen. Macrofagen 
zijn belangrijke cellen van het immuunsysteem, die zich onder andere in grote getale in de 
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lever en de milt bevinden. Polymeren op het oppervlak kunnen dit proces echter 
belemmeren. De liposomen worden dan ‘langcirculerend’ en krijgen daardoor beter de kans 
om langzaam op te hopen op zieke plekken in het lichaam, omdat de bloedvaatwanden op 
die plekken doorlaatbaar zijn. Het voor dit doel meest gebruikte langcirculerende liposoom 
zijn de zogenaamde ‘PEG-liposomen’, die gemodificeerd zijn met het polymeer 
polyethyleenglycol (PEG). Deze indirecte manier van het bereiken van de gewenste plaatsen 
wordt ook wel ‘passief gestuurd geneesmiddeltransport’ genoemd (‘passive drug targeting’). 
In Hoofdstuk 2 worden de varianten en mogelijkheden van active drug targeting en passive 
drug targeting met liposomen op een rij gezet in een uitgebreid literatuuroverzicht. 
 Vooral passive drug targeting met langcirculerende liposomen lijkt aantrekkelijk om de 
effectiviteit van glucocorticoïden in ontstekingsziekten zoals reuma en multiple sclerose te 
verbeteren en de schadelijke neveneffecten te verminderen, omdat met langcirculerende 
liposomen het toegediende glucocorticoïde selectief naar de ontstekingshaarden kan worden 
gebracht. Het voornaamste doel van het onderzoek dat in dit proefschrift beschreven is, was 
dan ook het ontwerpen, evalueren en optimaliseren van langcirculerende glucocorticoïde-
bevattende liposomen voor de intraveneuze behandeling van inflammatoire aandoeningen. 
Het eerste deel van het proefschrift, hoofdstuk 3 tot en met 6, richt zich op het 
therapeutische effect van langcirculerende glucocorticoïdebevattende liposomen in een 
aantal experimentele ziektemodellen in proefdieren. Het tweede deel omvat hoofdstuk 7 tot 
en met 9 waarin de mogelijke neveneffecten van liposomale glucocorticoïden worden belicht 
en mogelijkheden worden bestudeerd om dit nieuwe therapeutische preparaat verder te 
optimaliseren. 
 
 
2. Therapeutisch effect van liposomaal glucocorticoïde 
 
2.1 Reumatoïde artritis 
Het onderzoek dat in dit proefschrift beschreven is richtte zich aanvankelijk grotendeels op 
reumatoïde artritis. Reumatoïde artritis, of kortweg reuma, is een chronische inflammatoire 
aandoening die zich manifesteert in de vorm van gewrichtsontstekingen en op den duur leidt 
tot onherstelbare gewrichtsschade. De gewrichtsontstekingen kunnen met verschillende 
geneesmiddelen worden bestreden, maar voor een snelle, effectieve onderdrukking van 
ernstige uitbarstingen van de ontstekingen (‘exacerbaties’) is men veelal aangewezen op 
glucocorticoïden. Dat glucocorticoïden vaak achter de hand gehouden worden als ‘laatste 
redmiddel’ moet worden toegeschreven aan het relatief ongunstige neveneffectenprofiel van 
deze geneesmiddelen na intraveneuze of orale toediening. Lokale toediening door injecties 
direct in het gewricht kan een enorme vooruitgang betekenen, maar met één injectie kan 
slechts één gewricht tegelijk worden behandeld terwijl er meestal meerdere gewrichten 
tegelijk zijn ontstoken. 
 In Hoofdstuk 3 van dit proefschrift wordt het therapeutische effect beschreven van 
het glucocorticoïde prednisolonfosfaat, verpakt in PEG-liposomen, bij een kunstmatige, 
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experimentele vorm van artritis in ratten, het zogenaamde ‘rat adjuvant artritis’-model. De 
resultaten wezen op een snel, sterk en langdurig effect dat al gerealiseerd kon worden met 
één enkelvoudige injectie (dosis: 10 mg/kg). Binnen twee dagen na de behandeling waren 
alle gewrichtsontstekingen volledig verdwenen en het therapeutisch voordeel bleef zichtbaar 
tot twee weken na behandeling. Prednisolonfosfaat in vrije vorm bleek niet effectief. Pas na 
dagelijkse toediening van het vrije glucocorticoïde over een periode van zeven dagen werd 
een matig effect geobserveerd. Vervolgens werd bekeken of deze drastische verbetering 
inderdaad het resultaat was van passive drug tageting. Dit kon worden bevestigd na de 
waarneming dat prednisolonfosfaat in liposoomtypen, die in mindere mate terechtkomen in 
ontstoken gewrichten, ook minder therapeutisch actief zijn. 
 Vergelijkbare resultaten werden gevonden bij een andere experimentele vorm van 
artritis: het ‘collageen type II-geïnduceerde artritis’-model in muizen. Hoofdstuk 4 laat zien 
dat met een enkelvoudige dosis, vergelijkbaar aan die in rat adjuvant artritis, ook in deze 
vorm van artritis een volledige en langdurige remissie van de gewrichtsontstekingen kon 
worden bewerkstelligd. Prednisolonfosfaat in vrije vorm was alleen beperkt effectief bij 
dagelijkse injecties van vergelijkbare doses. Het effect van vijf maal dagelijks vrij 
prednisolonfosfaat bleek vergelijkbaar met het effect van één enkele – tien maal lagere – 
dosis liposomaal prednisolonfosfaat, hetgeen goed de sterke geneeskrachtige werking van 
het liposomale preparaat illustreert. Uit microscopische bestudering van kniegewrichten van 
muizen die behandeld waren met goud-gemarkeerde liposomen bleek heel duidelijk dat de 
liposomen in hoge mate worden opgenomen door actieve ontstekingscellen in de gewrichten. 
Ook bleek dat de kraakbeenschade in het gewricht sterk kan worden verminderd met de 
behandeling met liposomaal prednisolonfosfaat. 
 De resultaten in de hoofdstukken 3 en 4 lijken aan te geven dat liposomaal 
glucocorticoïde veelbelovend kan zijn voor de behandeling van reumapatiënten. Dat met een 
enkele injectie voldoende geneesmiddel kan worden afgeleverd voor een langdurig effect in 
alle ontstoken gewrichten, betekent niet alleen dat een groter therapeutisch voordeel met 
minder neveneffecten kan worden verwacht, maar dat deze behandelingsstrategie tevens 
minder belastend kan zijn voor de patiënt. Immers, het onderzoek suggereert dat een 
eenmalige behandeling voldoende is om een exacerbatie van gewrichtsontstekingen volledig 
te bestrijden. Dat ook de gewrichtsschade lijkt te worden vertraagd door behandeling met 
liposomaal glucocorticoïde is belangrijk omdat de behandeling van reuma met 
glucocorticoïden vaak bekritiseerd wordt vanwege het gebrek aan vermogen van 
glucocorticoïden om naast de ontsteking ook de toenemende gewrichtsschade een halt toe te 
roepen. 
 
2.2 Multiple sclerose 
Multiple sclerose (kortweg ‘MS’) is net als reumatoïde artritis een inflammatoire aandoening. 
Bij MS komen de ontstekingen voornamelijk voor in het centrale zenuwstelsel. Daar leiden ze 
tot toenemende schade aan en uitval van zenuwcellen zodat er langzaam maar zeker steeds 
meer verlammingsverschijnselen optreden gedurende het ziekteverloop. 
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  Voor de behandeling van MS zijn nog maar heel weinig adequate geneesmiddelen 
voorhanden. Regelmatig worden intraveneus hoge doseringen glucocorticoïden gegeven (1 
tot 2 gram methylprednisolon dagelijks gedurende drie tot vijf dagen) om de 
ontstekingsreacties enigszins te kunnen onderdrukken. In Hoofdstuk 5 wordt het 
therapeutisch effect beschreven van liposomaal glucocorticoïde in een experimenteel 
diermodel van MS. Net als bij experimentele reuma liet ook dit diermodel zien dat de 
liposomen selectief ophopen in ontstoken weefsel, in dit geval het ruggenmerg. Bovendien 
werden ook in dit model de goud-gemarkeerde liposomen ter plaatse teruggevonden in de 
macrofagen, de immuuncellen die mede verantwoordelijk worden gehouden voor de 
ontstekingen. De verhoogde concentraties glucocorticoïde die zo door de liposomen in de 
ontstekingshaarden worden opgebouwd, leidden tot uitschakeling en verlaagde infiltratie van 
ontstekingscellen en tot een volledig herstel van de beschadigde bloed-hersenbarrière, het 
vlies dat het centraal zenuwstelsel scheidt van het bloedvaatstelsel. Bovendien werden de 
verlammingsverschijnselen bij de dieren verminderd, hetgeen niet kon worden bewerkstelligd 
met hoge doses vrij glucocorticoïde. 
  Deze resultaten suggereren dat het therapeutische voordeel dat kan worden geboekt 
door insluiting van glucocorticoïden in langcirculerende liposomen van toepassing is voor 
meerdere inflammatoire aandoeningen. Indien er sprake is van ontstekingshaarden waar 
liposomen in kunnen ophopen vanuit de bloedbaan valt er therapeutisch voordeel te 
verwachten van glucocorticoïden in langcirculerende liposomen. Dit betekent dat ook 
inflammatoire darmaandoeningen zoals colitis ulcerosa of de ziekte van Crohn of 
huidaandoeningen zoals psoriasis in aanmerking zouden kunnen komen voor behandeling 
met liposomaal glucocorticoïde. Of dit inderdaad zo is zal moeten blijken uit nader 
experimenteel onderzoek.  
 
2.3 Toepassing in de oncologie 
Operatieve verwijdering of behandeling door bestraling kunnen succesvol zijn bij de patiënten 
die lijden aan vormen van kanker waarbij sprake is van geïsoleerde, toegankelijke tumoren. 
Helaas zijn veel tumoren moeilijk verwijderbaar of zijn er al uitzaaiingen geconstateerd. In die 
gevallen is de patiënt meestal aangewezen op chemotherapie. Chemotherapie behelst de 
behandeling met de zeer giftige ‘cytostatica’, stoffen die aangrijpen op sneldelende cellen. 
Het belangrijkste probleem van chemotherapie is dan ook de schadelijkheid voor gezond 
weefsel, waardoor maar beperkte hoeveelheden cytostatica toegediend kunnen worden, met 
vaak slechts een beperkte anti-kankerwerking als gevolg. 
 Om dezelfde reden als bij inflammatoire aandoeningen kunnen langcirculerende 
liposomen mogelijk uitkomst bieden. Net zoals bij ontstekingen is er bij tumoren vaak sprake 
van verhoogde vaatwandpermeabiliteit zodat zich in het bloed bevindende liposomen 
selectief kunnen uittreden en het tumorweefsel kunnen bereiken. Studies met cytostatica als 
doxorubicine, cisplatina en taxol hebben laten zien dat insluiting in langcirculerende 
liposomen leidt tot verhoogde en verlengde blootstelling van de tumor aan het ingesloten 
geneesmiddel en dat dit resulteert in een verbeterd effect. Desondanks blijft de behandeling 
appendices 
178 
met cytotoxische stoffen bedreigingen op de lange termijn met zich meebrengen, zoals 
mutageniciteit (afwijkingen in het genetisch materiaal van gezonde cellen) en teratogeniciteit 
(genetische afwijkingen bij het nageslacht). Daarom besteedt men veel aandacht aan 
geneesmiddelen die op een andere manier bij kanker werken dan cytostatica. Zo worden 
momenteel stoffen onderzocht die aangrijpen op de bloedvoorziening van de tumor en zo op 
een indirecte wijze de tumorgroei kunnen remmen. 
 Glucocorticoïden horen ook bij de groep geneesmiddelen die de bloedvoorziening van 
tumoren kunnen aantasten. Alleen wordt dit effect slechts gezien bij zeer hoge doseringen 
die frequent toegediend dienen te worden en ronduit levensbedreigend kunnen zijn bij 
klinische toepassing. In Hoofdstuk 6 laten we in experimentele tumormodellen bij muizen 
echter zien dat, met een enkelvoudige behandeling met een gangbare dosis glucocorticoïde, 
ingesloten in langcirculerende liposomen, al een sterk anti-tumor effect kon worden 
bewerkstelligd. Naast een vrijwel volledige remming van de tumorgroei werden ook op 
microscopisch niveau interessante verschijnselen in de tumoren waargenomen, zoals 
massale uitval van tumorcellen, obstructies in het tumorvaatbed en inkapseling van de tumor 
in bindweefsel zodat als het ware de tumor ‘los’ komt te liggen van het gezonde weefsel. Al 
met al zou deze behandelingsstrategie van grote waarde kunnen zijn, als een op zichzelf 
staande behandeling of in combinatie met operatieve verwijdering of chemotherapie. 
Toekomstig onderzoek zal moeten uitwijzen bij welke vormen van kanker liposomaal 
glucocorticoïde succesvol kan zijn. 
   
 
3. Neveneffecten van liposomaal glucocorticoïde 
 
3.1 Neveneffecten van het ingesloten glucocorticoïde 
Hoewel met langcirculerende liposomen het ingesloten glucocorticoïde op gerichte wijze naar 
de aangetaste plaatsen gestuurd wordt, betekent dit zeker niet dat er helemaal geen 
glucocorticoïde meer in gezond weefsel terechtkomt. Naast ontstekingen en maligniteiten 
nemen ook organen als lever, milt en beenmerg liposomen op. Dit wordt veroorzaakt doordat 
zich in deze organen macrofagen bevinden, die gespecialiseerd zijn in het verwijderen van 
ongewenste indringers. Als deze macrofagen glucocorticoïde-bevattende liposomen opnemen 
uit de bloedbaan zou dit hun functioneren kunnen aantasten, omdat glucocorticoïden in het 
algemeen een remmend effect hebben op cellen van het immuunsysteem. Dit type 
neveneffect wordt niet beschreven in een van de hoofdstukken van dit proefschrift, maar is 
wel onderzocht. Voorlopige resultaten wijzen erop dat dit risico inderdaad bestaat, maar het 
onderdrukkende effect blijft zeer beperkt en meer dan 99% van de capaciteit van 
macrofagen om ziekteverwekkende indringers te elimineren blijft onaangetast. 
Bovendien kan het ingesloten glucocorticoïde na opname door macrofagen uit deze 
cellen ontsnappen en opnieuw in de bloedbaan terecht komen maar dan in vrije vorm. Op die 
wijze kan het zich alsnog over het lichaam verspreiden en neveneffecten veroorzaken als 
ware het in vrije vorm toegediend. Voorbeelden van neveneffecten van glucocorticoïden in 
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vrije vorm zijn onder andere verhoging van het bloedsuikergehalte en veranderingen in 
lichaamsgewicht. Deze  worden ‘systemische’ neveneffecten genoemd omdat ze in principe 
het lichaam in zijn geheel betreffen. In Hoofdstuk 7 worden genoemde neveneffecten in 
ratten bestudeerd, zowel na toediening van vrij als van liposomaal glucocorticoïde. Het blijkt 
dat deze neveneffecten kunnen worden vermeden mits een speciaal type glucocorticoïde 
wordt verwerkt in de liposomen dat in vrije vorm snel uit de bloedbaan wordt verwijderd door 
de lever. Dit type glucocorticoïde wordt al met groot succes toegepast bij lokale behandeling 
van ontstekingen, zoals bijvoorbeeld in inhalatietherapie bij astma. Immers, mocht er 
ondanks de lokale toediening toch glucocorticoïde in staat zijn de bloedbaan te bereiken dan 
zal dit snel wordt geïnactiveerd. Welnu, targeting met langcirculerende liposomen kan in feite 
ook gezien worden als een manier van lokale behandeling. Het liposoom beschermt het 
glucocorticoïde tegen voortijdige afbraak en route naar de ontstekingen waar het zeer effectief 
zijn werk kan doen, terwijl de snelle inactivatie in de lever voorkomt dat eventueel in de 
bloedbaan vrijgekomen glucocorticoïde systemische neveneffecten kan veroorzaken.  
 
3.2 Neveneffecten van de liposomale drager 
Hoofdstuk 8 gaat in op een heel ander type neveneffect dat niet gerelateerd is aan het 
glucocorticoïde, maar wordt veroorzaakt door het liposoomdeeltje zelf. Het betreft een acute 
allergische reactie die ontstaat bij 5 tot 10% van de patiënten direct bij aanvang van de 
infusie van de liposomen en die zich uit in roodheid, benauwdheid en 
bloeddrukveranderingen. De reactie is meestal mild en verdwijnt snel als de infusie wordt 
gestopt. Vaak kan de reactie voorkomen worden door te starten met een voldoende lage 
infusiesnelheid. De reactie wordt in verband gebracht met het zogenaamde 
‘complementsysteem’, een onderdeel van het immuunsysteem dat bestaat uit een serie 
plasma-eiwitten die in een soort kettingreactie elkaar onderling kunnen activeren en op die 
manier allerlei afweerreacties in het lichaam kunnen uitlokken. 
 Om er achter te komen welke componenten van de liposomen verantwoordelijk 
kunnen worden gehouden voor deze complementactivatie-reacties, bestudeerden we de 
activatie van het complementsysteem na toediening van verschillende liposoomtypen aan 
humane bloedmonsters. De overgevoeligheidsreacties zelf werden gemeten in varkens die, 
blijkens vorige studies, uitstekend kunnen fungeren als een proefdiermodel als het gaat om 
complement-gerelateerde overgevoeligheid. Het optreden van complementactivatie en 
complementgerelateerde overgevoeligheid bleek echter niet zozeer gerelateerd te zijn aan de 
samenstelling van de liposomen, maar eerder te maken te hebben met de grootte van de 
liposoomdeeltjes. Liposomen van zeer klein formaat, met een rigide vetlaag en zonder PEG 
op het oppervlak bleken zowel in de bloedmonsters als in varkens het enige liposoomtype te 
zijn dat geen complementactivatie veroorzaakte. Dit type liposomen bleek ook heel goed 
bruikbaar voor targeting van glucocorticoïden in ontstekingsziekten. Het lijkt dus mogelijk 
acute overgevoeligheidsreacties te reduceren door de afmeting van de liposomen te 
reduceren en de samenstelling nauwgezet te definiëren. 
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4. Verdere ontwikkelingen 
 
4.1 Nieuwe liposoomtypen 
Het meest gebruikte langcirculerende liposoomtype in de studies beschreven in dit 
proefschrift zijn de PEG-liposomen. Zoals aangegeven in de inleiding zorgt de PEG-laag op 
het oppervlak van dit liposoom voor de langcirculerende eigenschap doordat het de opname 
uit de bloedbaan door lever en milt sterk reduceert. Hoofdstuk 9 beschrijft de ontwikkeling 
van een nieuw type polymeren voor langcirculerende liposomen. Deze polymeren zijn 
opgebouwd uit gemodificeerde aminozuren, hetgeen betekent dat ze chemisch gezien 
overeenkomsten vertonen met eiwitten en dus net als eiwitten biologisch afbreekbaar zijn. 
Deze polymeren kunnen van belang zijn voor de ontwikkeling van liposomen voor active drug 
targeting (zie pagina 174). De polymeren kunnen bijvoorbeeld bepaalde functionele 
moleculen in de vetlaag van het liposomen afschermen zolang het liposoom nog niet op de 
plaats van bestemming is. Na aankomst op de aangetaste plaatsen kan door de verhoogde 
enzymactiviteit op deze plaatsen de polymeerlaag afgebroken worden zodat de functionele 
moleculen hun werk kunnen gaan doen. 
Zo ver zijn we nu echter nog niet. In dit proefschrift onderzoeken we slechts of passive 
drug targeting mogelijk is. De gevonden resultaten geven aan dat liposomen die bereid 
worden met de nieuwe polymeren even lang kunnen circuleren als PEG-liposomen met 
dezelfde afmeting. Ook kunnen op succesvolle wijze glucocorticoïden gestuurd worden naar 
plaatsen van ontsteking, zoals blijkt uit een studie met deze liposomen in een experimenteel 
proefdiermodel voor reuma. De resultaten geven aan dat de nieuwe polymeren uitstekende 
eigenschappen bezitten voor de verdere ontwikkeling van langcirculerende liposomen voor 
passive drug targeting. 
 
4.2 Nieuwe ontwikkelingen op het gebied van de ingesloten glucocorticoïden 
Ons huidig onderzoek richt zich niet alleen op de liposomale drager zelf, maar ook op het in 
te sluiten glucocorticoïde. Op pagina 179 is het belang van het gebruik van glucocorticoïden 
die in vrije vorm snel door de lever uit de bloedbaan worden verwijderd beschreven. Er zijn 
echter nog twee andere mogelijkheden om het effect te optimaliseren en de neveneffecten te 
minimaliseren. Allereerst laten recente wetenschappelijke publicaties een nieuw ontdekt 
werkingsmechanisme zien waarmee glucocorticoïden ontstekingen kunnen remmen. Het 
betreft hier een direct effect op celmembranen in plaats van het veelbeschreven remmende 
effect van glucocorticoïden op de vorming van ontstekingsbevorderende 
boodschappermoleculen. Dit directe ontstekingsremmende effect staat in het bijzonder op 
de voorgrond bij bepaalde glucocorticoïden en is alleen van belang wanneer hoge 
concentraties worden gecreëerd op plaatsen van ontsteking. Wanneer deze glucocorticoïden 
worden ingesloten in liposomen zou dit werkingsmechanisme dan ook, als gevolg van 
targeting naar plaatsen van ontstekingen, voor een extra ontstekingsremmend effect kunnen 
zorgen. Deze glucocorticoïden willen we in de nabije toekomst aan nader onderzoek 
onderwerpen. 
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 Een ander interessant type glucocorticoïden zijn de zogenaamde 11-keto-
glucocorticoïden. Deze zijn chemisch zo gemodificeerd dat ze in principe niet actief zijn, 
maar slechts geactiveerd kunnen worden met behulp van een specifiek enzym (11ß-
hydroxysteroïde-dehydrogenase). Aangezien dit enzym zich in relatief hoge concentraties 
bevindt op plaatsen van ontsteking, zou men door het insluiten van 11-keto-glucocorticoïden 
in langcirculerende liposomen een extra vorm van selectiviteit kunnen genereren voor de 
ontstoken plaatsen in het lichaam. Ook deze benadering zal in toekomstig onderzoek aan de 
orde komen. 
 In de huidige bereidingswijze wordt uitgegaan van de wateroplosbare natriumfosfaat-
vorm van glucocorticoïden waarvan normaal gesproken zo’n 5% van de uitgangshoeveelheid 
in de liposomen wordt ingesloten als de op pagina 174 beschreven bereidingsmethode wordt 
gehanteerd. De liposomen die zo gevormd worden kunnen ongeveer een jaar in de koelkast 
bewaard worden zonder dat er essentiële veranderingen in het preparaat optreden. Om het 
insluitpercentage van 5% verder te verhogen en de bewaartermijn te verlengen zijn we 
momenteel bezig met het ontwikkelen van een techniek waarmee voorgevormde, lege 
liposomen zichzelf kunnen opladen met het aangeboden geneesmiddel. Op deze wijze zou in 
principe 100% van de uitgangshoeveelheid glucocorticoïde kunnen worden ingesloten. 
Tevens kunnen liposomen die op deze wijze bereid zijn vaak op eenvoudige wijze 
gevriesdroogd worden zonder dat dit ten koste gaat van de integriteit van de 
liposoomstructuur. Vanuit het oogpunt van farmaceutische stabiliteit kunnen gevriesdroogde 
liposomen veel langer bewaard worden dan liposomen bewaard in de vorm van een waterige 
dispersie. 
 
 
5. Liposomaal glucocorticoïde: hoe nu verder? 
 
De meeste studies die in dit proefschrift zijn beschreven zijn preklinische studies, dat wil 
zeggen: in proefdieren uitgevoerd. Op korte termijn willen we liposomaal glucocorticoïde ook 
daadwerkelijk in patiënten te testen. Momenteel wordt met de afdeling Reumatologie van het 
Academisch Ziekenhuis te Nijmegen een planning gemaakt voor een studie bij 
reumapatiënten. Omdat het doorlopen van de verschillende klinische onderzoeksfasen een 
zeer kostbaar traject is, wordt overwogen of op termijn commercialisatie van de liposomen 
haalbaar is. Op die manier kan dan met investeringskapitaal een bedrijf gestart worden dat 
de liposomen voor de verschillende toepassingen (reuma, MS, vormen van kanker) gaat 
evalueren in de kliniek. Bij positief resultaat zullen de liposomen voldoende commerciële 
marktwaarde krijgen om in licentieovereenkomsten verder te worden ontwikkeld door grotere 
farmaceutische bedrijven. Om deze plannen verder uit te werken is een aanvraag ingediend 
bij een fonds van de Nederlandse organisatie voor Wetenschappelijk Onderzoek (NWO). Deze 
aanvraag is inmiddels gedeeltelijk gehonoreerd, in afwachting van nadere evaluaties met 
betrekking tot de octrooipositie van het op te richten bedrijf. 
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LIST OF ABBREVIATIONS 
 
AA  adjuvant arthritis 
AT-EAE adoptive transfer-experimental autoimmune encephalomyelitis 
BBB   blood-brain-barrier 
BOC  tertiary-butoxycarbonyl 
BUP  budesonide phosphate 
Chol  cholesterol 
CIA  collagen type II-induced arthritis 
CNS  central nervous system 
CO  cardiac output  
CVP  central venous pressure 
DCC  dicyclohexylcarbodiimide 
DMF  dimethylformamide 
DODA  dioctadecyl amine 
DODASuc N-succinyl-dioctadecylamine 
DPPC  dipalmitoyl phosphatidylcholine 
DPTS  4-(dimethylamino)pyridinium-4-toluene sulfonate 
DSPC  distearoyl phosphatidylcholine 
DSPE  distearoyl phosphatidyl ethanolamine 
DTPA  diethylene triaminepenta-acetic acid 
DXP  dexamethasone phosphate 
EAE  experimental autoimmune encephalomyelitis 
EPC  egg phosphatidylcholine 
EPG  egg phosphatidylglycerol 
GC  glucocorticoid(s) 
3H  (radioactive) tritium 
HEPES N-(-2 hydroxyethyl) piperazine-N’-ethane sulfonic acid 
HOA  heptadecyl octadecyl amine 
i.v.  intravenous(ly) 
ID  injected dose 
IL-1  interleukin-1 
IL-6  interleukin-6 
111In  (radioactive) indium-111 isotope 
LCL  long-circulating liposome(s) 
LEVDP left ventricular end-diastolic pressure 
Mϕ  macrophage(s) 
MBP   myelin basic protein 
MP   methylprednisolone 
MPS   mononuclear phagocyte system 
MS   multiple sclerosis 
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MS  multiple sclerosis 
NCA  N-carboxy anhydride 
ODA  octadecyl amine 
PAP  pulmonary artery pressure 
PBLA  poly(benzyl L-aspartate) 
PBLG  poly(benzyl L-glutamate) 
PBS  phosphate buffered saline 
PEG  poly(ethylene glycol) 
PEG-DSPE  PEG2000-distearoyl phosphatidylethanolamine 
PEG-PE PEG2000-phosphatidylethanolamine 
PGPG  poly(hydroxypropyl L-glutamine) 
PHBG  poly(hydroxybutyl L-glutamine) 
PHEA   poly(hydroxyethyl L-asparagine) 
PHEG  poly(hydroxyethyl L-glutamine) 
PL   prednisolone liposomes 
PL  prednisolone liposomes 
PLP  prednisolone phosphate 
PVR  pulmonary vascular resistance 
RA  rheumatoid arthritis 
s.c.  subcutaneous(ly) 
SAP  systemic arterial pressure 
SC5-b9 protein S (vibronectin)-bound complement terminal complex 
SCL  short-circulating liposome(s) 
SD  standard deviation 
SEM  standard error of the mean 
SSL  sterically stabilized liposome(s) 
SVR  systemic vascular resistance  
TC   T cell(s) 
99mTc  (radioactive) technetium-99m isotope 
THF  tetrahydrofurane 
TNF-α   tumor necrosis factor-α. 
 
 
appendices 
184 
CURRICULUM VITAE 
 
Bart Metselaar was born on July 6th 1971 in Rotterdam, The Netherlands. In 1990 he 
finished high school education (Dutch system: VWO) at the Melanchton College in Rotterdam 
and started with the study Pharmaceutical Sciences at the Faculty of Pharmacy, Utrecht 
University. In 1994 he participated in an undergraduate research program entitled 
‘Pharmacokinetics and pharmacodynamics of topical glucocorticoids in dogs’ at the 
Department of Pharmaceutics, University of Florida in the USA. He graduated in 1995 and 
obtained his pharmacist’s license in 1997. From 1998 until 2001 Mr. Metselaar has been 
working as a graduate student at the Department of Pharmaceutics, Utrecht University on 
his thesis: ‘Liposomal targeting of glucocorticoids, a novel treatment approach for 
inflammatory disorders’ under supervision of Prof. Dr. G. Storm, Prof. Dr. D.J.A. Crommelin 
and Dr. M.H.M. Wauben. Presently he is investigating the possibilities of commercializing the 
formulations designed and evaluated during this thesis. He aims at setting up a small life 
science company and successfully applied for financial support from the Dutch organization 
of Scientific Research (‘NWO’), which enables him to further realize this aim. Mr. Metselaar’s 
main research interests are: advanced drug carrier design and optimization, 
pharmacokinetics and biodistribution of colloidal therapeutics, and immunology and 
pharmacology of autoimmune disorders. Currently, he lives in Amsterdam and besides 
enjoying the cultural life and heritage of the Dutch capital city, he spends his free time on 
culinary activities and (playing) music. He also has a great interest in architecture, 
astronomy, cartography and geography, philosophy and theology. 
 
 
 
curriculum vitae and list of publications 
  185 
LIST OF PUBLICATIONS 
 
Scientific papers and abstracts 
J.M. Metselaar, E. Mastrobattista, and G. Storm. Liposomes for intravenous drug targeting: design and 
applications. Mini Rev in Med Chem 2: 319-29, 2002. 
J.M. Metselaar, M.H.M. Wauben, O.C. Boerman, and G. Storm. Intravenous targeting liposomal 
corticosteroids as a novel treatment of arthritis. Inflammation Res 50 (abstract) Suppl 3, 170, 2001. 
J. Szebeni, L. Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M. Metselaar, G. Storm, A. 
Chanan-Khan, L. Liebes, F.M. Muggia, R. Cohen, Y. Barenholz, and C.R. Alving. Role of complement 
activation in hypersensitivity reactions to Doxil and hynic-PEG liposomes: experimental and clinical 
studies. J Liposome Res 12: 165-72, 2002. 
 J.M. Metselaar, M.H.M Wauben, O.C. Boerman, P.L. Van Lent, and G. Storm. Long-circulating 
liposomes for i.v. targeted delivery of glucocorticoids in arthritis. Cell Mol Biol Lett. 2002;7:291-2. 
J.M. Metselaar, M.H.M. Wauben, J.P.A. Wagenaar-Hilbers, O.C. Boerman, and G. Storm. Joint targeting 
of glucocorticoids with long-circulating liposomes induces complete remission of experimental 
arthritis. Submitted for publication. 
J.M. Metselaar, W.B. van den Berg, A.E.M. Holthuysen, M.H.M. Wauben, G. Storm, and P.L.E.M. van 
Lent. Targeting glucocorticoids to synovial lining cells with long-circulating liposomes increases 
therapeutic benefit in collagen type II-induced arthritis. Submitted for publication. 
J. Schmidt, J.M. Metselaar, M.H.M. Wauben, K.V. Toyka, G. Storm, and R. Gold. Drug targeting by 
long-circulating liposomal glucocorticoids increases therapeutic benefit in a model of multiple 
sclerosis. Submitted for publication. 
J.M. Metselaar, M.H.M. Wauben, J.P.A. Wagenaar-Hilbers, L. van Bloois, D.J.A. Crommelin and G. 
Storm. Therapeutic index can be optimized by encapsulating high-clearance glucocorticoids in long-
circulating liposomes. Submitted for publication. 
J.M. Metselaar, P. Bruin, L.W.T. de Boer, T. de Vringer, C. Snel, C. Oussoren, M.H.M. Wauben, D.J.A. 
Crommelin, G. Storm , and W.E. Hennink. A novel family of L-amino acid-based biodegradable 
polymer-lipid conjugates for development of long-circulating liposomes with effective drug targeting 
capacity. Submitted for publication. 
J.M. Metselaar, S. Sanders, R. van Lamoen, L. van Bloois, P. Laverman, L. Baranyi, S. Savay, J. 
Milosevits, M.H.M. Wauben, C.R. Alving, G. Storm, and J. Szebeni. Complement activation - related 
hypersensitivity reactions caused by  PEGylated liposomes. Manuscript in preparation. 
 
Patents 
J.M. Metselaar, M.H.M. Wauben, and G. Storm. Composition for treatment of inflammatory disorders. 
PCT Int. Appl. WO 02/45688, filed 2000, published 2002. 
J.M. Metselaar, W.E. Hennink, T. de Vringer, L.W.T. de Boer, C. Oussoren, G. Storm, and P. Bruin. 
Lipid-polymer-conjugates. PCT Int. Appl. WO 02/98951, filed 2001, published 2002. 
J.M. Metselaar, W.E. Hennink, T. de Vringer, L.W.T. de Boer, C. Oussoren, G. Storm, and P. Bruin. 
Lipid-polymer-conjugates. PCT Int. Appl. WO 02/98952, filed 2002, published 2002. 
J.M. Metselaar, M.H.M. Wauben, and G. Storm. Composition for treatment of inflammatory disorders. 
Eur Pat Nr, 02077338.8, filed 2002. 
R.M. Schiffelers, J.M. Metselaar, G. Molema, G. Storm. Corticosteroids for treatment of cancer. Eur Pat 
Nr, 02078525.9, filed 2002.   
appendices 
 
 186 
 
acknowledgements 
   187 
 
  
 
 
 
 
 
 
 
